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ABSTRACT 
Previous studies suggest that life events and chronic stress increase the risk of 
relapse in inflammatory bowel disease. Furthermore, experimental stress has been shown 
to worsen inflammation in animal models of colitis. Hypnotherapy is effective for 
functional gastrointestinal (GI) disorders and claimed by some patients to improve 
ulcerative colitis (UC). 
Two major hypotheses are tested in this thesis: 
i) Psychologic6d stress can worsen inflammation via its effects on various 
systemic and rectal mucosal inflammatory variables in quiescent UC. 
ii) Relaxation achieved through hypnosis can reduce inflammation via its 
effects on various systemic and mucosal inflammatory variables in active UC. 
Patients with UC and healthy controls underwent an experimental stress test, 
hypnotherapy session or control procedure. Various systemic and, in patients with UC, 
rectal mucosal inflammatory measures were assessed before and after each procedure. 
The major findings are as follows: 
i) In patients with inactive UC, acute experimental stress increased LPS- 
stimulated TNF-a and IL-6 production by whole blood. Stress also increased leukocyte 
count, Natural Killer (NK) cell count, platelet activation and platelet-leukocyte 
aggregeate (PLA) formation. At the mucosal level, stress increased TNF-a in peri- 
mucosal fluid, and mucosal ROM production; it reduced rectal mucosal blood flow 
(RMBF). 
ii) In patients with active UC, one session of hypnotherapy reduced serum 
IL-6 concentration and caused a transient reduction in NK cell numbers. At the mucosal 
level, hypnotherapy caused a reduction in the concentration in peri-mucosal fluid of 
Substance P, histamine and IL-13 and reduced RMBF. 
iii) Chronic stress, as assessed by psychometric questionnaires, did not affect 
the response to acute experimental stress. 
iv) There was no difference between the responses of patients with UC and 
healthy volunteers to any protocol. 
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In conclusion, stress increased, whilst hypnotherapy reduced various 
inflammatory measures at both the systemic and mucosal level in patients with UC. 
These effects might contribute to the reported adverse effects of stress and therapeutic 
efficacy of hypnotherapy in UC. 
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CHAPTER 1 
INTRODUCTION 
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1.1 INTRODUCTION 
In this chapter I will first provide a very brief overview of inflwnmatory bowel 
disease (1131)). This will be followed by a more detailed description of the factors 
involved in the aetiology of IBD. Particular attention will be paid to the role of 
psychological stress in the pathogenesis of IBD, as this subject forms the basis for much 
of this thesis. I will also give a description of the pathogenesis of IBD with an emphasis 
placed on the cells and inflammatory mediators studied in this thesis. 
1.1.1 INFLAMMATORY BOWEL DISEASE 
Crohn's disease (CD) and ulcerative colitis, (UC) are chronic, relapsing and 
remitting inflammatory diseases of the gastrointestinal (GI) tract. They are characterised 
by a marked temporal variation in mucosal inflammation, from near normýal in remission 
to severe ulceration during relapse. Both diseases are life-long, usually requiring 
continuous medication and often surgery. 
1.1.2 CROIIN'S DISEASE 
CD is characterised by chronic transmural granulornatous intestinal inflammation 
with a tendency to form strictures and fistulae. It can affect any part of the GI tract, and 
often does so in discontinuity to form "skip" lesions. Most commonly it affects terminal 
ileum and ascending colon (ileocolonic disease). 
CD is classified according to the site, extent and behaviour of disease. These 
factors govern the clinical symptoms. Active CD characteristically produces the triad of 
abdominal pain, diarrhoea and weight loss, although'the preponderance of each symptom 
varies within and between patients. Small bowel CD is often complicated by the 
development of luminal stenosis due to inflammatory or fibrotic strictures leading to 
obstructive symptoms; fistulation and local abscess formation are more common. 
Colonic CD is less often complicated by strictures and tends to cauk more severe 
diarrhoea than small bowel CD. However, in contrast to UC, significant rectal bleeding 
is unusual. 
27 
CD can present at any age but the commonest age for onset is between 15-40 
years. 
1.1.3 ULCERATIVE COLITIS 
7be inflammation in UC involves only the mucosa of the colon and rectum, and is 
characterised by diffuse infiltration of the lamina propria by mixed acute and chronic 
inflammatory cells leading to epithelial damage and formation of crypt abscesses. It 
affects only the large bowel, although in rare cases there can be a "backwash" ileitis. It 
most commonly involves the rectum and extends proximally in continuity to a varying 
degree. 
Bloody diarrhoea is the characteristic symptom of active UC. During acute 
attacks, systemic features such as anorexia, fever and malaise are also common. 
The commonest age for initial presentation is 15-30 years and there is a second 
smaller peak at 50-70 years. 
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1.2 AETIOLOGY 
The aetiology of both CD and UC involves a complex interaction between genes 
and environment. 
1.2.1 GENETIC FACTORS 
Ethnic and Racial Studies 
Epidemiological data has shown that the incidence of CD and UC varies 
according to ethnic background. The incidences of CD and UC in the Caucasian 
population of Western Europe and North America are approximately 6 per 100,000 and 8 
per 100,000 respectively (1; 2). The incidence of both diseases is lower among African 
Americans, Hispanics and Asians, although exact estimates vary (3). Among ethnic 
groups in the USA, Jews have the greatest risk for developing IBD, with an incidence 
rate 2 to 4-fold greater than non-Jewish Caucasians (4). 
Family Studies 
IBD has been shown to cluster in families. Between 10-20% of patients with IBD 
have a first degree relative who also has 1131) (5; 6). The empiric risk for developing 1131) 
in siblings and offspring of a patient with CD is 10% and 16% respectively, and 3% and 
6% for those of a patient with UC (7). The percentage of cases aggregating in families is 
higher in paediatric 1131), suggesting that genetic factors may play a stronger role in early 
onset disease. The average age of onset for familial CD is 22 years, compared with 27 
years for sporadic cases (8). Similarly the average age of onset for familial UC is 23 
years compared to 29 years for spontaneous onset cases (9). There is also good 
phenotypic concordance between family members with CD, indicating that the 
susceptibility gene may vary from one family to another. 
Relatives of a patient with CD are more likely to develop CD than UC, but there 
is also a higher incidence of UC in such relatives than in the general population, 
suggesting that the two diseases are related at least at the level of genetic susceptibility. 
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The expression of perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) 
and antibodies to the cell wall mannan polysaccharide Saccharomyces cerevisiae (ASCA) 
has also been observed to be a familial trait in IBD (10). High levels of p-ANCA 
antibody are associated with UC whilst ASCA antibodies are associated with small bowel 
CD. 
Twin Studies 
Twin studies have helped to determine the relative contributions of genes and 
environment to disease aetiology. Tysk et al reported the relative concordance rates for 
monozygotic twins to be 63% for CD and 19% for UC, indicating that there is a greater 
genetic component to the aetiology of CD than UC (11). 
Taken together, the evidence from ethnic and family studies of 1131) is in keeping 
with a model of disease pathogenesis involving multiple susceptibility genes, with some 
common to both CD and UC, and some separately linked to one disease or the other. 
Genetic Linkage Studies in Inflammatory Bowel disease 
Genetic linkage studies use genome wide scans to type genetic markers in 
families containing more than one affected member for the purposes of identifying 
chromosomal regions shared in excess of statistical expectation. If the disease- 
susceptibility gene is located close enough to the marker it is less likely to be separated 
during meiosis and will therefore be co-inherited. Once linkage is identified, the 
identification of specific genes requires the use of genetic association studies. 
Numerous genome wide scans have identified several 1131) susceptibility loci. 
The IBDI locus 
The IBDI locus is in the peri-centromeric region of chromosome 16 and is the 
best understood susceptibility gene. It shows positive linkage for CD but not UC (12). 
Linkage to this region is now recognised as being largely due to 3 major, relatively 
uncommon, amino acid polymorphisms within the NOD2/CARD15 gene (see below). 
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The IBD2 locus 
The lBD2 locus is located on chromosome 12 and has a greater linkage to UC 
than CD (13). A number of candidate genes have been investigated in this region but 
thus far none has been found to be linked to UC or CD. 
The IBD3 locus 
The IBD3 locus is located on chromosome 6p and includes genes encoding the 
major histocompatability complex (14-16). It has been consistently shown to have 
linkage to both UC and CD. The HLA region has been shown to contribute 64%-100% 
for UC and 10-33% for CD to the genetic risk for this region (17; 18). The IBD3 locus 
also contains the gene encoding turnour necrosis factor (TNF). 
The IBD5 locus 
A genome wide scan in 158 Canadian families identified a region on chromosome 
5q as contributing to susceptibility for early onset CD (19). This region contains the 
genes encoding for a number of immunoregulatory cytokines including Interluekin (IL)- 
3, IL-4, IL-5 and ILA4, but thus far a specific gene has not been identified. 
Genetic association studies in IBD 
Genetic association studies test for differences in allelic frequency in patients 
compared with control individuals. In contrast to genetic linkage studies, in out-bred 
populations disease associations are observed typically over much more limited regions 
containing only a few functional candidate genes. Most candidate genes studied thus far 
have concentrated on those thought to play a role in immune regulation. 
NOD2/Caspase-Activation Recruitment Domains 15 
Genetic association studies have consistently shown that the association with CD 
at the 1131) 1 locus can be attributed to mutations in the NOD2/CARD 15 gene (20; 2 1). 
NOD2/CARD15 is expressed in peripheral blood monocytes and other mucosal cell types 
such as Paneth cells (22), and is related structurally to R proteins in plants. It is well 
conserved through many species of plants and animals and mediates host resistance to 
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microbial pathogens. The C-terminus contains a leucine-rich repeat (LLR) domain which 
functions to recognise broad types of microbial components such as bacterial 
lipopolysaccharides and peptidoglycan (21; 23). lbree major coding polymorphisms 
within or near the LRR of NOD2/CARD15 have been found to be highly associated with 
CD. In the European and North American Caucasian population having one altered copy 
of the gene increases the risk for CD by 2-4 fold whilst having two copies increases the 
risk by 20-40 fold. This indicates that NOD2/CARD15 functions to a large extent in an 
autosomal recessive, fashion. 8-17% of patients with Crohn's disease in this population 
are recessive for one of the mutations. The frequency of alleles, however, is considerably 
lower among the African American population (24), and in the Japanese population no 
association between NOD2/CARD 15 mutations and CD has been shown (25). 
NOD2/CARD15 and genotype-phenotype correlations in CD 
In multiple studies a significant association has been shown between ileal disease 
and one or more of the NOD2/CARD15 alleles (26; 27). In particular, individuals who 
are homozygotes for NOD2/CARD15 mutations rarely develop colonic CD. Lesswell 
established is the relation of NOD2/CARD15 mutations to the behaviour of CD. This in 
part relates to the different systems used to classify CD and also that disease behaviour 
may vary over time. However, some studies have shown an association between 
NOD2/CARD15 mutations and a stricturing disease phenotype. 
The function of NOD2 
Quite how a mutation in NOD2 leads to a predisposition to CD is unknown. 
Transient transfection assays using the major Crohn's disease-associated NOD2 mutants 
have consistently shown defective cytokine responses to muramyl dipeptide, a 
component of peptidoglycan and a NOD2 ligand (28). In contrast, CD is associated with 
an increased production of these inflammatory cytokines. 
Several theories have been proposed to explain this paradox, Kobayashi et al 
have proposed that a loss of NOD2 function in epithelial cells leads to a reduced 
production of defensins. Defensins are naturally occurring anti-bacterial proteins which 
are produced by Paneth cells. Kobayashi et al propose that it is this NOD2 mutation- 
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related reduction in defensin production which predisposes to the development of 
Crohn's disease (29). 
Maeda et al found that bone marrow-derived macrophages from mice into which a 
NOD2 mutation had been introduced, in fact showed a greater response to murarnyl 
dipeptide rather than a reduced repsonse. They suggest that macrophages of patients with 
a NOD2 mutation also show an enhanced responsiveness to bacterial peptidoglycan, and 
that this could underlie the predisposition to Crohn's disease (30). 
A third proposal is that NOD2 normally functions to inhibit signals delivered via 
the stimulation of TLR2 by muramyl dipeptide. A loss of this inhibiting signal leads to 
enhanced cytokine responses by macrophages (or dendritic cells) to commensal bacteria 
and resultant inflammation Q 1). 
Association studies and the IILA region (IBD3 locus) 
The MIIC genes included in the IBD3 region encode for IILA proteins which are 
responsible for presenting peptides to T-cells. HLA class I proteins are present on all 
cells whilst HLA class 11 molecules are expressed only on specialised immune cells. 
There is a high degree of polymorphism within these proteins in the region of the 
peptide-binding groove and, hence, individual differences in the capacity to bind and 
present antigenic peptides to the acquired arm of the immune system. 
There is evidence that specific IILA class 11 associations contribute to overall IBD 
disease pathogenesis, particularly UC. A meta-analysis of 29 studies showed an 
association of UC with DR2, DR9 and DRB 1 *0103 and a negative association with DR4. 
DRB 1* 103 is present in 0.2% to 3.2% of the general population compared with 6 to 10% 
of patients with UC (32). DRB 1* 103 also affects UC phenotype as it is present in 16% 
of patients with extensive UC and is associated with increased rates of surgery (33). For 
CD, a positive association has been demonstrated with DR7, DRB3*301 and DQ4 and a 
negative association with DR2 and DR3 (34). 
Association studies and the Tumour Necrosis Factor gene (IBD3 locus) 
TNF-a is a major inflammatory cytokine which has been shown to be pivotal in 
the inflammatory process in both CD and UC (see section 1.3.10.1). Increased 
33 
concentrations are shown in the mucosa of patients with both CD and UC and anti-TNF-a 
therapy has been shown to be of benefit in both diseases (35; 36). 
TNF-a expression involves a variety of elements located in the gene's promoter 
region. Three promoter polymorphisms have been shown to be associated with an 
increased susceptibility to CD in a Japanese population, and one with an increased 
incidence of CD in a European population (37; 38). 
IL-23 receptor polypmorphisms and Crohn's disease 
Recently an association has been found between CD and the IL-23 receptor region 
on chromosome lp31 (39). IL-23 is a newly discovered member of the IL-12-related 
cytokine family, and is primarily involved in the differentiation of pathogenic T cells 
characterized by their production of IL-17 (40). IL-17 is a pro-inflammatory cytokine 
thought to be important in a number of autoimmune diseases. This IL-23/IL-17 
inflammatory axis may be important in the pathogenesis of 1131). A coding variant of this 
region (rsI 1209026, c. 1 142G>A, p. Arg38 IGIn) has been shown to confer protection 
against Crohn's disease. Additional non-coding IL23R variants have also been found to 
be independently associated with CD (39). 
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1.2.2 ENVIRONMENTAL FACTORS 
Even within the same ethnic group there is a geographical variation in the 
prevalence of IBD. The observed concordance rate for monozygotic twins is only 63% in 
CD and 19% in UC (41). These two observations together suggest that environmental 
factors make a considerable contribution to disease incidence and phenotype in Crohn's 
disease and even more so in UC. However, the environmental factors which both 
predispose to disease development and provoke disease relapse are poorly understood. 
Table 1.1 Environmental factors which may be important in disease incidence and 
phenotype in IBD. 
Environmental Factor Crohn's disease Ulcerative Colitis 
Microbial Factors 
Mucosa associated flora Increased E. coli Increased E. coli 
Mycobacteria 
Enteropathogenic organisms 
Possible causative agent 
Associated with relapse 
No association 
Associated with relapse 
Dietary Factors 
High carbohydrate diet 
Sulphur intake 
Toothpaste 
Refrigerated food 
Increased incidence 
Possible causative agent 
Possible causative agent 
Possible causative agent 
No association 
Possible causative agent 
Possible causative agent 
Possible causative agent 
Drugs 
NSAIDs Associated with relapse Associated with relapse 
Oral contraceptive pill Increased incidence No associadon 
Appendicectomy No association Decreased incidence 
Smoking Increased incidence - Decreased incidence 
Psychological Stress Associated with relapse Associated with relapse 
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1.2.2.1 Microbial factors 
Mucosa-associated flora 
As already described it is likely that the inflammatory response in 1131) 
represents an abnormal ' 
immune reaction to luminal bacteria. Evidence for this comes 
from the observation that IL- 10 knockout mice, which normally develop a coliti s, do not 
do so in sterile conditions. The identification of a specific causative bacterium has not 
yet been established; this in part reflects the complexity of the normal luminal flora. In 
the normal individual there are. 500-1000 species of bacteria in human gut and only 20% 
of these have been successfully cultured. In contrast, some commensal flora, such as 
bifidobacteria and Lactobacillus, may have beneficial effects, either by modifying the 
actions of pathogenic bacteria, or by actions on host mucosal function (42; 43). 
Several studies have reported that mucosal associated E. coli are more common in 
biopsies taken from individuals with Crohn's disease (44-48). Two of these studies have 
also reported an increase in mucosal associated Ecoli in individuals with UC (44; 47). 
The correlation between the site of the bacteria and the presence of inflammation is poor 
suggesting that the E. coll may play a pathogenic role rather than merely colonising 
inflamed mucosa (44; 46). There is also evidence that in patients with CD, Exo1i are not 
just present in increased numbers on the mucosal surface but also invade the underlying 
lamina propria. Ecoli can be cultured from tissue in patients with CD but not in healthy 
controls(49). These lamina propria Ecoli are present not just in the stroma but also 
within macrophages where they may appear in clusters (50). In these sites they are likely 
to contribute further to disease activation through stimulation of production of 
chemokines and cytokines, such IL-8 and TNF-a (5 1), which are central to the 
pathogenesis of IBD. The mechanisms underlying increased adherence and penetration 
into the mucosa of E coli in IBD are unknown. 
Work in our laboratory supports these observations. Using the technique of 
fluorescent in situ hybridisation (FISH) (see section 3.17), our unit has shown that there 
are greater numbers of mucosa surface-associated Exo1i in mucosal biopsies from 
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patients with CD and active UC than in non-inflammatory controls (52). Ecoli were also 
found as individual bacteria and in clusters within macrophages in the lamina propria in 
patients with CD and UC but not in controls. Epithelia-associated counts of 
bifidobacteria were reduced in both active and inactive UC compared to controls (52). 
Mycobacteria 
CD bears many histqlogical similarities to intestinal tuberculosis and hence there 
has been considerable speculation as to whether CD might be due to a mycobacterial 
cause (53). Mycobacterium avium subspecies paratuberculosis (MAP) is an acid-fast 
bacillus capable of infecting the criteric tract in cattle mainly, leading to Johne's disease, 
an illness characterised by granulornatous inflammation similar to that seen in Crohn's. 
Mycobacterium avium subspecies paratuberculosis (MAP) has been detected in 
tissue of patients with Crohn's disease by culture and other molecular methods (54; 55). 
The importance of this finding is unknown as MAP is widespread in the environment and 
can also be detected in the tissues of many individuals who do not have IBD. Long term 
trials of treatment with conventional anti-tuberculous medication have not yielded 
promising results (56) with most recently a multicenter Australian study of triple anti- 
MAP therapy given over a two year period producing a negative outcome (WS Selby, 
verbal communication, British Society of Gastroenterology, Bin-ningharn. March 2005). 
Enteropathogenic organisms in relapses of patients with IBD 
Several studies have demonstrated an increased frequency of enteropathogenic 
organisms in patients with 1131) who have relapsed, compared to the general population. 
The incidence and species of bacteria found varies according to study. A recent study in 
our own unit found the overall incidence of concomitant infection to be 11% in patients 
relapsing with IBD, with clostridiurn difficile being the commonest agent (57). 
1.2.2.2 Dietary factors 
Elemental diets are an effective treatment for active Crohn's disease, although 
probably less efficacious than corticosteroids (58). Many patients feel that dietary factors 
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are important in determining disease behaviour but proving a relationship between 
dietary factors and IBD has remained extremely difficult. 
An excess of each of the major components of the diet has been advanced as 
being important for the development of IBD. Increased carbohydrate intake, and in 
particular increased intake of refined sugar, has been shown consistently to be associated 
with CD (59; 60). Trials of diets low in unrefined carbohydrates, however, have not been 
shown to be of therapeutic benefit in maintaining remission or controlling flares of CD 
(61; 62). Fat intake has been reported as having a positive association with UC, whilst 
fruit, vegetables and fibre decreased the risk of 1131) (60). 
Sulphur intake 
Roediger et al have suggested that dietary intake and luminal metabolism of 
sulphur-containing compounds by sulphate-reducing bacteria are important in the 
aetiology of 1131) (63). Over the last century the modem diet has incorporated increasing 
amounts of sulphur-containing compounds. Sulphur not recycled by an intestinal 
scavenging pump passes into the colon where it is metabolised by sulphate-reducing 
bacteria, a group of bacteria identified as being more common in individuals with UC and 
in particular in those with active disease (64). Metabolism of sulphur by these bacteria 
generates sulphoxide compounds which have been shown to be deleterious to colonic 
mucosa (65). These compounds also reduce the uptake of butyrate and other short chain 
fatty acids (SCFA) by colonocytes, which are important in maintaining mucosal integrity. 
However, treatment of UC with SCFA enemas has generally produced negative results 
(66). 
Toothpaste and microparticles 
A variety of substances contained in toothpaste have been demonstrated as being 
harmful to the GI tract in animal studies (67). In particular some of the particulate 
materials used as abrasives, such as tri-calciurn phosphate and quartz, have been 
identified as capable of penetrating the epithelium and creating enteric lesions similar to 
those seen in CD. However, the possibility has not been rigorously studied and there is 
little supportive data in man. 
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The possibility of microparticles as a causative factor in IBD, and especially in 
Crohn's, has been taken further by some investigators. They suggest that microparticles 
have become an increasing component of a modern diet and this explains the increasing 
incidence of IBD. Powell et al have proposed that fitanium, silicon and dluminium 
oxides are all ingested as food additives (68). These microparticles are taken up by 
specialised epithelial M-cells but are undegradable and accumulate in lymphoid tissue. 
They are proposed to act as adjuvants permitting the absorption of other antigens and 
preventing their appropriate disposition by the immune system, altering normal mucosal 
tolerance and stimulating an immune response. In an initial pilot randomised double- 
blind controlled trial, 20 patients were allocated to either a normal diet or to a diet low in 
microparticles. Adherence to the low microparticle diet for four months led to a fall in 
the Crohn's Disease Activity Index (69). There was little change in the control group. 
However, 'in a later study by the same group with larger numbers of patients, the addition 
of diets'low in microparticles or calcium lead to no additional benefit beyond oral 
corticosteroids in patients with active CD (70). Also when Crohn's patients were 
compared with a control group for their intake of microparticlulates, no differences were 
observed (71). 
Refrigerated Food 
Another theory suggests that IBD results from chronic exposure to organisms 
which can survive at low temperatures, such as Listeria monocytogenes, Yersinia 
enterocolitica, Clostridium botulinunt, and Bacillus ceraus. Exposure to these organisms 
has increased over the last century due to the increasing use of refrigeration in the 
preservation of food (72). In support of this theory, Liu et al found that 75% of intestinal 
and mesenteric lymph node specimens from 16 individuals with CD stained positively 
with antibodies to listeria. Macrophages and giant cells immunolabelled for this antigen 
were found in the samples underneath intestinal ulcers, along fissures, around 
abscesses, within the lamina propria and within the germinal centres of lymph nodes (50). 
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1.2.2.3 Drugs 
Non-steroidal anti-inflammatory drugs 
The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown in 
some studies, but not all, to be positively associated with a higher risk of relapse in 
quiescent 1131) (73). The inconsistency between studies is likely to be due to small 
sample sizes and methodological problems. One study found that administration of 
naproxen or nabumetone for 9 days led to a 20% relapse rate in patients with 1131), with a 
corresponding increase in levels of faecal calprotectin (74). Taking diclofenac: for 14 
days has been shown to lead to the formation of small bowel pathology, as detected by 
wireless capsule endoscopy, in 70% of healthy volunteers, again with a corresponding 
increase in faecal calprotectin (75). 
There is less data on the effects of selective COX-2 inhibitors in patients with 
IBD. One study has reported a higher incidence of disease relapse in patients with 1131) 
who were taking rofecoxib (76). There is currently no data to suggest COX-2 inhibitors 
are less likely to cause relapse than conventional NSAIDs. 
Some supporting evidence for a role for NSAIDs in provoking replapse in 1131) is 
provided by animal models. IL-10 knockout mice develop a far more rapid and severe 
colitis when given NSAIDS (77). The mechanism may involve the blockade of the 
production of protective prostaglandins, such as PGE2, or the increased intestinal 
permeability observed with NSAID use (78). 
The oral contraceptive pill 
The relative risk of Crohn's disease has been found to be increased for women 
taking the oral contraceptive pill (OCP). A relative ri sk of 1.44 (95 % Cl 1.1- 1.9) was 
calculated in a meta-analysis of OCP use in an 11313 population (79). The mechanism by 
which this might occur is unknown, although it may involve the increased likelihood of 
thrombosis leading to multifocal mucosal micro-infarction (80). 
40 
1.2.2.4 Appendicectomy 
The prevalence of UC is lower in patients who have developed appendicitis whilst 
under the age of 20 than those who have not (81). Patients with UC also have lower rates 
of appendicectomy than the general population. Performing appendicectomy electively 
can prevent the development of colitis in some mouse models, but has yet to be shown to 
be consistently efficacious in man (82). 
1.2.2.5 Smoking 
Tobacco exposure, and in particular cigarette smoking, is the most well 
established environmental factor which influences IBD. Smoking has been shown 
consistently to be associated with an increased incidence of, and have an adverse effect 
on, the clinical course of CD, but to have a protective effect against UC. 
Smoking and Crohn's disease 
Approximately 50% of patients with Crohn's disease smoke: this is considerably 
higher than the prevalence of cigarette smoking in the general population. In a large 
meta-analysis the odds ratio for Crohn's disease was 2.0 (95% Cl 1.65-2.47) for smokers 
and - 1.8 (95% CI 1.33-2.5 1) for ex-smokers compared to the general population (83). 
Cigarette smoking has also been shown to have an adverse effect on clinical 
course. Patients with Crohn's colitis who smoke experience more relapses than those 
who do not (84). Cottone et al found smoking to be an independent risk factor for the 
development of clinical, surgical and endoscopic reccurrence in 182 patients who had 
undergone surgery for Crohn's disease (85). In contrast, smoking cessation has been 
shown to reduce the future requirement for steroids and the risk of operations for 
recurrent Crohn's disease (86). Non-smoking is also associated with a higher rate and 
longer duration of response to infliximab therapy (87). Smoking also affects disease 
phenotype and is associated with a higher incidence of ileal disease and a fistulizing 
pattern of disease behaviour (88). 
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Smoking and ulcerative colitis 
In contrast to CD, the prevalence of smoking in patients with UC is 11-23%, 
lower than the prevalence of smoking in the general population. In a meta-analysis the 
pooled odds ratio of UC was 0.41 (95% CI 0.34-0.48) in smokers compared to non- 
smokers (83). There was also a dose-response relationship with heavier tobacco 
consumption increasing the protective effect. 
Smoking also appears to alleviate the clinical course of UC. In a study of 30 
intermittent smokers with UC, resuming smoking led to an improvement in symptoms in 
50% of cases (89). Those who responded were on average heavier smokers than those 
who did not. Smoking has also been shown in some studies to be associated with lower 
rates of hospitalisation and colectomy (90; 91). 
Transdermal nicotine and nicotine enemas have been shown to have clinical 
benefit in active UC in a limited number of trials. Pullan et al treated 72 patients with 
active left-sided UC with either transdermal nicotine or placebo over six weeks (92). 
Mesalamine and steroids were also continued. The improvement in clinical and 
histological grades was greater in the group treated with nicotine. However, nicotine 
patches have not been found to be effective in preventing disease relapse in patients with 
quiescent UC (93). 
In two small pilot trials in active distal UC, liquid nicotine enemas were effective. 
However the liquid enemas were difficult to retain, limiting their practical use (94; 95). 
Possible Pathogenic Mechanisms of Smoking on IBD 
The active ingredient in tobacco and the exact mechanisms by which it affects 
1131) are unknown. Smoking is known to affect a wide range of both adaptive and innate 
immune functions which may have relevance to the pathogefiesis of IBD. Carbon 
monoxide exposure reduced lipopolysaccharide-stimulated secretion of inflammatory 
cytokines by macrophages (96). Smoking led to a reduction in IL-lbeta, IL-2, IL-8, IL- 
10 and TNF-a levels in peripheral blood mononuclear cells and of IL-lbeta and IL-8 in 
colonic tissue from healthy controls and patients with IBD (97-100). Heavy smokers 
have reduced IgA levels in both saliva and intestinal secretions (101; 102). Smokers also 
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show an increase in suppressor CD8+ T cells and a diminished ratio of CD4/CD8 T cells 
in peripheral blood (103). 
Patients with UC are reported to have an increased rectal blood flow (104). Rectal 
blood flow has been reported to be reduced by smoking, and may be one of the 
mechanisms whereby smoking influences the courseof UC (104). 
Smoking increases the pro-coagulant activity of blood and promotes 
microvascular thrombosis (105; 106). This may be of relevance to Crohn's disease if the 
theory of chronic mesenteric vasculitis as a pathogenic mechanism is correct (80). 
It is also tempting to speculate that another mechanism by which smoking might 
affect UC is through its ameliorative effects on stress. Patients often claim that smoking 
reduces stress levels and it is possible that this reduction may lead to the beneficial 
effects of smoking seen in UC. However, there is as yet no data to support this theory 
directly. 
Psychological stress 
As the effects of stress and stress reduction therapy in UC forms the basis for this thesis, 
the role of stress in the aetiology of IBD will be discussed separately at the end of this 
chapter. 
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1.3 PATHOGENESIS 
Although the exact mechanisms of the pathogenesis of IBD are unknown, it is 
generally accepted that CD and UC involve immune dysregulation, with a genetically 
determined abnormal mucosal response to the bacterial flora of the intestine (107). 
Normal immune tolerance to bacterial antigens appears to be lost and an inflammatory 
response develops. 
The most important cell-types, cytokines and mediators in this process, and 
particularly those relevant to this thesis, will be discussed in turn. 
1.3.1 INTESTINAL EPITHELIAL CELLS 
The epithelial cell layer is in constant contact with both pathogenic and 
commensal bacteria and acts as a barrier, preventing invasion of the underlying mucosa. 
Epithelial cells are capable of a variety of immunological functions including the 
production of inflammatory cytokines such as IL-8 (108). Specialist epithelial cells, 
named M-cells, which overlie the Peyer's patches, continually sample the mucosal flora 
for potential antigens (109). These antigens are passed to dendritic cells which process 
and present the antigens to T-cells (see below). Paneth cells, another kind of specialised 
epithelial cell, produce a range of antimicrobial peptides and proteins such as defensins. 
1.3.2 DENDRITIC CELLS 
Dendritic cells are now recognised as the principal antigen-presenting cell of the 
gut. They process bacterial antigens, which have either been sampled directly from the 
gut lumen or received from M-cells, and present them via major histocompatibility class 
II (MHQ to T-cells (110). This interaction leads to the production of cytokines and 
chemokines and the development of an inflammatory response. 
1.3.3 T-CELLS 
CD4 positive T helper cells are regarded by many as the pivotal cell type in 
determining and driving the inflammatory response in IBD (111). They bear T-cell 
receptors which are capable of recognising foreign antigens when they are presented in 
44 
conjunction with major histocompatibility type 11. This interaction, if accompanied by 
other co-stimulatory molecules, causes stimulation of the T-cell and the production of 
pro-inflammatory cytokines and chemokines. This leads to the recruitment of further T 
cells and other inflammatory cell types from blood vessels with the consequent 
development of acute mucosal inflammation. 
1.3.4 MACROPHAGES 
Macrophages play an important role in both the innate and adaptive immune 
responses of healthy individuals and are likely to be important in the pathogenesis of 
IBD. They are able to recognise micro-organisms and their products, and respond by 
phagocytosis, microbial killing and the secretion of cytokines such as IL- 12 and IL- 18 
(112; 113). Stimulation of toll-like receptor 4 (TLR-4) on the macrophage cell surface by 
bacterial LPS, leads to the expression of ILlbeta and 7NF-a (114; 115). Macrophages 
also present antigens to T-cells, affecting the adaptive immune response. 
There are a large number of macrophages in the lamina propria of non-nal small 
and large bowel. In healthy individuals a number of the inflammatory responses of these 
macrophages, such as their ability to produce ILA beta and to respond to stimulation by 
LPS, seem to be down-regulated. However, in individuals with IBD this is not the case, 
with lamina propria macrophages capable of greater inflammatory responses (116; 117). 
The ability of macrophages to respond to LPS is also affected by mutations in the NOD-2 
gene (see above), supporting the theory that this interaction is important in IBD 
(I I S; 119). 
1.3.5 MAST CELLS 
Mast cells arise from CD34-positive bone marrow precursors and circulate in an 
immature form, only maturing once in a tissue site. Two types of mast cells are 
recognised, those from connective tissue and those found in mucosae, whose activities 
are T-cell-dependent (120). Mast cell granules contain a range of inflammatory 
mediators which are released when the mast cell is activated. Some of these are 
relatively specific to mast cells such as histamine and tryptase, whilst others, such as 
TNF-a, are released by a range of inflammatory cells (121). There is increased 
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activation of mucosal mast cells in active UC (122) and increased lurninal release of 
histamine and other mast cell mediators (123). Activated mast cells may be a source of 
the increased mucosal release of TNIF-a seen in active IBD active IBD (121). Tryptase 
has a number of inflammatory actions which may contribute to the pathogenesis of IBD. 
It leads to increased expression of P-selectin (see section on platelets and platelet 
leukocyte aggregates below) and increased neutrophil recruitment to the lamina propria. 
Tryptase also activates the protease-activated receptor 2 (PAR2) intracellular signaling 
pathway (124), which by altering colonic epithelial intercellular tight junctions may 
increase mucosal permeability to bacteria (125). In this context, PAR2 expression is 
increased in UC (126), and has been shown to induce experimental colitis (127). 
Increased mast cell activation may be mediated at least partly through stimulation of their 
TLR4 receptors (128). 
A pathogenic role for mast cells in IBD is suggested by open-label studies 
indicating that an inhibitor of the mast cell mediator, tryptase, may have benefit in mild- 
moderately active UC (129). The mast cell stabilizer, ketotifen, has also been shown to 
have benefit in a pilot open-labelled study of ten children with IjC (130). 
1.3.6 NATURAL KILLER CELLS (NK CELLS) 
NK cells are traditionally considered a component of the innate immune system, 
killing tumour and virally infected cells via their interaction with MHC 1 (131). More 
recently they have also been shown to affect adaptive immunity via their interactions 
with dendritic cells (132). NK cells can localise to areas of inflammation and interact 
with immature dendritic cells causing maturation and proliferation of both the dendritic 
cell and NK cell. The mature dendritic cells interact with T-cells, determining the 
inflammatory response, whilst the stimulated NK cells are able to produce cytokines such 
as TNF-a and IFN-gamma (Figure 1.1) (133). 
NK cells are not generally regarded as an important cell type in the pathogenesis 
of IBD although there are some reports of increases in both mucosal numbers and 
activation of NK cells in active 1131) (134; 135). Increases in NK cell number are one of 
the most consistent findings associated with acute stress and hence our evaluation of this 
variable in this study (136; 137). 
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1.3.7 NATURAL KILLER T CELLS (NKT CELLS) 
Natural killer T (NKT) cells are defined by the bearing of both T-cell receptors 
and NK receptors. They can recognise antigens presented in association with CDld, an 
MHC class-1 like molecule present on the surface of dendritic and other antigen 
presenting cells. Classical NKT cells bear an invariant T-cell receptor (TCR) with a 
particular Va chain (in humans Va24/JaQ) usually associated with a particular Vo chain 
(in humans Vol 1) (138). NKT cells are thought to playa role in both innate and acquired 
immune responses. 
Recent evidence suggests that UC may be mediated by a mucosal population of 
NKT cells. Oxazolone-induced colitis, a murine model of GI inflammation which 
resembles UC, is mediated by a population of mucosal NKT cells which produce IL- 13 
(see section 1.3.10.3) (139). Inflamed tissue from patients with UC also contains 
increased numbers of non-classical NKT cells which produced markedly increased 
amounts of IL, 13. These NKT cells are cytotoxic to epithelial cells in vitro, an effect 
which is increased in the presence of IL-13 (140). 
1.3.8 PLATELETS AND PLATELET-LEUKOCYTE AGGREGATES 
Platelets circulate in a higher activated state in patients with 11313 and platelet 
activation may be important in pathogenesis by causing thrombosis formation and 
microinfarction secondary to microvascular ischaernia (141). Platelets are also capable of 
producing inflammatory cytokines, such as platelet activating factor (PAF) and 
leukotriene B4 (LTB4), which may contribute to the inflammatory response (142). 
P-selectin, which is expressed by activated platelets, is key to the formation of 
platlelet-leukocyte aggregates (PLAs). PLA formation is raised in patients with IBD 
(143) and may cause reciprocal activation of platelets and leukocytes. Furthermore as a 
consequence of increased expression of adhesion molecules, neutrophils complexed with 
platelets may be more likely to adhere to vascular endothelium and subsequently migrate 
extravascularly (Figure 1.2). 
48 
(14 
1-4 
0 
P 
u 
(1) 
C 
E 
0 /- 
0 
I- 
0 
C 
C 
C'n 
LA 
ct 
z 
y 
-0 
u 
0 
CK% 
0) 
(D 
L- 0) 
cc 
92- 
m 
lit 
47 
i1 £1- 
.Z 
ms 
-v E 0 ce 
.e1; 
2 
Z -Z, 2 
ý LONDM , 
um u 
3eýCU 
1.3.9 ENTERIC NEURONES 
The enteric nervous system (ENS) contains 100 million neurones and regulates 
the motility, exocrine and endocrine functions and microcirculation of the GI tract (144). 
The gut is also supplied by the sympathetic and parasympathetic autonomic nervous 
system (ANS). The ANS and ENS contain various neurotransmitters, including 
catecholarnines, vasoactive intestinal peptide, angiotensin 11, neurotensin, somatostatin 
and SP, which are capable of affecting lymphocytes, macrophages, neutrophils, and other 
inflammatory cells at the neurone-immune cell junction (145-147). 
Various abnormalities of the enteric neurones have been reported in tissue 
samples from patients with IBD. Immunohistochemical staining demonstrates increased 
numbers of mucosal nerve fibres. Of particular relevance to this project, substance P- 
containing neurones have been reported as being increased (see below) (148-150). 
1.3.10 CYTOKINES AND CHEMOKINES 
Cytokines are local mediators produced principally by cells of the lymphoid and 
macrophage lineage, and to a lesser degree by epithelial and mesenchymal cells. They 
are involved in a variety of biological processes including cell activation, growth and 
differentiation. They are also central to the development of inflammation and immunity. 
Chemokines act as chemical attractants leading to the recruitment of further 
inflammatory cells. The pattern of cytokines and chemokines expressed by 
immunoreactive cells determines the nature of the inflammatory response. 
Cytokines can be broadly split into those with mainly pro-inflammatory effects 
such as IL-1, interferon-gamma (IFN-, y) and TNF-a, and those with more regulatory roles 
such as IL-2 and IL-10. Others, such as IL-8, function more as chemokines. 
The pattern of cytokine and chemokine production differs between CD and UC 
and is thought to determine the differing pattern of inflammation observed between the 
two diseases. CD is well described as a THI type immune response (151). This is 
characterised by the production of large amounts of IL-1, IL-2 and IFN-y. The 
production of these cytokines by CD4-positive T helper cells stimulates cell mediated 
immunity, with increased T cell cytotoxicity characteristic of CD. Increased mucosal 
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production of IL-12 has also been demonstrated in CD and it has been suggested that IL- 
12 may play a key role in determining a THI type immune response (151-153). IL-23 
shows close homology to IL-12 and recent genetic evidence suggests IL-23 may also be 
important in the pathogenesis of CD (39). Mucosal production of IL-18 is also increased 
in CD, and is thought to be involved in perpetuating the THI cell responses (112; 154). 
The immune response in UC is more difficult to classify than that of CD, but is 
more in keeping with a TH2 type immune response. There is the production of large 
amounts of ILA, IL-5, IL-10 and IL-13 with reduced production of IFN-y (155). These 
cytokines are more associated with the stimulation of B-cells and an antibody response. 
However, the division of CD and UC into the classic TH I and TH2 paradigm is overly 
simplistic and it is likely that these pathways co-exist rather than being mutually 
exclusive. 
In addition to affecting T and B cells, certain cytokines such as IL-1, TNF-a and 
IFN-, y lead to upregulation of adhesion molecules and chemokines such as IL-8. These 
mediate the recruitment of further blood-borne inflammatory cells via activated 
endothelium. This leads to amplification of the inflammatory cascade and secretion of 
more inflammatory mediators, destructive enzymes and free radicals leading to futher 
tissue injury. 
Table 1.2 
Cytokine changes in Crohn's disease and UC 
Crohn's disease Ulcerative Colitis 
Cytokine pattern TH1 type T112 type 
Increased Increased 
ILA, IL-2, IL-12, IL-23, ILA, IL-5, IIAO, 11,43, 
ILAS, IFN-y, INF-a TNF- a 
Decreased Decreased 
IL-10 IFN-y 
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CYTOKINES OF PARTICULAR RELEVANCE TO THIS THESIS 
1.3.10.1 Tumour necrosis factor-alpha 
Tumour necrosis factor-a is a 17-kD pleiotropic cytokine produced by 
macrophages, monocytes, T cells and more pertinently to this study by NK and mast cells 
(121). Although regarded as a THI type cytokine, TNF-a production is increased in both 
CD and UC, and it is recognised as playing a key role in the pathogenesis of 1131) 
(156; 157). 
TNF-a is released in large amounts by macrophages in response to stimulation by 
bacterial products such as LPS. TNF-a has a range of inflammatory actions including 
stimulating increased production of other inflammatory cytokines such as IL-1, IL-6 (see 
below) and IL-8 (158). One of the key actions of TNF-a in the pathogenesis of IBD 
appears to be to stimulate increased production of IFN-y (158). TNF-a also stimulates 
the expression of adhesion molecules, proliferation of fibroblasts, as well as initiating 
cytotoxic, apoptotic and acute phase responses (158; 159). Many of the pro-inflammatory 
actions of TNF-a are mediated via increases in the nuclear transcription factor NF-kappa 
B (160). 
Animal studies have demonstrated prevention of the development of colitis in 
TNF-a knockout models (161). Correspondingly a lethal colitis develops in animals 
harbouri ng a TNF-a transgene (162). 1 
Increased TNF-a producing cells and the spontaneous production of TNF-ct have 
been demonstrated in studies of isolated lamina propria mononuclear cells (LPMCs) in 
inflamed and non-inflamed mucosa in patients with IBD (163; 164). Several studies have 
reported that elevated serum levels of TNF-a correlate with clinical and laboratory 
indices of disease activity. Correspondingly, therapy with antibodies to TNF-C( has been 
shown. to be effective in both CD disease and more recently UC (35; 36). 
1.3.10.2 Interleukin-6 
Interleukin-6 is a major inflammatory cytoldne produced by many different 
immune cell types including monocytes, macrophages, T-cells, B-cells, eosinophils and 
mast cells (165; 166). It is one of the major physiological mediators of the acute phase 
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reaction and is responsible for stimulating the production of C-reactive protein (CRP) by 
hepatocytes (167). It has a range of pro-inflammatory actions including both promoting 
maturation of B-cells and differentiation of mature and immature T-cells into cytotoxic 
T-cells. 
ILA also stimulates the release of corticotrophin releasing factor (CRF) in the 
hypothalamus leading to adrenocorticotrophic hormone (ACTII) release by the pituitary 
and consequently increased glucorticoid production in the adrenal cortex (168; 169). As 
the principal action of glucocorticoids is anti-inflammatory, this mechanism forms a 
negative feedback loop linking the immune and neuroendocrine systems which is 
relevant to this thesis. I 
Serum and saliva IL-6 concentrations have been found to be increased in patients 
with inflammatory bowel disease (170; 171). The mucosal production and concentration 
of IL-6 has also been found to be increased in both CD and UC (172; 173). IL-6 has also 
been found to bean important mediator in animal models of colitis (174). Ithasbeen 
suggested that one important action of IL-6 in the pathogenesis of IBD involves IL-6 
binding to its soluble receptor (sIL-6R) forming a complex which interacts with gpl30 on 
CD4 T-cells. This leads to an increased expression and nuclear translocation of STAT-3 
causing the induction of anti-apoptotic genes. This is thought to lead to an augmented 
resistance of lamina propria T-cells to apoptosis with an ensuing T-cell expansion and the 
continuation of colonic inflammation (175; 176). 
In a pilot study involving 36 patients with active CD, a humaniscd monoclonal 
antibody to IL, 6 receptor led to a greater clinical response rate than placebo. The drug 
was given as biweekly 8mg/kg infusions and was well tolerated. There was a 
normalisation of the acute phase response in all patients given the active treatment but 
there was no difference in terms of endoscopic or histological response compared to 
placebo (177). 
1.3.10.3 Interleukin-13 
As discussed above mucosal production of IL- 13 has shown to be increased in 
oxazolone-induced colitis and the development of GI inflammation in this model can be 
prevented by the administration of an IL-13 inhibitor (178). 
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Lamina propria mononuclear cells (LPMCs) from patients with UC produce more 
IL-13 in response to stimulation with antibodies to CD2 and CD28 than LPMCs from 
individuals with CD (179). IL-13 also impaired epithelial barrier function in IIT-29 cells 
in vitro, due to an increased incidence of apoptosis and an increased expression of the 
pore-forming tightjunction protein claudin-2 (180). 
1.3.11 REACTIVE OXYGEN SPECIES 
In vitro studies have shown that rectal mucosal biopsies ftom patients with UC 
produce more reactive oxygen metabolites (ROMs) than rectal mucosal biopsies from 
healthy controls (181). ROMs are produced by a wide variety of inflammatory cells, in 
particular neutrophils as part of the oxidative burst. Many of these molecules are highly 
injurious to tissue. It is possible that much of the mucosal damage observed in 
inflammatory bowel disease is mediated by the acute inflammatory infiltrate of 
neutrophils and the production of ROMs (182). 
While there have been no controlled studies to assess the efficacy of specific 
antioxidants in 1131), the beneficial effects of 5-ASAs are thought to be caused, at least in 
part, by their ROM scavenging properties. 5-ASAs have been shown attenuate the 
production of ROMs by stimulated polymorhponuclear leukocytes in vitro at 
concentrations comparable to clinical doses (183-185). They also protect cells in culture 
from the oxidative damage produced by activated neutrophils (186; 187). Colonic 
epithelial cell loss secondary to ROMs is reduced by 5-ASAs in animal models of colitis 
(188). 
1.3.12 SUBSTANCE P 
Substance P is a peptide neurotransmitter, common throughout the GI tract. It is 
produced principally by neurones, but is also released by macrophages, eosinophils, 
lymphocytes and dendritic cells. In addition to its action as a neurotransmitter, SP also 
has pro-inflammatory actions: it enhances cytokine production and stimulates chernotaxis 
of inflammatory cells (189). It also increases the expression of leukocyte adhesion 
molecules on microvascular endothelium, and of CD IIb on neutrophils, facilitating 
leukocyte adhesion at sites of inflammation (189). 
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Elevated levels of SP and increases in neurones containing SP have been reported, 
in some but not all studies, in colonic tissue from patients with IBD although its possible 
contribution to the pathogenesis of IBD is largely unproven. SP-containing neurones are 
found in close association with mast cells and incubation with SP of colonic biopsies 
from patients with IBD increases mast cell-mediated histamine release (190). 
55 
1.4 THE ROLE OF PSYCHOLOGICAL STRESS IN 
INFLAMMATORY BOWEL DISEASE 
Psychological stress has long been anecdotally reported as increasing the 
likelihood of relapse in patients with IBD (191). 
1.4.1 STRESS AND THE STRESS RESPONSE (Figure 1.3) 
To maintain homeostasis, a living organism must constantly adapt at a molecular, 
cellular, physiological and behavioural level to environmental alterations. Stress can be 
defined as any threat to an organism's homeostasis (192). ne function of the stress 
response is to maintain homeostasis and may involve both physiological and behavioural 
'adaptations. 
The stress response involves the complex integration of a series of interconnected 
regions within the brain, most notably the hypothalamus, amygdala and hippocampus 
(193). This network receives input from both visceral and somatic afferents, and from 
higher cortical structures. In turn, it governs the neuroendocrine stress response via two 
interconnected effector pathways: the IIPA axis and the autonomic nervous system 
0 (ANS). 
Stress stimulates the release of corticotrophin releasing factor (CRF) from the 
hypothalamus causing the release of adrenocorticotrophic hormone (ACTII) from the 
anterior pituitary gland. This in turn stimulates the secretion of cortisol, the principal 
glucocorticoid, from the adrenal cortex. 
Stress activates direct descending neural pathways from the hypothalamus to the 
pontomedullary nuclei which control the autonomic response. Stimulation of the 
sympathetic nervous system in response to stress causes the release of adrenaline and 
noradrenaline from the adrenal medulla. 
, 
Neurones of the sympathetic ANS also supply 
the entire gut directly, whilst the vagus and sacral nerves provide parasympathetic input 
to the upper gut and to the distal colon and rectum, respectively (144). The efferent and 
afferent neurones of the sympathetic and parasympathetic ANS communicate with the 
gut's own rich nerve supply, the ENS, and this network has been termed the brain-gut 
axis (144). 
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1.4.2 PSYCHONEUROIMMUNOLOGY 
It is increasingly recognised that the HPA axis, ANS and ENS can interact 
directly with the immune system. Psychoneuroirnmunology is the study of the 
mechanisms by which behavioural factors and CNS function can influence inflammation 
and the immune system at both systemic and local tissue levels (145-147). 
. Nerve fibres of the ANS form close effector junctions with lymphocytes and 
macrophages in lymph glands, bone marrow, thymus, spleen and mucosa-associated 
lymphoid tissue (145). As already discussed, a variety of neurotransmitters contained in 
the neurones of the ANS and ENS are able to affect inflammatory cells within the gut 
(145-147). Lymphocytes and other inflammatory cells also carry receptors for the 
hormones and neuropeptides of the HPA axis such as growth hormone, ACTII, 
corticosteroids and CRF (145; 146). 
At high concentrations glucocorticoids, released from the adrenal cortex in 
response to ACTH from the pituitary, have a mainly immunosuppressive action. They 
increase the synthesis ofanti-inflammatory proteins such as lipocortin-1, intericukin-I 
receptor antagonist and IL-10 (194). The transcription of several inflammatory cytokines 
and chemokines such as ILA, IL-6 (195) and TNF-a (196), is reduced by glucocorticoids 
via an inhibitory effect on the transcription factors AM and NF-kappa-beta (197; 198). 
Glucocorticoids also promote apoptosis in inflammatory cell types which include T cells 
and eosinophils (199). However, at lower concentrations cortisol exhibits an 
immunostimulatory effect. For example, pre-treatment with low dose cortisol increases 
the production of IL-6 and TNF-a by macrophagcs in response to LPS (200). 
Similarly adrenaline and noradrenaline have mixed effects on immune and 
inflammatory function. Adrenaline infusion causes a rise in serum IL-6, and increases in 
LPS-induced IL-8 and IL-10 synthesis by wh6le blood (201-203). It also increases the 
number of circulating cytotoxic T-cells and NK cells, but decreases TNF-a production by 
monocytes (204; 205). 
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1.4.3 THE EFFECTS OF STRESS ON THE SYSTEMIC IMMUNE SYSTEM IN 
HUMANS (Table 1.3) 
The effects of psychological stress on the systemic immune and inflammatory 
system are complex, and depend on both the duration and intensity of the stressor (206). 
Both chronic stress and acute stress are associated with alterations in systemic immune 
and inflammatory function which may have relevance to the pathogenesis of IBD. 
1.4.3.1 Chronic psychological stress, adverse life-events and systemic immune and 
inflammatory function (Table 1.3) 
Chronic sustained stress, such as that due to adverse life events, causes a 
prolonged increase in cortisol over several days which is characteristically associated 
with immunosupression (207). Bereavement, depression and marital separation have all 
been shown to reduce the numbers of CD8+ lymphocytes, natural killer (NK) cells and 
macrophages found in blood (208-212). 
However, in addition to immunosuppression, chronic psychological stress has 
also been shown to be associated with sub-clinical increases in inflammation. Patients 
with depression, and middle-aged and elderly patients with reduced heart rate variability, 
a measure of increased sympathetic tone and chronic stress, have both been found to have 
a raised serum CRP (213; 214). The inflammatory theory of depression suggests that 
depression can be considered a psychoneuroirnmunological disorder with an increase in 
inflammatory cytokines within the brain (215). Antidepressants of several classes 
decrease the production of several inflammatory cytokines within the brain such as TNF- 
alpha and IFN-gamma iq animal models (216; 217). In humans, tricylcic antidepressants 
have been found to reduce the production of various inflammatory cytokines by 
peripheral blood mononuclear cells (218). 
1.4.3.2 Acute psychological stress, experimental stress and systemic immune and 
inflammatory function (Table 1.3) 
Examining the in vivo effects of psychological stress is difficult as stress is a 
subjective experience which is hard to define objectively and to simulate in a controlled, 
experimental environment. Placing patients under sustained psychological stress would 
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also be unethical. Despite these limitations, various experimental models have been 
designed which are capable of inducing mild acute psychological stress as assessed by 
the ANS and HPA response (see Section 3.5) (219; 220). 
The dichotomous listening test, where different auditory inputs are played into the 
subject's ears, has been one of the commonest techniques used to assess the effects of 
psychological stress on human GI physiology (221). Difficult mental arithmetic tests 
(MAT), which include negative feedback and varying degrees of auditory distraction, are 
also used and are easily reproducible (137; 222). The Trier Social Stress Test (TSST) 
involves an oral presentation in front of a critical audience (220; 223; 224) whilst the 
Stroop word-colour interference test involves identifying the colour of ink used to write a 
word which is different to the meaning of the word itself; for example the word blue 
written in red ink (225). 
Both real-life acute stress and experimental stress tests cause acute stimulation of 
the sympathetic nervous system, with an almost immediate rise in adrenaline and 
noradrenaline (226). Ibis is followed by a rise in cortisol but both changes are 
maintained over only a few hours. Stimulation of the stress axes in this way is associated 
with an immune enhancement (227). There is an increase in the serum levels and the 
production by whole blood of inflammatory cytokines known to be important in the 
pathogenesis of 1131). Whole blood from medical students taken the day before an 
examination produced more TNF-a, IL-6 and IFN-y when stimulated with 
lipopolysaccharide (LPS) than when taken several weeks later (228). Similarly blood 
stimulated with LPS for 24 hours produced more IL-6 and IFN-y after an acute stressor 
than before (229-233), and serum levels of IL-6 and IL-2 receptor antagonist were 
increased two hours after a stressful behavioural task (234). Another study reported 
reduced IL-10 production by peripheral blood mononuclear cells (PBMCs) stimulated 
with phytohernagluttinin (PIIA) after an acute stressor compared to before. 
Acute stress has also been shown to cause a Icucocytosis in healthy subjects with 
a rapid redistribution of the lymphocyte population. There is a rise in the percentages of 
CD8+ cytotoxic T-cclls and NK cells, and a corresponding increase in their cytolytic 
activity as assessed by chromium release assays (136; 219; 235; 236). 
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Platelet activation, as assessed by aggregation and production of inflammatory 
mediators and platelet-dependent thrombin generation, has been shown to be increased by 
experimental stress in healthy subjects (237-239). As aforementioned platelets circulate 
in a higher activated state in patients with IBD (143) and platelet activation may be 
important in pathogenesis by causing thrombosis formation and microinfarction 
secondary to n-dcrovascular ischaernia (240). The stress-induced activation of platelets 
could be inhibited by beta-blockers rather than aspirin, suggesting that sympathetic 
stimulation is key in the process (241). Platelet-leukocyte aggregate formation is also 
increased by acute experimental psychological stress (242); this variable is also raised in 
patients with IBD (143). 
An acute stressor has also been reported as causing a transient increase in 
neutrophil activation as assessed by the oxidative capacity of whole blood to reduce 
nitro-blue tetrazolium (243). 
1.4.3.3 The response to acute stress in the presence of chronic stress (Table 1.3) 
The physiological and immune response to acute experimental stress is 
exaggerated by the presence of chronic psychological stress. Individuals with high 
chronic stress levels, such as those caring for a long-term dependent or women with a 
strong family history of breast cancer, showed greater and more prolonged increases in 
sympathetic activation in response to acute stressors than controls (137; 223). This was 
associated with a greater increase in NK cell numbers, albeit with an attenuated increase 
in their activity, in the chronically stressed subjects than in controls (137). Fatigued 
breast cancer survivors also show a greater inflammatory response to an experimental 
stressor, with increased IL-Ibeta and IL-6 production by LPS-stimulated whole blood 
than controls (231). 
Antidepressant treatment with citralopram has been reported in one study to 
normalise the cardiovascular response to acute stress in depressed individuals (244). 
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1.4.3.4 The response to acute experimental stress in the presence of chronic 
inflammatory disease (Table 1.3) 
The immune response to acute experimental stress may also altered by the 
presence of chronic inflammatory disease. Patients with systemic Jupus erythematosus 
(SLE) showed an increase in IL-4-producing peripheral blood mononuclear cells, as 
assessed by staining of intracellular cytokines, in response to the Trier Social Stress Test, 
where as control subjects did not (233). The stress-induced redistribution of the 
leukocyte subsets was also altered in patients with SLE, with an attenuated increase in the 
number of NK cells and their cytolytic activity in comparison to healthy controls (245). 
However another study failed to find any differences between patients with chronic 
psoriasis and healthy individuals in response to an acute experimental stressor (230). 
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Table 1.3 Summary of the effects of adverse life events and acute experimental 
stress on systemic immune and inflammatory function in man. 
Stress Number of Effect Reference 
subjects 
Stressful Life 
Events 
Bereavement 20000 widows and Increased mortality Lusyne et al 
widowers (2001)(246) 
Bereavement 37 widows Decreased NK and cytotoxic Irwin et al 
T-cell activity (1997)(208) 
Major 36 HV Reduced NK cell number Frank et al 
depression (2002)(209) 
Major 46 depressed Reduced NK cell activity Chu et al, 
depression patients and 46 IIV (2002)(210) 
Geriatric 166 depressed Reduced CD4 and CD8 Fortes et al 
depression patients lymphocytes (2003)(211) 
Adolescent 36 depressed and Reduced NK cell number Schleifer et al. 
depression 36 fIV (2002)(212) 
Academic 64 adolescents Reduced lymphocyte Kang et al 
examinations proliferation and neutrophil (1996)(247) 
production of superoxides 
Academic 38 HV Increased TNF-a, IFN- Maes et al 
examinations gamma, IL-6 production by (1998)(228) 
LPS stimulated whole blood 
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Stress Number of Effect Reference 
subjects 
Acute Expedmental Stress 
TSST 32 HV Increased IL-6 production by Goebel et al 
LPS stimulated whole blood (2000)(229) 
TSST 25 HV Increased IL- I beta and TNF- Ackerman et al 
a production by LPS (1998)(232) 
stimulated whole blood 
TSST 15 HV Increased IFN-gamma and Jacobs et a] 
IL- 10 production by P13 MC (2001)(233) 
TSST 15 breast cancer Increased IL-1 beta and IL-6 Bower et al 
survivors production by whole blood (2007)(231) 
TSST 23 psoriasis Increased CD3, CD8 and NK Buske-Kirschbaum 
patients and 23 IIV cells. Increased IFN-y and (2007)(230) 
decreased IL-10 production 
Stroop 13 IIV Intreased serum IL-6 levels Steptoe et al 
(2001)(234) 
TSST 30 HV Increased C138 lymphocytes Marsland et a] 
and NK cells (1995)(219) 
TSST, MAT 15 dtopic Increased CD8 and NK cells Schmid-Ott et al, 
dermatitis, 1511V (2001)(236) 
TSST 15 HV Increased NK cells Pawlak et al 
(1999)(245) 
MAT 23 HV Increased NK cell number Pike et al 
and lyfic activity (1997)(137) 
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TSST 39 female HV Increased NK cells Wright et al (2007) 
(235) 
Stroop 11 HV under 35 Increased thrombi n-i nduced Wallen et al 
platelet fibrinognen binding (1999)(238) 
MAT 12 IIV Increased platelet dependent Kawano et al 
thrombin generation (2000)(241) 
Stroop 40 HV Increased platelet dependent Malkoff et al 
'ATP secretion (1993)(239) 
Stroop 8 IIV Increased platelet dependent Naesh et al 
beta-thromboglobulin and (1993)(237) 
serotonin secretion 
Stroop 37 HV Increased PLA formation Stcptoe ct al. 
(2003)(242) 
TSST 17 HV Transient increased Ellard et al (2001) 
ncutrophil activation (243) 
TSST Trier social stress test, MAT mental arithmetic test, Stroop word-colour 
interference test, HV healthy volunteers, NK natural killer, LPS lipopoysaccharide, PLA 
platelet-leukocyte aggregate, PBMC peripheral blood mononuclear cell 
1.4.4 PSYCHOLOGICAL STRESS AND GASTROINTESTINAL IMMUNE AND 
INFLAMMATORY FUNCTION IN MAN 
1.4.4.1 Psychiatric disease and HID (Table 1.4) 
In the 1950s, 1131) was classified as a psychosomatic disorder (191; 249) with 
many early studies finding an association between 11313 and psychiatric diagnoses (249- 
251). However, a review in 1990 of 138 such studies found most to have serious flaws, 
whilst in the seven which did not, there was no association between psychiatric disease 
and UC (252). In contrast, in a study published in 2004, Mittermaier et al reported that 
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patients with inactive UC had a significantly increased chance of relapse over the next 
eighteen months if their baseline score on the Beck's Depression Inventory was raised 
(253). 
1.4.4.2 Stress and the development of 1BD (Table 1A) 
Although there have been may studies examining whether stress can provoke 
relapse in established 1131) there have been few analyses of stress as an initiating factor. 
In the 1960s it was observed that Bedouin Arabs developed an increased prevalence of 
colitis when moved from nomadic communities into government housing (254). It was 
proposed that it was the stress of relocation which caused the'increased risk of developing 
IBD. However, studies on the same population since have suggested that in fact exposure 
to new environmental factors such as hygiene or food may be more important (255). Li 
et al used retrospective population data to examine whether a stressful life event could 
predispose to IBD (256). They found the incidence of 1131) to be the same in the group of 
21,000 individuals who had lost a child as in the general population. Inacase-control 
study, Lerebours et al found there to be a greater incidence of adverse life events in the 6 
months prior to the onset of disease in 167 patients with CD and 84 patients with UC. 
However, once adjusted for depression, anxiety scores and lifestyle differences in a 
multivariate analysis, the association was no longer significant (257). 
1.4.4.3 Stress and Relapse in IBD (Table 1.4) 
Surveys consistently show that between 50 and 75% of patients with IBD believe 
that stress plays a role in causing relapse of their disease (249; 258). Placebo response 
rates in many therapeutic trials , of IBD remain as high as 30-40% (259). This response 
rate relates not only to subjective measures such as patients' feelings of well being, but 
also to objective measures such as the degree of mucosal inflammation seen at 
endoscopy, and provides further evidence to suggest that changes in psychological state 
can affect disease activity (260). 
Over the years there have been many case studies which have suggested that 
adverse life events can be a causal factor in relapse in 1131). However, although ' 
suggestive, these retrospective studies are frequently flawed by recall bias. Well. 
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designed, prospective investigations of stress as causative factor for relapse in 1131) are 
difficult to perform. They require a long study period to allow a sufficient number of 
relapses to occur to test for correlation, and a high degree of patient compliance for the 
collection of detailed diary records of life events and GI symptoms. There are often 
confounding changes in medication during the study period. Lastly, the definition of 
what constitutes a stressful life-event and what constitutes relapse is variable. In the latter 
context many of the clinical scoring systems commonly used to assess disease activity in 
1131) such as the CDAI (261) and SCCAI (262) contain variables, such as stool frequency, 
which are known to be affected adversely by stress but which do not necessarily reflect a 
worsening of inflammation. 
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Table 1.4 Summary of studies assessing association between stress and IBD 
Variable Patients Finding Reference 
DEVELOPMENT OF 1BD 
Retrospective analysis following Bedouin arabs Increased incidence Salem SN 
relocation into government of colitis (1967)(254) 
housing 
Retrospective 16 year analysis of 21,062 parents 
prevalence of 1131) in patients who who lost a child 
lost a child and controls 
No increased Li ct al (2004) 
prevalence of IBD (256) 
Retrospective case control study 167 CD No association Lerebours 
of life events and 1131) onset 74 UC (2007)(257) 
RELAPSE IN ESTABLISHED IBD 
L Chronic Stress 
Adverse Life-events 
Retrospective analysis of life 60 patients with Positive association Fava GA 
events preceding disease onset uc (1976)(263) 
Retrospective 2 year analysis of 70 patients with Positive correlation Paar et al 
life events preceding disease CD, 44 patients with relapse in CD (1988)(264) 
relapse with UC but not UC 
Analysis of life events preceding 30 patients with Positive association Bach ct al 
relapse UC (1990)(265) 
Prospective 6 months of life 124 patients with Positive association Duffy ct al 
events preceding exacerbation IBD with no lag time (1991)(266) 
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Prospective 2 year analysis of life 32 patients with No association North et al 
events preceding disease relapse IBD (1991)(267) 
Prospective I year analysis of 108 patients with No association Von 
adverse life events and disease 1131) Wietersheirn et 
relapse al (1992)(268) 
Retrospective analysis of 122 patients with Greater incidence Tocchi et al 
incidence of adverse life events in UC of life events in (1997)(269) 
preceding 12 months in patients preceding 12 
with UC and healthy controls months in patients 
with UC 
I year prospective analysis of life 60 patients with Positive association Bitton et al 
events and disease relapse uc of life events and (2003)(270) 
relapse in the 
following month 
Prospective 2 year analysis of 18 patients with Positive association Mardini et al 
depression and life events and CD of life events and (2004)(271) 
disease relapse depression with 
disease relapse 
simultaneously and 
at 8-12 weeks 
Prospective study II month 163 patients with No association Vidal (2006) 
analyses of life events and disease 11313 (272) 
relapse 
Chonic Perceived Stress 
Prospective 2 year analysis of 62 patients with Increased risk of Lcvcnstein ct al 
PSQ score and disease uc exacerbation with (2000)(273) 
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exacerbation increased PSQ 
score . 
Analysis of mucosal endoscopic 46 patients with Increased PSQ Levenstein ct al 
appearance and PSQ score asymptomatic UC score in patients (1994)(274) 
with mucosa 
abnormalities 
H. Acute Stress 
Daily Stress 
Prospective 28 days of daily 10 patients with Positive association Garrett et al 
stress with self-rated disease CD (1991)(275) 
severity 
Prospective I year analysis of II patients with Positive association Greene et al. 
stress with disease exacerbation IBD (1994)(276) 
CD Crohn's Disease, UC UC, 1131) inflammatory bowel disease, PSQ perceived stress 
questionnaire 
1.4.4.4 Adverse life events and relapse in IBD (Table 1.4) 
Most of the prospective analyses of the role of stress in 1131) are studies of the 
relationship between adverse life events and disease relapse. Probably for the reasons 
cited above, these studies have produced mixed results (Table 1.4). Two more recent 
analyses, in which meticulous attempts were made to address these methodological 
problems, both found life events to be associated with a higher risk of subsequent relapse. 
Bitton et al found the number of stressful life events in the preceding month to be a risk 
factor for relapse in aI year prospective study of sixty patients with UC (270). Similarly, 
Mardini et al found depression and life events to be predictors of relapse in a two year 
prospective study of eighteen patients with Crohn's disease (271). However, in an 
analysis of 163 patients with both types of IBD enrolled in remission, Vidal et al. found 
no association between adverse life events and the likelihood of relapse in the following 
month (272). 
70 
One possible explanation for the inconsistent findings in these studies is that 
stress affects disease activity in only certain individuals with IBD. In a study of 148 
patients with UC, Maunder et al found that disease activity correlated with measures of 
psychological distress only in p-ANCA negative individuals. In p-ANCA positive 
subjects there was no correlation (277). 
1.4.4.5 Chronic perceived stress and relapse in IBD (Table 1.3) 
It is now also recognised that an individual's stress response depends on their 
perception of the significance of the stressor, a factor which is not taken into account in a 
standard record of life events. The Perceived Stress Questionnaire (PSQ) was developed 
to overcome this limitation. In a prospective cohort study of 62 patients with UC, a score 
in the upper tertile of the PSQ over the previous two Years significantly increased the 
actuarial risk of an exacerbation and was also predictive of mucosal abnormalities in 
patients with UC who reported no symptoms (273; 274). Ninety percent of patients who 
scored in the upper tertile of the PSQ experienced a relapse during the study as compared 
with 44% in the lower tertile. In these studies a chronic state of heightened stress 
appeared important in predicting relapse. 
1.4.4.6 Acute daily stress and relapse in IBD (Table 1.4) 
Only two studies have examined whether daily stress can affect disease activity in 
IBD. In the first study involving 10 patients with CD, it was found that in certain 
individuals daily stress was strongly correlated with self-rated disease activity (275). In. 
the second, a study of II patients with IBD, a positive concurrent relationship was found 
between both daily and current monthly psychosocial stress and IBD activity (276). 
However, levels of stress in the month before were found to be inversely correlated with 
IBD activity. Both studies involved only small numbers of patients with relatively short 
periods of follow up. Therefore on the basis of this evidence it is hard to be sure whether 
daily stress pre-disposes to relapse in IBD. 
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1.4.4.7 Acute experimental stress and gastrointestinal immune and inflammatory 
function 
There have been few examinations of the effects of experimental stress on 
gastrointestinal inflammation in man. One study found that physical stress, induced by 
immersion of the hand in iced water, increased the luminal jejunal concentration of the 
mast cell mediators tryptase and histamine in healthy volunteers and even more so in 
those with food allergies (278). A second study found that repeated administration of the 
same stress over several days lead to an increase in the proportion of degranulating and 
activated mucosal mast cells seen at electron microscopy in mucosal biopsies from both 
patients with CD and UC (279). 
There is also limited anecdotal evidence that artificially induced alterations in 
neural function can affect gastrointestinal inflammation. One reported example is of a 
man whose previously refractory UC went into complete remission following a Brown- 
Sequard paralysis at the level of C5 (280). Kemler described a patient who suffered 
recurrent flares of his UC in association with spinal cord stimulation given for post- 
traumatic pain in his ann (281). Neuromodulatory drugs such as lidocaine (282), which 
decreases neuronal release of Substance P, clonidine (283) and nicotine (284) have been 
claimed for many years to have benefit in UC in clinical trials and remain potential 
therapeutic agents in IBD (285). 
1.4.4.8 Functioning of the stress axes in IBD 
Several studies have suggested that the functioning of the IIPA axis may be 
altered in patients with IBD and this may be important in relation to stress-induced 
increases in disease activity. Usually, the release of CRF within the pituitary, and hence 
the serum concentration of cortisol, is increased by inflammatory cytokines, particularly 
IL-6. As the prevailing action of cortisol is anti-inflammatory in this context it provides a 
negative feedback which reduces inflammation. However, in a study of 64 patients with 
UC, serum concentrations of cortisol were found to bear no relation to serum IL-6 levels 
or to scores of disease activity (286). 
In a second study, Straub et al examined the correlation between sympathetic 
tone, as indicated by serum levels of neuropeptide Y, and IIPA axis stimulation, as 
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measured by serum cortisol, in healthy controls and patients with IBD (168). In healthy 
volunteers, the two variables were positively correlated. However, in patients with IBD, 
there was no such correlation, with a higher level of neuropeptide Y and a lower level of 
cortisol. Although in this study the concomitant use of oral steroids may have affected 
results, the authors suggest that in patients with IBD there may be uncoupling of the 
sympathetic nervous system and HPA axis. Chronically raised levels of inflammatory 
cytokines in the blood due to active IBD may thus blunt the response of the HPA axis to 
both inflammation and acute stress, as has been found in other chronic inflammatory 
diseases. 
The function of the ANS may also be altered in patients with IBD as some authors 
have reported marked autonomic nervous hyperreflexia in patients with UC and CD 
(287). Maunder et al found an atypical reduced pattern of ANS activation in response to 
stress to be associated with reduced disease activity months later (288). 
1.4.4.9 Acute psychological stress and gastrointestinal motility and water and ion 
secretion (Fig 1.4) 
Acute psychological stress has effects on gastrointestinal motility and water and 
ion secretion. Tbus, in healthy human volunteers acute short term stress in the form of 
painful stimuli, dichotomous listening tests and stressful interviews enhanced colonic 
motility (289). Dichotomous listening tests and cold pain stress have also been shown to 
increase jejunal water and sodium and chloride ion secretion (278; 290; 291). Although 
these are non-inflammatory changes, they could contribute to stress-induced increases in 
symptornatology in patients with 11313. 
1.4.4.10 Psychological stress and pain processing 
Acute psychological stress has been shown to decrease thresholds for the 
perception of pain. Dichotomous listening tests decreased the threshold for the 
perception of pain in response to rectal distension in both patients with IBS and healthy 
volunteers (292; 293). Although this experiment has not been repeated with patients with 
IBD, if stress does lower pain thresholds in these patients it may, in part, explain how 
acute stress can worsen 1131) symptomatology. 
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The central release of Substance P (SP) from afferent neurones has been shown to 
be important in mediating stress-induced gastrointestinal hyperalgesia. The central 
administration of a SP antagonist prevented restraint stress-induced hypersensitivity to 
rectal distension in the guinea pig. However, the SP antagonist had no effect on rectal 
sensitivity in animals which had not been sensitised with restraint stress (294). 
1.4.4.11 The role of peripheral substance P (Fig 1.4) 
In addition to its central effects, the peripheral release of SP from the ENS may 
have a role in stress-induced increases in mucosal inflammation. Although there is no 
published data to show an increase in mucosal SP in response to stress, SP-containing 
neurones are found in close association with mast cells, a cell type implicated as central 
in mediating stress-induced permeability changes (see Section 1.4.5.4). SP has been 
shown to increase histamine release from mucosal mast cells in patients with IBD (190). 
Lastly, SP can act not only as a neurotransmitter but also an inflammatory cytokine in its 
own right, enhancing cytokine production and stimulating chernotaxis of inflammatory 
cells (189). It also increases the expression of leukocyte adhesion molecules on 
microvascular endothelium, and of CDI Ib on neutrophils, facilitating leukocyte adhesion 
at sites of inflammation (189). 
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1.4.5 PSYCHOLOGICAL STRESS AND GASTROINTESTINAL IMMUNE 
AND INFLAMMATORY FUNCTION IN ANIMALS 
1.4.5.1 Chronic psychological stress and animal models of IBD 
Like humans, some animals may develop bowel inflammation when 
chronically stressed. Cotton top tamarins are at increased risk of a colitis closely 
resembling UC when subjected to the chronic stress of living in captivity, with 
remission being induced by return to natural living conditions (295). Similarly, 
Siamese gibbons can also develop a fatal colitis when held in captivity (296). 
1.4.5.2 Acute psychological stress and animal models of 1111) 
As in humans, experimental models of psychological stress have been 
developed to allow the study of the role of psychological stress in animal models of 
IBD. A period of restraint stress (RS) or wrap restraint stress (WRS), where an 
animal's movements are restricted by gentle binding, is the commonest technique 
used in the rodent to simulate acute stress. This can be combined with either a cold 
environment or partial immersion in water. The water avoidance stress (WAS), 
where an animal is placed on a small platform surrounded by water, is another model 
used for acute stress. Prolonged maternal separation is used to simulate chronic stress 
and depression. A confounding factor, which requires use of appropriate control 
groups in all animal experiments, is that routine handling is inherently stressful (297). 
Experimental psychological stress appears able to contribute to both the 
initiation and reactivation of GI inflammation in animal models of colitis. Rats 
subjected to restraint stress for the four days prior to the induction of colitis by 2,4,6- 
trinitrobenzenesulfonic acid (TNBS) developed an increased mucosal inflammatory 
response (298). Restraint stress in the absence of any other co-stimuli caused a 
partial reactivation of mucosal inflammation in rats which had recovered from TNBS 
colitis six weeks previously; there was an increase in colonic mycloperoxidase, 
although there. were no inflammatory changes detectable by light microscopy (299). 
A period of restraint stress also lowered the dose of TNBS required to reactivate 
colitis in mice which had recovered from TNBS colitis eight weeks previously (300). 
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This susceptibility was transferable between mice by a population of CD4-rich 
lymphocytes taken from spleen and mesenteric lymph nodes, suggesting that stress 
induced-reactivation is dependent on the presence of key immune cells. The recipient 
mice did not develop colitis immediately, but required a lower dose of TNBS in 
combination with restraint stress to cause mucosal ulceration than did controls. Stress 
induced reactivation of colitis in healed mice also appears to be dependent on 
noradrenergic and cholinergic pathways as it can be blocked by treating the animals 
with hexamethoniurn (a nicotinic cholinergic ganglion blocking agent) or the co- 
administration of atropine (a muscarinic antagonist) and bretylium. (a noradrenergic 
ganglion blocking agent) (301). 
Chronic stress appears to render an animal with colitis more vulnerable to the 
effects of acute stress. Adult rats which underwent previous prolonged maternal 
separation and which were then subjected to a series of inescapable foot shocks, 
experienced a greater severity of DSS-induced colitis than did controls (297). This 
sensitivity to the colitis induced by DSS and acute stress, in chronically stressed mice, 
was abolished by the administration of antidepressants (302). 
1.4.5.3 Functioning of the stress axes in animal models of HID 
There have been no studies to assess the functioning of the stress axes in 
animal models with IBD. However, it has been shown that reduced HPA axis 
function renders rodents susceptible to stress-induced increases in GI inflammation. 
If, as discussed above, HPA axis function is reduced in patients with 1131) this 
-observation may be relevant to stress-induced increases in disease activity. LEW/N 
rats have a reduced CRF content of the hypothalamus and paraventricular nucleus 
compared to controls. They have a markedly decreased plasma ACTIT and 
corticosterone response to stressful stimuli, and have long been recognised as being 
more susceptible to inflammatory disorders such as the arthritis induced by intra- 
articular injections of streptococcal cell wall (303). LEW/N rats also show an 
increased susceptibility to TNBS-induced colitis, an effect which was found to be 
dependent on co-existing stress (304). Thus, although stress-naive animals developed 
a similar degree of intestinal inflammation to control rats at 7 days after TNBS 
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administration, intestinal inflammation was greater in LEWN rats than in appropriate 
control animals if they were restrained for 6 days prior to being given TNBS. 
1.4.5.4 Psychological stress and intestinal barrier function and bacterial-host 
interactions (Fig 1.4) 
Experimental stress in animals increases intestinal mucosal permeability and 
also alters bacterial-host interactions. These changes are likely to contribute to 
mucosal inflammation, and flt with the hypothesis that such inflammation is driven 
by mucosal flora (107). 
Restraint stress in rats has been shown to increase jejunal and colonic 
permeability to inert marker molecules, such as mannitol and Cr-EDTA, and to 
andgenic proteins such as horse radish peroxidase (IIRP) (305). Under normal 
conditions, HRP passes through the epithelial. cells via pinocytosis but, after chronic 
restraint stress, it also passed through the epithelial layer paracellularly. Although the 
gut mucosa appeared normal to examination under the light microscope, electron 
microscopy demonstrated increased HRP both within intracellular endosomes and in 
inter-epithelial cell tight junctions. (306) Acute stress reduced the expression of tight 
junctional proteins integral to the maintenance of GI barrier function (307). The 
effects of acute stress on pen-neability can be enhanced by the co-administration of a 
chemical iffitant. Rats subjected to foot shock stress and then given a dose of DSS 
too low to cause a colitis in isolation, show a greater increase in colonic permeability 
to EDTA than rats given stress or DSS alone (308). Again, chronic stress appears to 
enhance the effect of acute stress, since prior matemal separation augmented restraint 
stress-induced increases in permeability (309). 
The increase in permeability caused by stress appears to be dependent on 
cholinergic innervation, as it was blocked with atropine and was more marked in 
cholinesterase-deficient Wistar-Kyoto rats (310). Mast cells are also important in 
mediating permeability changes, since mast cell-deficient rats exposed to repeated 
restraint stress lost weight to a similar extent to wild-type rats but without showing 
changes in intestinal permeability (311). Restraint stress increased the histamine 
content of colonic mucosal mast cells in rats, an effect which appeared dependent on 
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both central CRF and IL-I (312). Increased colonic permeability caused by stress 
was also mimicked by the injection of peripheral CRF (306). 
In addition, it has recently been shown that bacterial-mucosal interactions are 
also affected by experimental stress in animal models. One hour sessions of water- 
avoidance stress for ten consecutive days increased the phagocytic uptake of killed 
Ecoli into follicle-associated epithelium in mice (313). Follicle-associated 
epithelium overlies Peyer's patches and contains M cells which are in close 
association with dendritic cells, the principal antigen-presenting cell of the gut. These 
changes were not found in villi-associated epithelium and did not occur in mast cell- 
deficient rats (313; 314). Prolonged neonatal separation in rats has been shown to lead 
to increased bacterial adherence and penetration into colonic epithelium compared to 
control animals (315). Further evidence that stress may increase GI uptake of bacteria 
is provided by the finding that psychological stress facilitates the translocation of 
indigenous bacteria into a host animal. Bailey et al found that both chronic restraint 
stress and repeated social disruption lead to an increase in the number of animals with 
detectable levels of bacteria in their inguinal and mesenteric lympli node compared to 
controls (316). 
Catecholamines also appear to have a role in altering bacterial adherence and 
uptake by gut mucosa. Chen et al reported that both dopamine and noradrenaline 
increased the adherence of E coli 0157 to murinc caccal mucosa (317), whilst Green 
at al found that pre-treatment of isolated porcinejejunal Peyer's patches with 
noradrenaline led to increased internalisation of Salmonella choleraesuis and Ecoli 
0157 but not of non-pathogenic E coli (318). 
It is possible that mast cells, stimulated by neurotransmitters such as CRF and 
substance P released by enteric neurones in response to stressful stimuli, increase 
bacterial adherence and uptake via the release of mast cell mediators. This in turn 
could lead to the sensitisation of T-cells and the production of IFN-y and TNF-a 
which may both initiate inflammation and cause a secondary increase in permeability. 
This theory is consistent with the recent finding that increases in intestinal 
permeability to the inert marker Cr-EDTA, in response to mixed restraint and 
acoustic stress, were dependent on the presence of T-cells and IFN-y (319). 
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Application of IFN-y to gastrointestinal epithelial cells in culture increased both 
paracellular permeability and internalization of Shigella sonnei (320). Expression of 
mRNA for TNF-a in mucosa correlates with endosomal uptake of horseradish 
peroxidase (HRP) in resected ileal mucosa mounted in Ussing chambers (321). 
1.4.5.5 Psychological stress and gastrointestinal motility and water and ion 
secretion (Fig 1.4) 
As in humans, acute stress in the form of restraint stress, loud noise, 
inescapable foot shock or water avoidance all increase colonic motility and defecation 
in the rodent (322). The mechanisms for these changes involve CRF and its receptors 
(see below) (323). 
Similar alterations in ion and water transport to those seen in humans are also 
well described in animals in response to psychological stress. Increases in GI water 
and chloride ion secretion occur in response to restraint stress in the rat (324). It is 
now recognised that, as with changes in intestinal permeability, this secretory 
response is related to both cholinergic nerves and mast cells as it was increased in 
cholinesterase-deflcient Wistar-Kyoto rats, blocked by pre-treatment with atropine 
and absent in mast-cell deflcient rats (310; 311). Restraint stress also increased 
colonic mucus secretion in ex-vivo colonic segments and in vivo as measured by 
histological goblet cell depletion (325-327). This effect could also be reproduced by 
peripheral CRF administration and inhibited by mast cell stabilisers (328). 
1.4.5.6 The role of CRIF in mediating stress-related gastrointestinal changes in 
animal models (Fig 1.4) 
CRF is a 41 amino acid neuropeptide which exerts its effects via two 
adenylate cyclase coupled receptors, CRF-R I and CRF-R2 (329).. It has a pivotal role 
in mediating the effects of stress on the gastrointestinal tract in animal models, some 
of which may relevant to stress-induced increases in 1131) activity in humans. 
Central injection of CRF in the rat induces behaviour normally seen in 
response to stressful stimuli (330). It also reproduces the motility changes usually 
seen in response to stress, with decreased gastric emptying and increased colonic 
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motility. The use of selective CRF-receptor antagonists has proven that central CRF 
increases colonic motility via stimulation of CRF-Rl and delays gastric emptying via 
stimulation of CRF-R2 (323). 
More recent evidence has also implicated a role for peripheral CRF in 
mediating stress-induced motility changes. The peripheral administration of CRF 
antagonists has been shown to abolish restraint stress-induced increases in colonic 
motility and decreases in gastric motility (331). As described above, both peripheral 
and central CRF are important in mediating stress-induced increases in 
gastrointestinal permeability. Furthermore, CRF appears to have a secondary 
peripheral action as an inflammatory cytokine. It stimulates IL-1, IL-2, and IL-6 
secretion and IL-2 receptor expression by peripheral blood mononuclear cells (332- 
334), T and B lymphocyte proliferation and enhancement of NK cytotoxicity (335). 
It exerts a mixed effect on cYtokine production by endothelial cells, with both a pro- 
inflammatory action via CRF-2 receptors, and an anti-inflammatory action via CRF- I 
receptors (336). More recent evidence for a functional role for CRF in animal models 
of GI inflammation comes from the finding that pre-treatment with a CRF antagonist 
reduced the inflammation caused by the injection of C. difficile toxin into rat terminal 
ileum (337). 
CRF levels are increased in caecal biopsies from rats with experimental colitis 
induced by the intra-mural injection of peptidoglycan-polysaccaride polymers (338). 
In the chronically inflamed caecum, abundant immunoreactive CRF was found in 
inflarnmatory cells, mesenchymal cells and myenteric plcxi; in contrast, in non- 
inflamed caecum only minimal CRF-containing cells were found. Whether CRF has 
a role in mediating stress-related gastrointestinal changes in humans with 1131) is 
unknown. However there is some evidence of a functional role for CRF in the 
pathogenesis of IBD as CRF levels are increased in lamina propria mononuclcar cells 
(LPMQ in colonic biopsies from patients with active UC (339; 340). 
1.4.5 STRESS-REDUCTION THERAPY IN IBD (Table 1.5) 
If psychological stress is indeed a pathogenic factor in IBD, then stress 
reduction therapy may have therapeutic benefit. However, despite recent advances in 
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our understanding of the relationship between psychological stress and IBD, most 
stress reduction therapy remains unformalised, and studies of its efficacy in patients 
with IBD are few. There are a wide variety of psychotherapeutic: interventions which 
could be assessed making standardisation difficult. Due to the nature of the 
intervention performing the trials in a blinded controlled manner is also difficult and 
as already discussed, with placebo rates of up to 40% (259; 260), genuine therapeutic 
effects can be hard to detect. 
The results of the few trials which have been reported are mixed (Table 1.5). 
Milne et al found that a stress management course in addition to conventional 
treatment significantly reduced the CDAI score over the follow up period of one year 
in a randomized trial of 80 patients with CD (341). However, the groups were not 
equivalent in CDAI score pre-treatment, with more patients in the non-treatmcnt 
group having a CDAI score <150 at baseline. In another study, self-guided stress 
management was found to reduce the symptoms reported by a group of 15 patients 
with CD compared to those given conventional treatment. However the symptom 
scores used were not validated scores of disease activity (342). 
Schwarz and Blanchard found that combined complementary medical 
treatment, including cognitive behavioural therapy, muscle relaxation techniques and 
patient education was successful in reducing stress but did not improve 1131) 
symptoms (343). However, the treatment groups were not comparable, with 70% of 
patients in the treatment group having CD compared with only 30% in the non- 
treatment group. In a well-designed study, Jantschek et al failed to find that the 
addition of short-term psychodynamic therapy and relaxation training led to a 
reduction in the number, duration or severity of relapses in a study of 108 patients 
with CD (344). Langhorst found that a comprehensive life-style modification 
program given to 60 patients with quiescent UC lead to an improvement in quality of 
life scores at 3 months but had no effect on disease activity (345). Further work is 
required before a view can be taken as to whether stress reduction therapy might have 
therapeutic benefit in IBD. 
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Table 1.5 Summary of trials of stress reduction therapy in IBD 
Intervention Patients Outcome Reference 
Cognitive behavioural 11 patients No improvement in 1131) Schwarz (343) 
therapy, muscle relaxation with IBD symptoms 
Psychotherapy 108 patients No reduction in number or Jantschek (344) 
with CD severity of relapses over 
two years 
Stress management 80 patients Reduced CDAI over next Milne (341) 
programme with CD year 
Stress management 45 patients Reduced 1131) symptoms Garcia-Vcga 
programme with CD over next year (346) 
Lifestyle modification 60 patients No effect on disease Langhorst (345) 
including stress reduction with UC activity 
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1.5 HYPNOSIS AND HYPNOTHERAPY 
1.5.1 TRANCE (347) 
T'he attainment of a "trance state" is central to the practice of hypnosis. 
However, despite hypnosis's long history, the trance state remains poorly defined. In 
essence it refers to a state of mind in which the individual is more receptive to the 
suggestions of the therapist. A trance state can also be described as a waking state in 
which the person's attention is focused away from his or her surroundings and 
absorbed by inner experiences such as feelings, cognitions and imagery. In this way 
the hypnotic trance is similar to the natural state of daydreaming or meditation but the 
subject's thoughts can be guided by the therapist. It has also been proposed that in 
this state the conscious mind can be bypassed and suggestions placed directly in the 
unconscious. In essence, the trance state is a receptive state in which to place positive 
suggestions and perform psychotherapy. 
1.5.2 FURTHER PROPE, RTIES OF THE TRANCE STATE 
Further properties of trance include the following which, although not 
guaranteeing trance, nor being exclusive to trance, do have an increased probability of 
occurrence in the trance state. 
1. Temporal distortion. Alteration in the experience of the passage of time with 
more often a loss of recollected time 
2. Some amnesia for events which clearly occurred as the subject responded at 
the time. This property is similar to that of "highway trance" where the 
subject has no memory of some part of the journey but was clearly awake at 
the time. 
3. Attenuation and increased tolerance to ongoing discomfort or pain. 
4. With regular practice an alleviation of the effects of stress. 
1.5.3 SUGGESTION AND IIYPNOTIIERAPY 
Suggestion is, in conjunction with trance, the other key component of 
hypnosis and hypnotherapy. A suggestion involves a communication conveyed 
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verbally by the hypnotherapist that directs the subject's imagination in such a way as 
to elicit intended alterations in sensations, perceptions, feelings, thoughts and 
behaviour. A post-hypnotic suggestion is intended to cause a delayed rather than 
immediate response, usually after the hypnosis session has been concluded: "You will 
feel increasingly confident over the next few days and weeks. " They are the 
commonest form of suggestion used in hypnosis as the desired goal of therapy is 
usually a long term change in feelings or behaviour. 
1.5.4 HYPNOSIS AND THE IMMUNE SYSTEM 
There have been relatively few investigations of the effects of hypnosis on the 
immune system. The majority of studies have examined whether hypnothcrapy can 
ameliorate the immune changes induced by chronic stress. Naito et al sampled blood 
ftom 48 medical students during a non-stressed period and also immediately prior to 
medical exams (348). In the time period between the two samples being taken the 
students were randomised to one of three groups taught either self-hypnosis, Johrei (a 
Japanese relaxation technique) or a control relaxation procedure. In the control group 
it was found that NK cell count and NK cell activity decreased whilst CD3(+)CD4(+) 
cells increased prior to exams. However, in the hypnosis group NK cell levels and 
CD3(+)CD4(+) cell levels were maintained. Similarly Gruzelier ct al found reduced 
levels of NK cells and CD8(+) lymphocytes in blood samples taken from students 
prior to exams (349). As before, in a group of students who had been taught and 
practised self -hypnosis these changes were reduced. 'In contrast to Naito et al, 
Keicolt-Glaser et al reported reduced levels of CD3(+) and CD4(+) leukocytes in 
blood samples taken from medical students prior to examinations (350). However, as 
with the other studies discussed, these changes were abolished in a group of students 
who had been taught self-hypnosis. 
Fewer studies have examined the direct effects of hypnotherapy on the 
immune system. Zachariae et al found that hypnosis, both with and without 
suggestions to enhance immune function, lead to a brief reduction in NK-cell activity 
and lymphocyte proliferative responses to mitogens (351). However, they did not 
observe any sustained immune changes in either group. Wood et al reported that the 
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proportion of T-cells expressing IFN-y and IL, 2 was reduced in blood samples taken 
from seven highly hypnotizable healthy volunteers immediately after hypnosis (352). 
The apparent contradiction in the effects of hypnosis on NK cells in the 
studies discussed above may well be due to the differing effects seen with single and 
repeated sessions. In this regard it is similar to the effects of stress on NK cells. 
Medical exams represent a chronic stress exerted over several weeks. This classically 
leads to a fall in NK cell numbers which is opposed by repeated sessions of self- 
hypnosis. Acute stress usually causes an acute increase in NK cells, whereas a single 
session of hypnotherapy has the opposite effect. 
1.5.5 IIYPNOTIIERAPY IN PSYCHOSOMATIC DISEASE 
A disease with a psychosomatic component is one in which the physical 
symptoms can be induced or worsened by psychological factors including stress. 
Hypnosis and other psychological treatments, such as cognitive behavioural therapy, 
have been shown to be effective in many of these disorders. 
Friedman et al found hypnosis to be an effective treatment for essential 
hypertension in a randomised study comparing hypnotherapy, cognitive behavioural 
therapy and a control procedure (353). Hypnosis has been used with positive results 
to treat the dermatological complaints of eczema, psoriasis and urticaria (354; 355). 
There is some evidence to suggest that hypnosis may be effective in asthma, 
an inflammatory disease with a psychosomatic component. Maher-Loughann et al 
found hypnosis to be superior to breathing exercises in the treatment of asthma and 
that the maximum improvement occurred between sessions 7 and 12 of a weekly 
treatment regime (356). Ewer et al found a 75% improvement in the degree of 
bronchial hyper-responsiveness to a standardised metacholine challenge test in 12 
highly hypnotisable adults with moderate asthma after a six week course of 
hypnotherapy (357). Langewitz et al reported significant improvements in visual 
analogue scale (VAS) scores of symptoms and well-being in a group of 79 patients 
with hay-fever taught either self-hypnosis or a control procedure (358). 
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1.5.6 HYPNOSIS IN GASTROINTESTINAL DISEASE 
There is a substantial volume of good scientific evidence to support the use of 
hypnotherapy in functional gastrointestinal disease. 
In 1984 Whorwell et al published a small but well-designed placebo- 
controlled trial of hypnosis as a treatment of irritable bowel syndrome (359). 30 
patients with severe refractory irritable bowel syndrome (IBS) were randomised to 
receive either seven sessions of hypnotherapy or psychotherapy and placebo pills. 
Hypnosis, in contrast to placebo, substantially improved the IBS symptoms of all 
patients. Since this first study the same group have published several other larger 
studies with longer follow-up (360). While the 100% response rate of the first trial 
has not been replicated, all the studies have shown a significant improvement in the 
hypnotherapy-treated group. In a prospective study of 204 patients with refractory 
IBS treated with 12 sessions of hypnotherapy over a3 month period, there was an 
initial improvement rate of 71% and this was maintained in 81% of these patients at 5 
years (58% improvement rate overall) (360). Although, in the initial phase, ' 
hypnotherapy is labour intensive, self-hypnosis is easily taught although its practice 
requires patient compliance. Whilst Whorwell's group remains the best established in 
the use of hypnotherapy in GI disease, several other groups both from within and 
outside the UK have also demonstrated the benefit of hypnothcrapy in IBS. 
The mechanism or mechanisms by which hypnothcrapy improves the 
symptoms of IBS remain largely unknown. Hypnosis does seem to have effects on 
GI physiology which may have relevance. The hypnotic state increases oro-caecal 
transit time and reduces colonic motility (361). Ilypnotherapy has also been Shown to 
increase pain thresholds to rectal distension in patients with IBS who have 
abnormally low baseline pain thresholds (362). However, it is equally possible that 
the mechanism may involve cognitive changes in perception of the disease and 
symptoms. 
Whorwell's group have extended the use of hypnotherapy to the treatment of 
upper GI tract disease. In a study of 126 patients with functional dyspepsia, 16 
sessions of weekly hypnotherapy lead to an improvement in short-terrn symptom 
scores in 59% of patients compared to 41% in the placebo group (363). Furthermore 
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this continued to improve after the treatment to an average of 73% at the one year 
follow-up point. A reduced need for alternative medication and an improved quality 
of life were also noted in the hypnosis treatment group. In an earlier study the same 
group assessed the efficacy of hypnotherapy in preventing relapse of duodenal 
ulceration (364). Thirty patients were successfully treated for a duodenal ulcer with 
ranitidine and then randomised to a further ten weeks of either drug treatment and 
hypnotherapy, or drug treatment alone. At one year, 8 of the hypnotherapy group 
(5 1 %) and 15 (100%) of the control group had relapsed. 
1.5.7 HYPNOSIS IN INFLAMMATORY BOWEL DISEASE 
There are several anecdotal reports from patients to suggest that hypnotherapy 
may have benefit in IBD. However, there has been only one non-blinded study; in 
this, a trend to improvement in the IBDQ score of 12 patients with active Crohn's 
disease and UC given six weeks of hypnotherapy did not reach statistical significance 
(p=0.08) (365). 
1.6 SUMMARY 
The aetiology of IBD is complex and represents an interaction of multiple 
genetic and environmental factors. Although there has been significant recent 
progress in identifying the genetic factors important in the actiology of IBD, the 
environmental factors remain incompletely understood. 
Although studies of the relationship between adverse life events and disease 
relapse in IBD remain inconclusive, with the development of the concept of the brain- 
gut axis there is an increasing awareness that psychological factors can affect al 
inflam madon. This is strongly supported by data from animal models of colitis which 
suggest that both acute and chronic stress can contribute to the development and 
relapse of GI inflammation. Alterations in intestinal permeability and changes in 
mucosal-bacterial interactions may both be important in effecting these changes and 
which also seem dependent on mast cells and corticotrophin releasing factor. Studies 
from humans with 1131) hint that alterations in the balance between the IIPA and ANS 
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may also be important. However, there is little data on the effects of acute stress in 
humans with 1131). 
Currently, analyses of the role of stress reduction therapy in 1131) are limited 
and have produced conflicting results. Hypnotherapy has been shown to be effective 
in functional gut disease and reported anecdotally as beneficial in IBD. The 
mechanisms by which hypnosis might act in 1131) have not been investigated. 
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CHAPTER 2 
HYPOTHESIS AND AIMS 
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2.1 INTRODUCTION 
Ulcerative Colitis is a chronic inflammatory condition of the bowel of 
unknown aetiology. It is characterised by periods of remission and relapse. As 
discussed in chapter 1, there is increasing evidence that both adverse life-events and 
chronic psychological stress and can increase the incidence of relapse in 11313 and in 
particular UC. T'here is also supporting evidence from animal models of colitis that 
acute stress can contribute to both the initiation and reactivation of GI inflammation. 
Stress is thought to act through as yet incompletely defined neuroirnmunomodulatory 
pathways. There have been few studies of the effects of acute psychological stress on 
GI inflammation in patients with 11313. 
There have been only a limited number of studies examining the therapeutic 
potential of stress-reduction therapy in 1131). Hypnotherapy is a formaliscd treatment 
approach using the induction of trance to treat specific problems with relaxation, 
suggestion and imagery. It is an effective treatment in irritable bowel ' syndrome, non- 
ulcer dyspepsia and relapsing duodenal ulcer disease and has been reported 
anecdotally to be of benefit in 1131). The effects of hypnotherapy in patients with 1131) 
and the mechanisms by which it might act have not yet been described. 
2.2 HYPOTHESES 
Two main hypotheses are tested in this thesis: 
1. Inflammation in quiescent UC can be increased by acute psychological stress 
2. Inflammation in active UC can be reduced by the relaxation achieved through 
hypnosis 
There are two other subsidiary hypotheses tested in this thesis: 
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1. An individual's autonomic and inflammatory response to acute stress is 
affected by levels of chronic stress 
2. The response of individuals with UC to acute psychological stress and 
hypnosis is different to that of healthy volunteers 
2.3 AIMS 
1. To investigate the effects of acute psychological stress on various measures of 
systemic inflammation and physiology in healthy volunteers and systemic and 
rectal mucosal inflammation and physiology in patients with quiescent UC 
1 2. To investigate the effects of a single session of hypnotherapy on the on the 
same measures in healthy volunteers and in patients with active UC 
3. To compare the effects of stress and hypnosis with those of a control 
procedure 
4. To assess the relationship between chronic stress and the response to acute 
stress and hypnosis in both healthy volunteers and patients with UC 
2.4 METHODS (Chapter 3) 
The measures used to assess the responses to stress and hypnosis had either 
been previously implicated in the response to stress or hypnosis (histamine (278), 
substance P (SP) (190), NK cells (219; 348; 349), rectal mucosal blood now (366)), 
are thought to play a pathogenic role in 1131) (ILA3 (367), TNF-a (368)) or appear to 
be involved in both the stress response and 1131) (IL-6 (369), platelet activation (141), 
platelet-leukopyte aggregate formation (143), reactive oxygen metabolite production 
(181)). 
ASSESSMENT OF SYSTEMIC AND RECTAL PHYSIOLOGICAL 
RESPONSE 
The systemic and rectal physiological response to stress, hypnotherapy and the 
control procedure was assessed by the methods described below 
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1. Systemic autonomic response. Pulse and blood pressure were measured 
before, at 15 minute intervals during and after each session of stress, 
hypnotherapy or control procedure 
2. Rectal autonomic response. Rectal mucosal blood flow was recorded in vivo 
using laser doppler flowmetry before and after stress, hypnosis or control 
protocols. 
ASSESSMENT OF SYSTEMIC INFLAMMATORY RESPONSE 
The following systemic inflammatory measures were tested before and after 
psychological stress, hypnosis and control protocol: 
1. Serum cytokines. Concentrations of the inflammatory cytokincs 11,6 and IL- 
13 were measured by ELISA 
2. Whole blood cytok-ine production in vitro. After incubation of whole blood for 
24 hours with lipopolysacharide, serum TNF-a and IL-6 concentrations were 
measured by ELISA. 
3. Total leuk-ocyte count. The circulating total leucoyte count was assessed using 
a standard automated coulter counter. 
4. Natural Killer (NK) cell numbers. Circulating NK cell numbers, as a 
percentage of leukocytes in peripheral venous blood samples, were measured 
using flow cytometry. 
5. Platelet activation. Platelet activation was assessed in periphcral blood 
samples by measuring the percentage of platelets expressing p-selectin using 
flow cytometry. 
6. Platelet-leuk-ocyte aggregateformation. PLA fonnation in peripheral blood 
was assessed using flow cytometry. 
ASSESSMENT OF RECTAL MUCOSAL INFLAMMATORY REPSONSE 
The following measures of rectal mucosal inflammation were tested before and after 
psychological stress, hypnosis and the control procedure: 
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1. Release of cytokines and other inflammatory mediators by rectal mucosa. A 
piece of filter paper was placed on the rectal mucosa and allowed to adsorb 
peri-mucosal fluid. The filter paper was then incubated in buffer for 24 hours. 
Cytokine (TNF-a, IL, 13), mast cell mediator (histamine) and neurotransmitter 
(Substance P) concentrations were then measured by ELISA. 
2. Production of reactive oxygen metabolites. Rectal biopsies were analysed for 
their production of reactive oxygen metabolites in vitro by incubating them 
with luminol and measuring chemiluminescence. 
3. Histology of rectal mucosal biopsies. Conventional liaemotoxalin and eosin 
histological staining was performed on rectal biopsies and inflammation 
scored by a blinded histopathologist. 
4. Mast cell numbers and degranulation. Immunofluorescence was performed on 
snap frozen rectal biopsies using antibodies to the mast cell mediator tryptase. 
The number and percentage of mast cells degranulating was scored by a 
blinded histopathologist. 
5. Mucosa-associated bacteria. Fluorescent in-situ hybridisation (FISII) studies 
were performed on snap frozen rectal biopsies. The numbers of Ecoli and 
total bacteria adherent to mucosa and in the lamina propria were scored by a 
blinded histopathologist. 
ASSESSMENT OF CHRONIC STRESS LEVELS 
To assess the relationship between the response to acute stress, hypnotherapy or the 
control procedure and chronic stress levels, subjects completed several well-validated 
psychometric tests of chronic stress: the Hospital Anxiety and Depression Score 
(HADS), the State-Trait Anxiety Inventory (STAXI), the Perceived Stress 
Questionnaire (PSQ) and the Bradford Somatic Inventory (BSI). 
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CHAPTER 3 
PATIENTS AND METHODS 
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3.1 PATIENTS AND HEALTHY VOLUNTEERS 
Patients with inactive and active UC were recruited from the outpatient clinics 
at the Royal London Hospital. Healthy volunteers comprised students and staff from 
the Royal London Hospital and Queen Mary's School of Medicine and Dentistry. As 
described in Chapter 2, exam-related stress has been shown to alter the immune 
response of medical students to experimental stress protocols. The medical students 
recruited were not undertaking any examinations at the time of their participation in 
the study. 
3.2 ETHICS 
Ethical approval for these studies was granted by the North-East London 
Strategic Health Authority Ethics Committee. Each patient gave written infon-ned 
consent before participation. 
3.3 EXPERIMENTAL PROTOCOL 
The stress, hypnotherapy and control sessions followed the same general 
experimental protocol. An overview of the general prot 
' 
ocol will be given first, 
followed by a separate more detailed discussion of the stress, hypnosis and control 
protocol. Equipment and reagents are listed separately for each section. All 
equipment and reagents were from Sigma-Aldrich UK (Gillingham, UK) unless 
otherwise stated. 
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3.3.1 OVERVIEW OF STRESS, HYPNOTHERAPY AND CONTROL 
SESSIONS 
Each protocol involved a 50 minute session of stress, hypnotherapy or control 
procedure, preceded by psychometric questionnaires, a baseline sigmoidoscopy and 
blood test, and followed by a second sigmoidoscopy and a further two blood tests 
(Figure 3.1). 
Timing and preparation 
In order to avoid the potential influence of diurnal variation due to changes in 
endogenous cortisol production, the stress, hypnothcrapy and control protocols were 
all performed between 9arn and 12 noon. As caffeine and nicotine are stimulants 
which can alter the stress response, patients were asked to have a light breakfast but 
to abstain from coffee, tea or cigarettes on the morning of the test. 
Previous work has shown that rectal blood flow varies in pre-menopausal 
females with the menstrual cycle. Rectal blood flow is raised and much more 
variable in the luteal phase of the cycle. Therefore in pre-menopausal female subjects 
measurements of rectal blood flow were performcd only during the follicular phase of 
their menstrual cycle. (370) 
Assessment of clinical activity (Table 3.1) 
Disease activity in subjects with UC was assessed using the simple clinical 
disease activity index (SCCAI) (262). This is a simple rive-point questionnaire which 
has been validated for use in assessing disease activity in UC. Answers to each 
question are given a score and scores are added to give an overall total. A total score 
of greater than three was taken as indicative of active disease. 
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Table 3.1. ' The Simple Clinical Colitis Activity Index (262) 
Symptom Score 
Bowel Frequency (day) 
1-3 0 
4-6 1 
7-9 2 
>9 3 
Bowel frequency (night) 
1-3 1 
4-6 2 
Urgency of defacation 
Hurry I 
Immediately 2 
Incontinence 3 
Blood in stool 
Trace I 
Occasionally frank 2 
Usually frank 3 
General well being 
Very well .0 
Slightly below par I 
Poor 2 
Very poor 3 
Terrible 4 
Extracolonic features I per manifestation 
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Psychometric Questionnaires 
On arrival, patients completed several psychometric tests: the Hospital 
Anxiety Depression Score (HADS), (371) the State-Trait Anxiety Index 
(STAXI), (372) the Perceived Stress Questionnaire (PSQ) (see Appendix 1), (373) and 
the Bradford Somatic inventory (BSI)(374) (see appendix I and Section 3.3.5 for 
further details). 
10 minute period of acclimatisation 
The patients were then asked to lie on an examination couch in a quiet room 
and all experiments were performed thereafter in this position. Subjects were first 
given 10 minutes, without disturbance, to acclimatise to their surroundings. 
Baseline Visual Analogue scale 
Subjects undergoing the stress or control sessions were asked to record on a 
10 point visual analogue scale (0 very relaxed, 10 very stressed) how they felt at that 
time. This was not part of protocol for subjects undergoing the hypnotherapy session 
as depth perception was used instead to assess the effectiveness of this procedure. 
Baseline Pulse and blood pressure 
Following the period of acclimatisation a baseline blood pressure (13P) and 
pulse reading was taken using a Dynamap blood pressure monitor. 
Baseline blood test 
An initial2,0 ml. blood sample was then taken from the antecubital vein using 
an 18G needle. 6ml of blood was transferred io an empty vacutainer for later use in 
the assessment of serum cytokine levels. 6ml was transferred to a tube containing 
lithium heparin for culture with LPS and 2ml to a vacutainer containing potassium 
ethylenediaminetetraacetic acid (KEDTA) for measurement of total leukocyte count. 
Finally, 4ml was transferred to a vacutainer containing KEDTA, and then a second 
vacutainer containing citrate, theophylline, adenosine, dipyridamole (CTAD). The 
KEDTA/CTAD sample was stored on ice as previous work has shown minimal ex- 
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vivo activation of platelets and minimal platelet-leukocyte aggregate formation in 
blood anti-coagulated with this combination and stored at 2-8"C. (143; 375) (The 
CTAD tubes were stored in light-protected boxes and removed immediately before 
use. ) 
Baseline Sigrnoidoscopy 
In the patients with UC, a rigid sigmoidoscopy was then performed and 
mucosal. appearance assessed using Baron's score (Table 3.2) (376). A score of 
greater than I was taken as indicating active disease. Rectal Mucosal Blood flow was 
measured using a MoorLAB laser Doppler flowmetcr and an MP6a endoscopic probe 
(see section 3.3.13). (370) After this, a sample of perimucosal fluid was collected 
using the filter paper technique for later assessment of mediator. and cytokine levels 
(see section 3.3.10). (377) Finally, a rectal biopsy was taken and placed in lml of pre- 
oxygenated Tyrode's solution for measurement of reactive oxygen metabolite (ROM) 
production (see section 3.3.11) (181) and conventional histology (378) (see section 
3.3.12) and/or in liquid nitrogen for assessment of mast cell degranulation by 
immunohistochernistry (see section 3.3.14) and mucosa associated bacteria by FISH 
(see section 3.3.15). 
Table 3.2 Baron's score of mucosal appearance in ulcerative colitis (376) 
Score Mucosal Appearance 
0 Nonnal 
Loss of vascular pattern (oedema) but no 
bleeding 
2 Friable, bleeding to light touch 
3 Ulcerated and or spontaneously 
hacmorrhagic 
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Stress, hypnotherapy and control protocol 
For details of stress, hypnotherapy and control sessions see sections 3.3.2, 
3.3.3 and 3.3.4 respectively. Throughout each of the 50 minute sessions a pulse and 
blood pressure reading were taken every 15 minutes. 
Immediate post-protocol blood test 
Immediately after completion of the test, a second 20ml blood sample was 
taken and processed like the first blood sample. 
Post-protocol sigmoidoscopy 
A second sigmoidoscopy was then performed with assessment of rectal 
mucosal blood flow, collection of pen-mucosal fluid and rectal biopsy as before. 
30 minute post-protocol blood test 
Thirty minutes after the completion of the test a third 20ml blood sample was 
taken and processed like the first two samples. 
Post-protocol visual analogue scale 
Subjects who had undergone the stress or control protocols were asked to 
mark once more on the same scale the maximum stress they had fclt during the stress 
or control session. 
Recovery pulse and blood pressure reading 
A final recovery pulse and BP reading was taken. 
Healthy volunteers underwent the same stress and control protocols as patients 
with UC except that rigid sigmoidoscopy together with assessment of rectal mucosal 
blood flow, collection of peri-mucosal fluid and rectal biopsy was not performed. The 
reason for this was that we believed that requesting healthy volunteers to undergo 
I 
rigid sigmoidoscopy with rectal biopsy twice would have reduced volunteer 
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recruitment and prejudiced ethical approval for the study. We also felt that, whilst 
patients with long standing UC, many of whom undergo such examination relatively 
regularly, do not find rigid sigmoidoscopy stressful, healthy volunteers would. 
Inclusion of this procedure could therefore have increased the stress induced by both 
the control and stress protocols in healthy volunteers compared to patients with UC, 
limiting the validity of comparisons between groups. 
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3.3.2 STRESS PROTOCOL 
Equipment 
IQ tests from Measure your own IQ. (379) 
2 portable CD players with removal of one earpiece from each set of headphones 
(Dixon's Superstore, Mile End, London, UK) 
Dynamap blood pressure machine (Critikon, Florida, USA) 
Methods 
As described in Chapter 1, simulating the effects of real-life stress with an acute 
experimental stress test is extremely difficult. However, several techniques have 
been developed and used previously in both psychological and gastroenterological 
research which seem capable of consistently inducing mild, acute, psychological 
stress. It has been repeatedly demonstrated that these techniques are capable of 
inducing both a cardiovascular response, with a rise in pulse and blood pressure and 
also an immune response. As described in chapter 1, leucoyte count and distribution, 
cytokine production by whole blood, platelet activation and platelet-leucocyte 
aggregate fon-nation have all been found to be altered in humans by these various 
methods. There is no data to suggest that one technique produces a different 
physiological or immune response to another. Nor is there any data to demonstrate the 
level of stress which must be induced to cause an immune response. Therefore an 
assumption had to be made that if a stress protocol was capable of inducing a 
consistent cardiovascular response it was also likely that it would be capable of 
inducing an immune response. 
Clearly the stress induced by these studies is by its nature artificial and therefore 
extremely difficult to comare with the stress of real life. However, in one study the 
effects of one of these techniques, the dichotomous listening test, was found to have 
similar stress-induced effects on GI motility to the real-life stress of driving in 
London traffic for several hours (221). 
The experimental techniques developed to incuce, stress in an experimental 
situation include: 
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1. Dichotomous listening tests 
Ibis technique has been used in several studies in the field of 
gastroenterology to examine the effects of psychological stress on GI 
physiology. Several variations of the technique have been used. 
L Conflicting musical inputs - In perhaps the simplest version 
contrasting types of music are played into each of the subject's ears. Folk and 
rock music are the commonest genres of music used. (380; 381) Subjects are 
asked to concentrate on one of the auditory inputs. 
ii. Spoken word dichotomous listening test - In a second version 
an extra requirement for mental concentration is added. The subject is played 
two spoken word inputs into either ear. They are asked to switch their focus 
from one input to the other at the sound of a bell which is rung at random. 
They are asked to repeat out loud every third word. (221; 382) 
iii. Auditory delay dichotomous listening test -A more complex 
technique involves reading aloud from a text whilst the subject's own voice is 
replayed into their ears after an added time delay. The time delay can be 
varied but is usually approximately O. Ims. This usually causes the subject to 
stutter in their reading. Additional pressure is exerted by informing the subject 
before commencing the test that they should stop as infrequently as possible. 
Each time a pause does occur the investiiator reminds the subject to begin 
once more as quickly as possible. (221) 
2. Trier Social Stress Test (TSST) 
The TSST has been used widely in the field of psychology for 
investigating 
the effects of psychological stress. The subject is requested to prepare and 
give a short oral presentation. The presentation is usually based around an 
imaginary stressful situation such as making a defence in a court case for a 
speeding fine. The number of presentations can be varied depending on the 
length of test required. The presence of an audience is vital to increase the 
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pressure. Ile audience is asked to give no positive feedback but to appear 
critical instead. (220; 223; 224) 
3. Mental arithmetic tests 
Subjects can be asked to perform difficult mental arithmetic as a test of 
mental concentration. (137; 222) The length and difficulty of the test can be 
varied as required. It can be performed in front of an audience who can be 
asked to give critical feedback. Alternatively an intrusive sound such as a 
buzzer can be added each time an incorrect answer is given. Auditory 
distraction can be added in the form of a simple dichotomous listening test. 
4. Stroop word colour interference test 
The Stroop colour word interference involves identifying the meaning of a 
colour word when it is written in ink of a different colour. For example, 
identifying the meaning of the word blue when it is written in a red ink. (225) 
The subject can be asked to give each answer in time to a metronome, limiting 
the time available and increasing stress. 
5. Immersion of the hand in iced water 
This is a well accepted procedure to induce a degree of physical 
discomfort and hence a stress response (279). However, the procedure cannot 
be sustained for 50 minutes due to the level of discomfort. It also represents a 
physical rather than psychological stress. 
It is possible to identify the following common features of these stress tests: 
1. A requirement for mental concentration 
2. Often there is an element of multi-tasking 
3. Critical feedback 
4. Time pressure 
5. Additional auditory distraction 
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Development of the stress protocol 
For the purposes of our experimental protocol the stress test was required to fulfil 
the following requirements: 
1. The stress test should cause an autonomic response with an increase in pulse 
rate and blood pressure (and therefore also assumed to be capable of inducing 
an immune response) 
2. The stress test should be subjectively stressful as rated on a visual analogue 
tcn point scalc 
3. The stress test should exert a sustained effect over 50 minutes. (This length of 
time was thought to be the optimum for a session of hypnotherapy. Thus by 
ensuring a stress test of the same time period the stress and hypnotherapy 
protocols were similar. ) 
Two volunteers performed several of the different stress tests. They rated their 
subjective experience of the test on a 10 point visual analogue scale and had their 
pulse and blood pressure measured every fifteen minutes. They also gave subjective 
general feedback as to their experience: 
1 Dichotomous listening test 
a. Conflicting musical inputs - Subjects did not find a simple 
dichotomous listening test, where different types of music arc played 
in either ear, subjectively stressful. After the initial sensation they 
rapidly adjusted to the test and were able to block out the conflicting 
sounds. There were also no changes in pulse or blood pressure. I'llis 
test was also not felt to be sustainable for 50 minutes. 
b. Spoken word dichotomous listening test - Switching attention between 
different spoken inputs and repeating aloud the third word was felt 
subjectively to be stressful initially. However, it was impossible for 
the investigator to assess whether the correct word was being given as 
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the auditory inputs were given via headphones. The subjects also lost 
interest long before 50 minutes. 
c. Auditory delay dichotomous listening test - Although initially rated as 
stressful, subjects were rapidly able to adjust to this form of auditory 
feedback. The test was therefore felt to be unsustainable for fifty 
minutes. 
2 Mental arithmetic tests - Subjects found the performance of mental arithmetic 
stressful. However there was no standardisation as to the difficulty of the test 
or the amount of time which should be allowed for the subject to complete the 
test. 
3 The Trier Social Stress Test was unsuitable for this protocol as it required the 
presence of an audience. 
4 The Stroop Colour Word interference test might have been suitable but the 
software for this test is restricted. 
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Final Stress Test Protocol 
It was felt that the best approach lay in modifying the mental arithmetic test 
and combining this with added auditory distraction of conflicting types of music 
being played simultaneously in either ear. 
After discussion, it was decided that an IQ test might be a suitable test 
requiring mental concentration. IQ tests have the advantage of having been 
standardised to the population. They are supposed to be of a level of difficulty which 
should allow all to attempt the test. The time taken to complete the IQ test has also 
been standardised. By giving the subjects less than the recommended time to 
complete the test, it was possible to make completing the test very difficult thereby 
increasing the stress level. 
Final Stress Test Protocol 
1. Prior to the test the patient was informed that they would be performing a test 
which would measure intelligence and its relationship to stress and UC. 
Subjects were told that it was important that they completed the test to the best 
of their ability and a particular emphasis was placed on the importance of 
completing the test. 
2. The test was begun and the volume of the two CD players set at a level 
deemed to be sufficiently loud to disrupt concentration. 
3. After 5 minutes the test was stopped temporarily. Ile first questions were 
worked through with the subject and the correct answers given. This ensured 
that those subjects who had no prior experience of an IQ test could see the 
type of thought process required to answer the questions. It also ensured that 
the subjects were aware that there were correct answers to each of the 
questions. (One subject stated that he thought that there might be no correct 
answers to any of the questions and that the whole test was a "trick". ) As all 
subjects gave at least one incorrect answer in the pilot run this also provided 
an opportunity for negative feedback. 
4. The test was then re-started. 
109 
5. After 15 minutes the first pulse and blood pressure reading was taken. 
6. After 25 minutes the subjects were informed that half of the allotted time had 
passed and that they should be half way through the test. In all cases the 
subjects were still on the first IQ test and so were encouraged to increase their 
speed in order to complete the test. 
7. After 30 minutes a second pulse and blood pressure reading was taken 
8. At 35 minutes subjects were informed that there were only 15 minutes left and 
again encouraged to increase their speed of answer in order to complete the 
test. 
9. At 45 minutes subjects were infon-ned that there were only five minutes 
remaining to complete the test. A third pulse and blood pressure reading was 
also taken. 
10. At 50 minutes the test was concluded. 
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3.3.3 HYPNOTHERAPY PROTOCOL (SEE APPENDIX Il FOR DETAILED 
DESCRIPTION OF HYPNOTHERAPY SESSION) 
Equipment 
Dynamap blood pressure monitor (Critikon, Tampa, Florida, USA) 
Methods 
Subjects underwent a 50 minute session of hypnotherapy focussed on 
achieving general relaxation and relieving specific GI symptoms. All sessions were 
performed by Dr D Jenkins, a medically qualified hypnotherapist and ex-president of 
the Medical Society of Hypnosis. Prior to the hypnotherapy session, a 20 minute 
interview was conducted to create rapport between subject and therapist and to 
provide information on which to base the session. Speigel's score of hypnotisability 
was also measured for each subject prior to beginning the hypnotherapy session 
(383). Trance was induced using a standard relaxation induction and deepening 
techniques. Hypnotherapy sessions combined both stress reduction and modification 
of their concept of inflammation in UC using visualisation. 
Throughout the hypnotherapy session subjective depth was assessed every 15 
minutes by asking the patient to rate on a scale of 0 to 10 (0 no trance, 10 very deep) 
how deep they felt themselves to be at that time. Pulse and blood pressure were 
recorded every 15 min during the session. After the session all subjects were 
questioned as to whether they had experienced time distortion. 
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3.3.4 CONTROL PROTOCOL 
Equipment 
CD Walkman (Dixon's superstore, Mile End, London, UK) 
Dynamap blood pressure machine (Critikon, Florida, USA) 
Methods 
Subjects were asked to listen to relaxing music of their choice for 50 minutes. 
Subjects were offered a choice of the following or allowed to listen to their own 
choice of relaxing music. 
1. Brahms - Piano concerto no 2. 
2. The Carpenters - Greatest flits 
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3.3.5 PSYCHOMETRIC QUESTIONNAIRES (SEE APPENDIX 1) 
Equipment 
Hospital Anxiety Depression Scale (HADS) (384) 
State Trait Anxiety Inventory (STAI) (385) 
Perceived Stress Questionnaire (PSQ) (373) 
Bradford Somatic Inventory was used by kind permission of Dr. D. Mumford, Dept 
of Psychiatry, University of Bristol, UK (374) 
Methods 
As described, subjects were asked to complete four commonly used 
psychometric questionnaires prior to beginning the experimental protocol. These four 
questionnaires are designed to measure stress over various periods of time ranging 
from the last few days to the last few years. 
1. The Hospital Anxiety and Depression Scale (386) 
The Hospital Anxiety Depression Scale (HADS) is a scif-assessment 
questionnaire designed to measure the states of both anxiety and depression. It 
consists of a simple questionnaire of 14 questions which are divided into two 
subscales; one measuring anxiety (A-scale) and the other depression (D-scale). Each 
is scored separately. The HADS is a present-state instrument as subjects are asked to 
state how they have felt over "the last few days. " 
The anxiety scale measures general anxiety and is not focused upon a specific 
situation. The questions cover the concepts off restlessness and anxious thoughts. 
The depression scale is largely focused upon loss of. interest and diminished pleasure 
response. This state, the lowering of hedonic tone, has been recognised as a reliable 
guide to the type of mood disorder of biological origin. 
7lie questionnaire is simple to complete and usually can be done within five 
minutes. The Anxiety and Depression subscales scores are determined by adding the 
numbers in the A and D columns respectively. Interpretation is then via the scoring 
bands below. 
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Table 3.3 Interpretation of the Hospital Anxiety and Depression Scale (scores 
apply to both scales) (387). 
Score Interpretation 
0-7 No anxiety or depresssion 
8-10 Mild anxiety or depression 
11-14 Moderate anxiety or depression 
15-21 Severe anxiety or depression 
2. The State-Trait Anxiety Index (388) 
The State-Trait anxiety index is a designed to measure both acute anxiety and 
also a tendency to anxiety. It consists of two twenty point questionnaires. The first 
relates to the current state of anxiety or how the subject is feeling "right now", the 
second relates to how the subject generally feels or their anxiety trait. Each point 
consists of a statement of mood related to anxiety and the subject is asked how this 
relates to how they feel on a four point scale. Scores for each question are totalled to 
give both a state and anxiety trait score. Whilst there is no definition of what 
constitutes a normal or abnormal score on either scale, individual scores can be 
compared with the published values of a normal population. 
Table 3.4. State-Trait Anxiety Index scores for working adults (mean and 
standard deviation shown) (389). 
Male Female 
S-anxiety score 35.7 ± 10.4 35.2±10.6 
T-anxiety score 34.9 ± 9.2 34.8 ± 9.2 
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3. The Perceived Stress Questionnaire (373) (See Appendix 1) 
The Perceived Stress Questionnaire (PSQ) is a research tool designed to 
measure stress in the context of clinical psychosomatic research. It consists of a 
thirty point questionnaire. Each question takes the form of a statement describing 
mood. The subject is asked to describe how often they believe each statement applies 
to them on a four point scale. A score of 1-4 is given for each question and the values 
totalled to give an overall score. The PSQ is a measure of long-term perceived stress 
as questions relate to how the subject has felt "in the long run, over the last year or 
two". No data is available on normal scores for the PSQ. 
4. The Bradford Somatic Inventory (374) (see Appendix I) 
The Bradford Somatic Inventory (BSI) is a tool used to identify somatic 
symptoms associated with anxiety and depression. It consists of a forty point 
questionnaire. Each question relates to whether a subject has experienced a particular 
symptom during the preceding month. The question is answered as a yes/no and the 
yes answers are added to give a total out of 40. The BSI was first developed for use 
with Pakistani patients and indigenous patients attending a UK hospital. It has, 
however, since been validated for use in many other languages and ethnic groups. A 
score of greater than seventeen is taken as being a possible indicator of a depressive 
or anxiety-related disorder. 
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3.3.6 SERUM CYTOKINES 
Equipment 
Vacutainers (BD Biosciences, Cowley, Oxford, UK) 
Reagents 
IL-6 ELISAs (R+D systems, Abingdon, Oxford, UK) 
IL-13 ELISAs (Immunodiagnostic systems, Tyne and Wear, UK) 
Methods 
Serum samples were collected and kept in frozen aliquots at -80'C until later 
analysis of IL-6 and IL- 13 levels by ELISA used according to the manufacturer's 
instructions. The coefficients of variation (CV) for duplicate estimates of serum IL-6 
and IL- 13 measurement was 3.1 (n=8) and 8.9% (n=8) respectively. Serum TNF-c( 
levels were below the minimum sensitivity of the ELISA in the majority of subjects 
and so were not assessed. 
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3.3.7 CYTOKINE PRODUCTION DURING CULTURE OF WHOLE BLOOD 
WITH LIPOPOLYSACCARRIDE 
Equipment 
Lithium-containing vacutainers (green top) (BD Biosciences, Cowley, Oxford, 
UK) 
Reagents 
Lipopolysaccharide 
24 well culture plates (Falcon plastics, Cannock, Saffs, UK) 
RPMI culture medium 
IL-6 and TNF-a ELISAs (R+D systems, Abingdon, Oxford, UK) 
Methods 
Lipopolysaccaride (LPS) is a gram-negative bacterial endotoxin which 
directly triggers monocyte activation via toll like receptor 4 (TLR-4). This leads to 
the release of large amounts of monocyte-produced cytokines such as IL-6, IL-12 and 
TNF-a. The culture of blood with LPS forms a model of whole blood monokine 
release and has been employed to characterise the inflammatory response of various 
patient groups such as those with multiple sclerosis (390) and rheumatoid arthritis 
(391). The method has also proved useful for ex-vivo monitoring of 
immunmodulatory treatments for example in patients treated with granulocyte colony 
stimulating factor (GCSF) (392). Whilst this technique is suitable for assessing the 
release of cytokines produced by monocytes such as TNF-a and IL-6, it is not suitable 
for assessing the release of IL-13, which is principally produced by lymphocytes 
(393). 
Published methodology for the culture of blood with LPS varies 
(229; 232; 390). Blood can be cultured with varying concentrations of LPS and can be 
diluted in various ratios with culture medium. Therefore, preliminary experiments 
were performed to determine the optimum concentration of LPS required to stimulate 
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a cytokine response and whether dilution with culture medium was required. IL-6 
production was used as the prototypical cytokine to assess the model. 
Blood was collected from a healthy volunteer into a vacutainer containing 
lithium heparin. For the culture of whole blood without dilution in culture medium, 
Iml of blood was placed in each well of a 24 well culture plate. Varying amounts of 
LPS were added to each well to give a range of final concentrations (1-100mcg/ml). 
The culture plate was then placed in an incubator at 37*C in an atmosphere of 
5%CO2 for 24 hours. After 24 hours the samples were collected and centrifuged at 
60OOrpm for 8 minutes. The supernatant was then collected and stored at -80*C for 
subsequent analysis in duplicate by ELISA for IL-6 concentration. 
For the culture of blood with 1: 10 dilution in culture medium 100mcl of blood 
was placed in each well of a 24 well culture plate and I ml of pre-warmcd RPM I 
culture medium added. LPS was then added and culture and analysis performed as 
before. Culture with each concentration of LPS was performed in duplicate. 
Figure 3.2 The production of IL-6 by neat blood and blood diluted 1: 10 with 
RPMI and stimulated with varying concentrations of LPS. Data points are the 
mean of 2 duplicates. Note the inverted U-shaped dose response curve in each 
instance. 
A. Neat Blood 
I 
LPS microgIml 
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B. Blood diluted 1: 10 with RPMI culture medium 
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It was decided that the culture of whole blood without dilution in culture 
medium gave the best graduated dose response curve. A sub-maximal stimulating 
concentration of LPS was chosen for future experiments as it was thought that this 
would allow the hypothesised increase in IL-6 release to be shown in response to 
stress and the hypothesised decrease to be shown in response to hypnothcrapy. 
25ncg/mI of LPS stimulated'IL-6 release in the region of midpoint of the dose 
response curve and therefore future experiments were performed with I ml of whole 
blood cultured neat with 25mcg/ml of LPS. 
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3.3.8 WHITE CELL COUNT 
Equipment 
Vacutainer containing EDTA (Beckman Coulter, High Wycombe, Bucks, 
UK) 
Coulter LLH 750 machine (Beckman Coulter, High Wycombe, Bucks, UK) 
Methods 
Total leukocyte count (WBC) was measured in blood samples anti-coagulated 
with EDTA using a standard Coulter LLH 750 machine (BD Biosciences, Cowley, 
Oxford, UK) in the Barts and London MIS Trust I laernatology laboratory (Royal 
London Hospital). 
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3.3.9 FLOW CYTOMETRY OF NATURAL KILLER CELLS, PLATELET 
ACTIVATION AND PLATELET-LEUKOCYTE AGGREGATE 
FORMATION 
Flow Cytometry 
Flow cytometry can rapidly measure specific characteristics of a large number 
of individual cells. Cells are labelled with an antibody which also carries a 
fluorochrome which is known to fluoresce with a specific frequency of light. The 
labelled cells are suspended in solution and then passed individually through the flow 
chamber of the flow cytometer at a rate of 1000 to 10000 cells per minute. 
Whilst being passed through the flow chamber the cells are also passed 
through a focussed beam of a laser light. Exposure of labelled cells to light at the 
correct excitation wavelength causes them to fluoresce. The emitted light is detected 
and processed and varies according to the forward (FSQ and side scattering (SSQ 
properties of the cell. By using antibodies labelled with fluorochromes which emit 
light with non-overlapping frequencies more than one molecule can be labelled. 
The flow cytometer was calibrated and standardised before use with 
fluorochrome-labellcd beads (Dako, Ely UK). 
All samples processed for flow cytometry were anticoagulated using 
ethylenediaminetetraacetic acid (EDTA) and citrate, theophyllinc, adenosine, 
dipyridamole (CTAD) (see section 3.3.1) (375). 
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Figure 3.3 Schematic representation of flow cytometric analysis 
Cells pass in single file in fromt of a laser beam. "Forward scatter"is proportional to 
the cell surface area and "side scatter" to cell granularity. Each cell can be 
characterised in terms of its size, granularity and fluorescence properties. 
Fluoresccnce 
analysis 
LASER 
SOURCE 
Forward scatter 
(FSC) 
(Cell Size) 
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Side Scatter (SSC) 
(Cell Granularity) 
3.3.9.1 Natural Killer cells 
Natural killer cells were defined as lymphocytes with dual positivity for the 
cell markers CD16 and CD56. 
Equipment 
FACScan equipped with CellQuest@ software (131) Biosciences, Cowley, 
Oxford, UK) 
Reagents 
Antibodies 
Mouse fluorescein isothiocyanate (FITC)-conjugated anti-human CD16 
(CD62P) (Coulter, Luton, UK) 
Mouse phycoerythretin (PE)-conjugated anti-human CD56 (Coulter, Luton, 
UK). 
Mouse IgGI-FITC and mouse IgGl-PE isotype control antibodies (Coulter, 
Luton, UK). 
CD16 
CD16 antibodies recognise a 50 to 65 kilodalton (kd) antigen present on 
human natural killer (NK) lymphocytes which is the IgG R receptor lll. (394) 
The CD16 antigen is expressed on approximately 15% of peripheral blood 
lymphocytes and is present on virtually all resting NK lymphocytes (395). TlieCD16 
antigen can also be expressed on CD3+ T lymphocytes in certain individuals and may 
be present on some neutrophils. Co-expression of CD16 and CD56 is present only on 
NK cells (395). 
CD56 
CD56 is an antigen which is the, 140-kilodalton (kDa) isoform of the neural 
cell adhesion molecule (NCAM). The 140kDa. core protein is extensively 
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glycosylated to give a mature antigen. The CD56 antigen is present on approximately 
10% to 25% of peripheral blood lymphocytes (395). It is present on essentially all 
resting and activated CD16+NK lymphocytes and approximately 5% of CD3+ 
peripheral blood lymphocytes (395). 
Methods 
100microlitres of blood was incubated with 10microlitres of each of the 
appropriate antibodies for 5 minutes on ice. The red cells were then haemolysed by 
processing the sample through a Coulter TQ Preparation machine. The sample was 
then centrifuged at 2200 rpm for 5 minutes and the supernatant discarded. The pellet 
of cells remaining was resuspended in Iml of Tyrode's solution and analysed by flow 
cytometry at a rate of 12 microlitres per minute. 
The monocytes and lymphocytes were first identified on a plot of FSC against 
SSC. These were then taken to a second plot of FITC positivity (Fill) against PE 
positivity (17112). NK cells were identified as a discrete population of cells positive 
for both CD16 (FITC) and CD56 (PE). This was expressed as a percentage of the 
total number of lymphocytes and monocytes. Non-spccific binding was assessed by 
incubating the sample with FITC-IgGl and PE-lgG1 isotypc control antibodies. The 
CV of duplicate measurements for NK cells was 1.5% (n=8). 
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Figure 3.4 Flow cytometric analysis of NK cell number as a percentage of 
lymphocytes and monocytes. 
Leukocytes are first identified on a plot of forward scatter (FSC) against side scatter 
(SSC). They are then taken to a second plot of CD16 versus CD56 positivity as 
shown below. CD16 and CD56 positivity are plotted on the x and y axis oil log scale. 
The cells highlighted as red within the region RI show both CD 16 and CD56 
positivity and represent NK cells. These are expressed as a percentage of the total 
number of lymphocytes and monocytcs in the plot. 
CD56 
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3.3.9.2 Platelet activation 
P-Selectin, a cell surface membrane glycoprotein, was used to assess platelet 
activation. 
Equipment 
FACScan equipped with CellQuest@ software (BD Biosclences, Cowley, 
Oxford, UK) 
Reagents 
Antibodies 
Mouse fluorescein isothiocyanate (FITC)-con . 
jugated anti-human P-sclectin 
(CD62P) (Coulter, Luton, UK) 
Mouse fluorescein isothiocyanate (FITC)-con. jugated immunoglobulin GI 
isotype control 
P-selectin 
P-selectin is a 140 kD inducible cell-surface lectin which is transported from 
alpha-granules to the surface of platelets during their activation in response to 
thrombogenic or inflammatory mediators (396). 
P-selectin is composed of an amino-terminal lectin domain followed by an 
epidermal growth factor-like domain, a number ofshort-consensus complement 
receptor related domains, a hydrophobic membrane-spanning region and a 
cytoplasmic domain. The storage sites of inactive P-selectin are the alpha-granules of 
platelets and Weibel-Palade bodies of endothelial cells. Within minutes of activation 
by a thrombogenic or inflammatory stimulus, P-selectin is mobilised to the cell 
surface where it acts as an adhesion molecule (396). Inducing agents include 
thrombin, histamine, complement fragments, ROMs and cytokincs. 
P-selectin mediates the interactions between platelets, the endothelium and 
inflammatory cells including neutrophils (395). Specific sialylated carbohydrate 
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moieties on neutrophils interact with P-selectin on the surface of platelets, an 
interaction mediated by the lectin domain of the P-selectin (143). 
P-selectin not only mediates the adhesion of platelets to inflammatory cells, 
but also primes these cells for subsequent responses that augment inflammation. 
Increased platelet P-selectin expression has been demonstrated in inflammatory 
processes in animals, as well as in man in various disease states including 1131) (141). 
Methods 
The use of flow cytometry to assess platelet activation allows analysis of 
samples of whole blood, minimising the manipulation of samples and thus preventing 
in vitro platelet activation and potential loss of sub-populations. 5 microlitres of 
blood was pipetted into a tube containing 5 microlitres of the appropriate FITC- 
labelled antibody. 90 microlitres of Tyrode's solution was added and the tube 
incubated for 5 minutes on ice. After this period the contents of the tube were diluted 
out by the addition of a further 0.9ml of Tyrodes solution. The sample was then 
analysed in the flow cytometer at a rate of 12 microlitres/minute using methods 
de veloped in our laboratory. (141) 
The platelets were first identified on a plot of forward scatter (FSQ against 
side scatter (SSC). The level of non-specific binding was assessed by incubating the 
blood with FITC-labeled isotype mouse antibody (IgG I). The platelets were taken to 
a plot of frequency of events against FITC fluorescence intensity. The threshhold of 
fluorescence required for the event to be regarded FITC positive was set so that <I% 
of platelets stained positive with the control antibody. CD62P positivity was assessed 
by incubating the blood with an FITC-labelled CD62P antibody. Changes in P- 
selectin expression were then recorded on the gated platelets. The CV of duplicate 
measurements of P-selectin expression was 7.2% (n=8). 
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Figure 3.5 Flow cytometric analysis of platelet activation as determined by p- 
selectin expression 
Platelets are first identified on a plot of FSC against SSC. They are then taken to a 
second plot of CD62p positivity versus number of platelets. The example below 
shows analysis of a blood sample taken before stress (green) and a sample taken after 
stress (red). There is a shift of the curve to the right with an increase in CD62p 
positivity. 
m 
v 
CD62p positivity 
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3.3.9.3 Platelet-leukocyte aggregate formation 
Platelet-leukocyte aggregates were identified using the leukocyte, marker CD45 and 
the platelet marker CD42a. 
Equipment 
FACScan equipped with CellQuest@ software (BD Biosciences, Cowley, 
Oxford, UK) 
Reagents 
Antibodies 
Mouse fluorescein isothiocyanate (FITC)-conjugated anti-human CD45 
(CD62P) (Coulter, Luton, UK) 
Mouse phycoerythretin (PE)-conjugated immunoglobulin anti-human CD42a 
(Coulter, Luton, UK). 
Mouse fluorescein isothiocyanate (FITC)-conjugated IgG2a isotype control 
antibodies (Coulter, Luton, UK). 
The principal of identifying platelet-leukocyte aggregates by flow cytometry involved 
identifying cells positive for both the leukocyte marker CD45, and the platelet marker 
CD42a. 
CD45 
CD45 is a protein tyrosine phosphatase (PTP) which is located in all 
hematopoietic cells except erythrocytes and platelets (395). CD45 is also called the 
common leukocyte antigen. CD45 has several isoforms and hematopoiefic cells 
express one or more of the isoforms. CD45 is uniformly distributed in the plasma 
membrane of T cells and B cells (395). CD45 consists of a long single chain 
transmembrane protein with approximately 1100-1300 amino acids. It is a protein 
tYrosine phosphatase that functions to regulate kinases required for T and B cell 
receptor-signal transduction (395). 
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CD42a 
CD42a is a 17-22 kilodalton (kd) single-chain platelet membrane glycoprotein 
also known as gp IX. Gp IX is a member of the leucine-rich glycoprotein (LRG) 
family of proteins, each of which is encoded by a separate gene(397). Gp IX is 
present on resting and activated platelets and on megakaryocytes and is essential for 
normal platelet adhesion and activation. It forms a complex with two other membrane 
bound glycoproteins gp Ib and gp V (397). The gp-lb-IX-V complex contains, a 
binding site for Von Willebrand factor (vWF) which mediates the activation- 
independent shear-dependent adhesion of platelets to the exposed vascular 
subendothelium. The Ib-IX-V complex functions as an attachment site anchoring the 
plasma membrane to its subjacent skeleton, thereby stabilising the membrane and 
maintaining platelet shape and vWF function (397). 
Methods 
Using methods already in use in our unit (141), five microlitres of blood was 
pipetted into a tube containing 5 microlitres of PE-labelled CD56 and either FITC- 
labelled CD16 or FITC-labelled IgG2a. 90microlitresof Tyrode's solution was 
added and the tube incubated for 5 minutes on ice. After this period the contents of 
the tube were diluted by the addition of a further 0.9ml of Tyrodes solution. The 
sample was then analysed in the flow cytometer at a rate of 12 
microlitres/minute. (143) 
Leukocytes were first identified on a plot of FFSC against SSSC. These were 
then taken to a plot of FITC against PE positivity. CD42a and CD45 positive events 
were recorded as a percentage of 1,000 gated leukocytes. Background non-specific 
antibody binding was assessed by measuring the proportion of IgG2a and CD45 
positive events. 
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Figure 3.6 Flow cytometric analysis of platelet-leukocyte aggregate formation 
Leukocytes are first identified on a plot of FSC versus SSC. They are taken to a plot 
of CD42a positivity versus CD45 positivity as shown below. Cells positive for both 
CD42a and CD45 represent platelet-leukocyte aggregates (shown in red) and are 
recorded as a percentage of the total number of leukocytes. 
CD 45 
CD42a 
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3.3.10 MEASUREMENT OF IN VIVO RECTAL MUCOSAL CYTOKINE 
AND MEDIATOR PRODUCTION IN ULCERATIVE COLITIS USING A 
FILTER PAPER TECHNIQUE 
Equipment 
Rigid siginoidoscope (Falcon plastics, Staffordshire UK) 
Rigid biopsy forceps 
Filter paper Whatmann no 42 
Reagents 
Bovine serum albumin 
Tris Buffer 
Aprotonin 
Tween 20 
TNF-a ELISAs (R+D systems, Abingdon, Oxford, UK) 
IL- 13, histamine and Substance P ELISAs (Immunodiagnostic systems, Tyne 
and Wear, UK) 
Methods 
Measuring the in-vivo mucosal production of inflammatory cytokines is 
methodologically difficult. In vitro biopsy methods using tissue obtained by 
endoscopic colorectal biopsy have demonstrated increased concentrations of 
prostaglandins (398), thromboxane (399), leukotrienes (400), platelet activating 
factor(401) and proinflammatory cytokines (402) in active UC. However, the trauma 
of biopsy collection may alter the profile of mediators generated by the mucosa (377). 
Rectal dialysis has been used to quantify mucosal production of cicosanoids 
(403), histamine (123) and interleukin-8. (404) Although safe for patients, the 
procedure is lengthy, taking up to four hours to complete. The technique is also 
limited to molecules which are small enough to pass through the dialysis membrane. 
In 1996, Hendal and colleagues described a method of assessing rectal 
mucosal production of interleukin-1 P and ILl receptor by direct application, via a 
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sigmoidoscope, of a filter paper to inflamed rectal mucosa for a period of up to one 
minute. (405) Carty et al in our unit then extended this technique to show that it could 
also be used to measure the in vivo production of TNF-a, thromboxane B2 (TXB2) 
and prostaglandin E2 (PGE2). Mucosal release of IIA P, TNF-a, TXB2 and PGE2 
was increased in active UC and was shown to be correlated directly with disease 
activity. (377) 
No bowel cleansing preparation was used prior to the study. Through a 
standard rigid sigmoidoscope, a piece of filter paper (Whatmann No 42,7mm x 
30mm) was apposed to the rectal mucosa until visibly soaked with luminal secretion 
(up to 60 seconds). The filter paper was then removed and placed in a vial containing 
Iml of Tris buffer OAM pH 7.4 in normal saline with human serum albumin (0.3%), 
sodium azide (0.1%) and Tween (0.002%). To inhibit degradation of peptides in vitro 
lKU of the protease inhibitor aproprotinin was added immediately prior to the 
addition of the filter paper. The vial was placed on a rocker and agitated gently for 24 
hours at 4C. Contaminating particles were then removed by centrifugation and the 
solution stored at -70C until analysis. 
Concentrations of Substance P, histamine, TNF-ct and IL- 13 in the buffer were 
then measured using commercially available ELISAs. Samples were analysed in 
duplicate or triplicate as recommended by the manufacturers' instructions. 
Recovery experiments 
For each mediator assessed by the filter paper method, in vitro recovery 
experiments were performed. 50 or I OOgL of a known concentration of each 
mediator was pipetted onto a strip of filter paper. This was then incubated in the 
buffer for 24 hours using the above protocol. The resultant concentration of the 
mediator in the buffer was then measured by 
LISA and the percentage of the 
mediator recovered calculated. These experiments were important given earlier data 
indicating that some cytokines, such as interferon-y, appeared to remain adherent to 
the filter paper and therefore give very low recoveries. (377) 
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Results 
Table 3.5 Recovery of inflammatory mediators and cytokines using the filter 
paper method. Median and IQR shown. 
Mediator N Recovery % 
Substance P 4 62(72-82) 
Histamine 4 81(69-103) 
IL-13 4 85(76-97) 
INF-a 4 89(79-99) 
IL, 6 8 0(0-0.5) 
As shown above, preliminary experiments revealed that IL-6 did not 
dissociate from the filterpaper into the buffer so that concentrations of IL-6 in peri- 
mucosal fluid could not be assessed using this method. 
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3.3.11 REACTIVE OXYGEN METABOLITE PRODUCTION BY MUCOSAL 
BIOPSIES 
Equipment 
Scintillation vials (Falcon Plastics, Cannock, Staffs, UK) - 
Bertholdt LB953 chemilunünometer (EG + G, Berthold, Bad Wildbad, Gerrnany) 
Reagents 
Luminol 
Dimethyl sulfoxide (DMSO) 
Tyrode's solution 
Methods 
Chemi luminescence is a non-specific but sensitive method of detecting 
oxidizing species. The luminol used reacts with 02- and H202 to form 3- 
aminophthalate and N-methylacridone. The excited electrons in these compounds 
revert to their ground state with the emission of energy as light which is detected by 
the photomultiplier tubes of the scintillation counter. 02- and 11202 are produced via 
a myeloperoxidase-catalysed reaction, the principal source for which is the 
neutrophil. (181) The amount of ROM production detected by this method has been 
shown to correlate well with disease activity in 1131) assessed both macroscopically 
and microscopically in previous studies here and elsewhere (18 1; 406). 
On the day of use luminol was dissolved in dimethyl sulfoxide (DMSO) at 
50mg/ml and then diluted to 300ýN inTyrode's solution. lml300[LMluminolwas 
placed in a scintillation vial and a background count was performed for 4 minutes. 
Biopsies were transferred from the pre-oxygenated Tyrode's solution to the 
scintillation vials. Luminescence from each sample was immediately counted for 4 
mins in the Bertholdt LB953 luminometer. Samples were then blot dried and 
weighed. Chemiluminescence was expressed as counts/min/mg tissue weight after 
subtraction of background. The CV for ROM production by paired biopsies assessed 
by this method is 47% (181). 
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Preliminary experiments on the effects of biopsy storage time on ROM 
production by mucosal biopsies 
As the experimental protocol dictated that each stress, hypnotherapy or control 
session lasted 50 minutes, the initial mucosal biopsy had to spend at least one hour in 
the pre-oxygenated Tyrode's solution before being analysed for ROM production. 
Preliminary experiments were therefore performed to assess how this would affect 
ROM production. Paired biopsies were collected at colonoscopy from 2 patients with 
active UC (both Baron's endoscopic grade 11), 2 patients with inactive UC (both 
Baron's endoscopic Grade 0) and I control patient with a normal colonoscopy. 
Ile first biopsy from each pair was processed immediately in the manner described 
above and the second after 2 hours. 
Results 
Table 3.6 Reactive oxygen metabolite production by paired mucosal biopsies 
immediately and 2 hours after being taken 
Sample Initial chemiluminescence Chemiluminescence after 2 
(photons/mcg/min) hours (photons/mcg/min) 
Active UC 1 313 458 
Active UC 2 776 689 
Inactive UC 1 82 129 
Inactive UC 2 46 38 
Control 24 29 
It was concluded from this result that storing the biopsies for up to two hours in 
oxygenated Tyrode's solution had no significant effect on ROM production 
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3.3.12 HAEMATOXYLIN AND EOSIN HISTOLOGY OF RECTAL 
MUCOSAL BIOPSIES 
After analysis of ROM production, rectal mucosal biopsies were coded and then 
transferred to formalin solution and stored. Pre- and post-stress rectal biopsies were 
later stained with a standard haematoxylin and eosin protocol. The degree of 
inflammation present in each biopsy was scored by a single histologist (Dr Roger 
Feakins, Department of Histopathology, Royal London Hospital), blinded to the 
origin of the samples. (378) 
Table 3.7 Saverymuttu Scoring System for Rectal Mucosal Biopsies (378) 
Lamina propria mononuclear cells 
Normal 0 
Slight increase I 
Moderate increase 2 
Marked increase 3 
Enterocytes 
Normal 0 
Loss of single cells I 
Loss of groups of cells 2 
Frank ulceration 3 
Lamina propria neutrophils 
Normal 0 
Slight increase I 
Moderate increase 2 
Marked increase 3 
Crypts 
Normal 0 
Single inflammatory cells I 
Cryptitis 2 
Crypt abscesses 3 
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3.3.13 RECTAL MUCOSAL BLOOD FLOW 
Equipment 
Rigid Sigmoidoscope (Falcon Plastics, Staffordshire, UK) 
Moorlab laser Doppler flowmeter (Moorlab, Axeminster, Devon, UK) 
Mp6a endoscopic probe (Moorlab, Axeminster, Devon, UK) 
Moorlab software (Moorlab, Axeminster, Devon, UK) 
Laser Doppler Flow measurement of blood flow 
Laser Doppler flowmetry measures the frequency shift in light which occurs 
during reflection of laser light from a moving object. In tissue, blood cells account 
for most of the moving structures and the speed of their movement determines the 
frequency of light which is reflected. The strength of the reflected signal and the 
degree of shift can be combined to give a value for flux which represents the volume 
of blood flow. The technique has found a wide variety of clinical applications within 
medicine including vascular disorders such as Raynaud's phenomenon and skin 
grafting. More recently the technique has also been adapted to allow measurement of 
rectal mucosal blood flow. (370) 
Laser Doppler Flow measurement of rectal blood flow 
Previous work has shown that, in healthy individuals, rectal blood flow, as 
assessed by laser Doppler flowmetry, remains reasonably constant over time. (370) 
The exception is in pre-menopausal women, where blood flow is greater and less 
reproducible during the luteal than the follicular phase of the menstrual cycle. Mean 
rectal mucosal blood is also increased after a standard meal; it decreases after 
smoking but returns to baseline after 30 minutes. (370) Hence as mentioned above, in 
pre-menopausal female subjects measurements of rectal blood flow were performed 
only during the follicular phase of their menstrual cycle and all patients were asked to 
have only a light breakfast and to abstain from cigarettes on the morning of the test. 
In healthy individuals, laser Doppler blood flow has also been shown to be a 
measure of extrinsic autonomic innervation to the gut. (407) Decreased sympathetic 
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tone, such as that induced by oral beta blockers, caused an increase in rectal blood 
flow. (370) 
Rectal blood flow in patients with ulcerative colitis 
In areas of inflamed mucosa or skin, such as in paiients with UC, capillary 
blood flow reflects not just extrinsic innervation but also the local action of 
inflammatory mediators. Many inflammatory mediators have a vasodilatory effect 
and vasodilatation is one of the classic inflammatory features of calor, rubor, tumor 
and dolor. In a study of sensitisation of the gut to food antigens, rectal blood flow, 
visible erythema and histological submucosal oedema were shown to be positively 
correlated. (408) 
Reports of rectal blood flow in UC are mixed. Srivasta et al reported that 
rectal mucosal blood flow was increased in patients with inactive UC compared to 
controls. (104) However, Guslandi et al found rectal blood flow to be decreased in 
patients with both inactive and active UC. (409) Some of these differences are likely 
to relate to differences in technical equipment with varying depths of penetration of 
the mucosa by the laser and different analysis software. 
The MOORlab Laser Doppler Flowmeter and rectal probe 
The Moorlab laser Doppler flowmeter produces a low intensity beam of 
monochromatic coherent 780nm light generated by an infrared laser diode source and 
delivered via a fibreoptic probe. Reflected light is detected by a photocell and the 
signal processed to determine frequency shift. The approximate area of measurement 
is lmrn2 at a depth of up to Imm from the probe. The flux signal is fed to a 
monitoring computer where the data is analysed by Moorlab software to form a trace 
of flux against time. From this trace the average flux can be calculated for any given 
time period. Movement artefact is also eliminated by the software which averages 
recorded values over 0.1 millliseconds. 
139 
Methods 
As stated in the overall protocol rigid sigmoidoscopy with assessmcnt of 
rectal blood flow was performed before and after the stress, hypnosis and control 
protocols. The patients were examined in the left lateral position with no prior bowel 
preparation. The rigid sigmoidoscope was inserted with minimal air insufflation. 
The laser Doppler probe was then placed next to the rectal mucosa through the rigid 
sigmoidoscope 10cm above the anal margin under direct visualisation. The blood 
flow reading was allowed to stabilise over 30 seconds. Four quadrantic thirty second 
readings of blood flow were then taken. The mean of these four readings was 
calculated and taken as the mucosal blood flow. The CV for qUadrantic sets of'rcc(, tl 
mucosal blood flow measurements was 17% in patients with inactive LJC and 31 I/c if] 
patients with active UC. 
Figure 3.7 Moorlab laser Doppler nowmeter and Mp6a endoscopic probe. 
The probe is shown being passed through a rigid sigmoidoscope as described in the 
above protocol. 
a 11 ý .-ý -- -4 
Probe tip 
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3.3.14 IMMUNOFLUORESCENCE OF MAST CELL DEGRANULATION 
Equipment 
Cryostat vials 
OCT mountant (H & E; Histological Equipment Ltd., Nottingham, UK) 
Microtome (Bal-Tec, Cheshire, UK) 
Vectabond 4 spot slides (Vector Laboratories, Burlingame, California, USA) 
Acetone 
Phosphate buffered saline (PBS) 
2% Rabbit serum (R+D systems, Abingdon, Oxford, UK) 
Anti-human tryptase mouse antibody (R+D systems, Abingdon, Oxford, UK) 
Anti-mouse FITC labelled rabbit antibody (R+D systems, Abingdon, Oxford, UK) 
Aqueous mountant (H & E; Histological Equipment Ltd., Nottingham, UK) 
Cover-slips (H & E; Histological Equipment Ltd., Nottingham, UK) 
Mast cells function to initiate an inflammatory response by the release, 
following degranulation, of inflammatory mediators. They are not readily identiflable 
with conventional routine histological staining. However, they can be stained with 
certain blue basic dies, such as toluidine blue, with which they appear 
characteristically as having a cytoplasm packed with large granules (410). 
A more reliable technique used to detect mast cells is that of 
immunofluorescent staining of biopsies. This technique involves first staining the 
specimens with an antibody which binds to the mast cell granules. Antibodies to 
tryptase, a molecule stored in mast cell granules but released upon activation, are the 
most commonly used (411; 412). This primary antibody is then labelled with a 
secondary antibody to which a fluorochrome is attached. Using this technique both 
resting and activated mast cells can be identified (see Figure). In this protocol, 
immunofluorescent staining of rectal biopsies for the mast cell mediator tryptase was 
used. 
Mast cells can also been seen well with electron microscopy. Both resting and 
degranulating mast cells can be identified with this technique (279). 
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The scientist performing the procedure (Dr Neil Rayment) was blinded to the 
source of each biopsy sample. 
Experimental Protocol 
Immediately after being taken, rectal biopsies were placed in cryostat vials and 
snap frozen in liquid nitrogen. Samples were stored at -80'C until future use. On the 
day of processing, the specimens were removed and orientated onto OCT mountant. 
5gm cryostat sections were cut using a n-dcrotome and mounted onto washed 
Vectabond 4 spot slides. The slides were stored at -20'C until use, as per 
manufacturer's recommendations. Sections were thawed and fixed in cold acetone 
for 15 mins before being washed briefly in PBS. In order to reduce non-specific 
background staining, slides were treated with a blocking antibody. In this case, 
sections were incubated in 2% normal rabbit serum in PBS for 20 mins at 210C. 
Sections were then washed three times in PBS at 2l*C for 5 minutes each wash. 
Next, the sections were incubated with the primary antibody. In this protocol, slides 
were incubated in a 1/100 dilution of anti-human tryptase mouse antibody for 60 mins 
at2l'C. Sections were washed a further three times in PBS at 21T for 5 minutes 
each wash. A 1150 dilution of anti-mouse FITC-labelled rabbit antibody was used as 
the secondary antibody and the slides were incubated in this solution for 45 mins at 
211C. Sections were then washed a further three times in PBS at 2VC for 5 minutes 
each wash and mounted in aqueous mountant (containing anti-fade). A cover-slip 
placed over the sample and a Zeiss Axiophot MOT microscope with conventional 
epi-fluorescence used to view them. An Axiocam HR digital camera attached to 
Axiocam software was used to photograph the slides. 
The total number of mast cells and the percentage degranulating were counted for 
each specimen. 
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Figure 3.8 Resting mast cell stained with anti-human tryptase antibody and 
anti-mouse FITC-labelled rabbit antibody. 
Mast cell is the fluorescent red cell in the middle of the figure. Tryptase is stored in 
granules within the mast cell cytoplasm. 
Figure 3.9 Degranulating (activated) mast cell labelled with anti-hunian ti-yptase 
mouse antibody and anti-mouse FFFC labelled antibody. 
The mast cell is the fluorescent cell within the middle of the figUrC. 'rile tryplasc call 
he seen being released with degranulation. 
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3.3.15 FLUORESCENCE IN-SITU HYBRIDISATION OF MUCOSAL 
ASSOCIATED BACTERIA 
Equipment 
Cryostat vials 
OCT mountant (H & E; Histological Equipment Ltd., Nottingham, UK) 
Microtome (Bal-Tec, Cheshire, UK) 
Vectabond 4 spot slides (Vector Laboratories, Burlingame, California, USA) 
Phosphate buffered saline (PBS) 
Paraformaldehyde 
Triton 
Tris-hydochloride 
Sodium Chloride 
Probes (a gift from Professor G Gibson, School of Food Biosciences, Reading 
University and synthesised by Microsynth, Lustenau, Austria) 
The pathogenesis of 1131) is likely to involve an abnormal immune reaction to 
colonic mucosal bacteria. Specifically adherent and invading strains of Ecoli may 
have a pro-inflammatory role (413). Most studies assessing mucosal flora have used 
the relatively non-specific technique of culture of biopsies obtained at colonoscopy. 
Others studies have relied on polymerase chain reaction-based techniques or electron 
microscopic examination of mucosal biopsies. 
Our own laboratory has developed a fluorescent in situ hybridisation (FISH) 
technique to identify mucosa-associated bacterial flora (64). The technique uses 
FISH probes and has the advantages of being quantitative, genera-specific and 
allowing direct visualisation of both bacteria adherent to the mucosa and bacteria in 
the lamina propria. A universal probe (EUB) allows quantification of the total 
number of bacteria. 
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Table 3.6 Species-specific oligonucleotide probes used for fluorescent in situ- 
hybridisation. Probes are labeled at the 51 end with the fluorescent label cy3. 
Bacterial species Clone Sequence 
E. coli 1531 5'-CAC-CGT-AGT-GCC-TCG-TCA-TCA-3' 
Total bacteria (EUB) 146 5'-TAC-GGA-TT7-CAC-TCC-T-3' 
Experimental protocol (64) 
As with the immnofluorescent staining technique used for assessing mast cells, 
specimens were snap frozen in liquid nitrogen and stored at -80'C until future use. 
On the day of processing, specimens were removed and orientated onto OCT 
mountant. 5[tm cryostat sections were cut using a microtome and mounted onto 
washed Vectabond 4 spot slides. The slides were stored at -20T until use. Sections 
were thawed briefly and fixed in 4% paraformaldehyde/PBS for 20 mins at 21*C. 
After a brief wash in PBS, sections were permeabilised by treating with 2% Triton x 
100/PBS for 20 mins at 21*C. This solution was removed by washing the sections 
three times for five minute each wash in PBS at 21T. The slides were then incubated 
in the hybridisation buffer (40Mrn Tris-110,1.8M NaCl, 0.5%SDS) for 60 mins at 
required hybridisation temperature. The hybridisation buffer was "tapped off" and 
replaced with a hybridisation buffer containing 200ng of the relevant probe; E. coli or 
total bacteria. A cover-slip was placed over each slide and the sections sealed in a 
moist chamber. This was then placed in a hybridisation oven at 50T for 16 hrs. 
Following removal from the oven, cover-slips were removed by dipping the slides 
briefly in PBS. The hybridization/probe solution was replaced with fresh 
hybridisation solution but without SDS and the slides incubated for 60mins at 21T. 
Slides were then washed once in PBS for 15mins at 210C. Slides were mounted in 
aqueous mountant (containing anti-fade) and a cover-slip placed over each sample. A 
Leica SP2 confocal microscope was used to view the slides. The number of Ecoli 
and total bacteria/mM2 of epithelial surface and the number of Ecoli and total 
bacteria/mm 2 of lamina propria were counted. 
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Figure 3.10 E. coli adherent to mucosa as shown by FISH technique 
E. coli can be seen as fluoreescent red objects on the surface of the mucosa. 
Figure 3.11 E. coli present in the lamina propria as shown by FISI I technique 
E. coh can be seen as fluorescent orange objects within a CD68 positive niacrol)higc 
in the lamina propria 
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3.4 CALCULATIONS AND STATISTICS 
Results are expressed as median and inter-quartile range (IQR) unless 
otherwise stated. A Kruskal Wallis test for non-paired non-parametric data was 
initially used to compare the baseline values for the three different groups: healthy 
volunteers, patients with inactive UC and patients with active UC. If the Kruskal- 
Wallis test was significant, a Mann Whitney U test was then used to compare 
individual groups. 
A Friedman test for paired non-parametric data was initially performed to 
compare the three time points before, immediately and 30 mins after the stress, 
hypnotherapy and control protocols. If the Friedman test was significant, individual 
time points were then compared by the Wilcoxon signed rank test. The Mann- 
Whitney U test for non-paired non-parametric data was used to compare the changes 
recorded in the variables in response to stress and hypnotherapy between patients 
with UC and healthy controls. Spearman's non-parametric rank test was used to 
assess whether levels of chronic perceived stress correlated with changes seen in 
response to the stress and hypnotherapy protocols. Spearman's rank test was also 
used to assess whether Spiegel's score of hypnotisability (383), or the self-rated score 
of depth perception, correlated with the changes seen in response to the hypnotherapy 
protocols. 
In each instance, 2-tailed P<0.05 was taken as statistically significant. The 
Bonferroni adjustment for multiple comparisons was not used as there was an a priori 
hypothesis of the effects of stress and hypnotherapy on the inflammatory measures 
assessed. (414) 
3.5 POWER AND SAMPLE SIZE 
At the time of the design of the experimental protocol, there was no data 
available on the effects of acute psychological stress or hypnotherapy on the 
autonomic and inflammatory response in patients with UC. Therefore it was difficult 
to perform formal power calculations. 
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However, to detect an autonomic response to the stress test and hypnotherapy 
protocol, we calculated that with a study sample size of 36 patients with a 2: 1 
randomisation to the stress or hypnotherapy and control protocols, we would be able 
to detect a change in pulse rate of 5 bpm with a power of 80% and a significance level 
of 0.05 (2 tailed) (the standard deviation of baseline heart rate being 5.8 bpm) (415). 
Similarly, a study sample size of 24 patients with UC and 12 healthy controls, would 
allow detection of a difference in pulse rate of 5 bpm in response to the stress or 
hypnotherapy protocol between the two patient groups with a power of 80%, and a 
significance level of 0.05 (2 tailed). 
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CHAPTER4 
BASELINE VALUES FOR SYSTEMIC 
MEASURES IN HEALTHY VOLUNTEERS AND 
PATIENTS WITH ACTIVE AND INACTIVE 
ULCERATIVE COLITIS 
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4.1 SUMMARY 
Aims: To compare the systemic autonomic and inflammatory measures described in 
Chapter 3, in healthy volunteers and patients with active and in active UC. 
Methods: As part of the stress and hypnotherapy protocols a range of systemic 
autonomic and inflammatory variables were assessed in the above three subject 
groups. 
Results: The principal findings in this chapter are: 
1. Of the autonomic measures, median pulse rate was 5bpm greater in patients with 
active UC than patients with inactive UC (p=0.01) and healthy volunteers (p=0.02). 
Median systolic BP was 10mmHg greater in patients with active UC and 7mmHG 
greater in patients with inactive UC than healthy volunteers (p=0.002 and p=0.03 
respectively). The median diastolic BP of patients with active UC was 8mmHg 
greater than that of healthy volunteers (p=0.02). 
2. Of the systemic inflammatory parameters assessed, serum IL-6 concentration was 
greater in patients with active UC than patients with inactive UC (p=0.005) and 
healthy volunteers (p<0.0001). Serum IL-6 concentrations were also greater in 
patients with inactive UC than healthy volunteers (p=0.0004). Serum IL-13 
concentrations were greater in patients with active UC than patients with inactive UC 
(p=0.0003) and healthy volunteers (p<0.0002). LPS-stimulated TNF-a production 
by whole blood was -greater in patients with active UC than both patients with 
inactive UC (p<0.0001) and healthy volunteers (p<0.0001). Leukocyte count was 
greater in patients with active UC and inactive UC than healthy volunteers (p<0.0001 
and p=0.01 respectively). Platelet activation was greater in active than inactive 
disease (p--0.04). 
3. With regards to the psychometric questionnaires, patients with active UC scored 
higher than patients with inactive UC and healthy volunteers on the Hospital Anxiety 
and Depression Scale (HADS), the State Trait Anxiety Inventory (STAI), the 
Perceived Stress Questionnaire (PSQ) and Bradford Somatic inventory (P<0.05 in 
each case). Patients with inactive UC scored higher than healthy volunteers on the 
HADS, PSQ and BSI (P<0.05 in each case). 
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Conclusions: The majority of the inflammatory measures assessed were greater in 
patients with active disease, suggesting that their levels reflect disease activity. 
Chronic stress levels as assessed by psychometric questionnaire were greater in 
patients with active UC than healthy volunteers and patients with inactive UC. 
4.2 INTRODUCTION 
The experimental protocols used in this thesis (Chapter 3) involved 
performing stress, hypnotherapy and control sessions in patients with active and 
inactive UC and in healthy volunteers. 
In this chapter we will compare the pre-protocol baseline values of both the 
systemic autonomic and inflammatory measures in these three groups: patients with 
active UC, patients with inactive UC and healthy volunteers. Several of these 
inflammatory measures have been assessed in these groups previously: serum IL-6 
(170; 171), platelet activation (141) and PLA formation (143) but the others have not. 
For the measures which have not been previously assessed, it is important to 
demonstrate whether they are raised in active UC, since this would support their use 
as relevant measures of inflammation. An appreciation of the magnitude of the 
differences between quiescent and active disease would put into perspective the 
changes observed in response to stress and hypnotherapy which are discussed in 
chapters 6 and 8. 
Psychometric questionnaires were used in the protocol to relate the effects of 
chronic stress to the response to acute stress. Baseline scores on these psychometric 
questionnaires are also described in this chapter. 
4.3 PATIENT DEMOGRAPHICS 
32 healthy volunteers, 35 patients with inactive UC and 25 patients with active UC 
partcipated in the studies involving the stress, hypnotherapy and control protocols. 
151 
Table 4.1 Sex, age, disease extent, treatment, Baron's sigmoidoscopic score and 
Simple Colitis Activity Index (SCCAI) for patients with inactive UC, active UC 
and healthy volunteers. Median (IQR) are shown except for age where median 
(range) is given. 
Patients N 
Inactive UC 35 
Age 45(23-65) 
Sex 16 Male 
Disease extent 43% total 
23% left-sided 
34% distal 
Treatment 80% 5-ASA 
I I% thiopurines 
3% oral methotrexate 
0% corticosteroids 
14% on topical therapy 
Baron's score 0(0-1) 
SSCAI l(O-2) 
Active UC 25 
Age 40(23-64) 
Sex 15 Male 
Disease extent 60% total 
16% left-sided 
24% distal 
Treatment 96% 5-ASA 
32% thiopurines 
4% oral ciclosporin 
0% corticosteroids 
20% Topical 
Baron's score 2(2-3) 
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SSCAI 
Healthy Volunteers 32 
Age 31 (23-59) 
Sex 15 Male 
4.4 RESULTS 
4.4.1 AUTONOMIC MEASURES 
4.4.1.1 Pulse Rate (Figure 4.1 and Table 4.2) 
The median pulse rate of the patients with active UC was 5bpm greater than 
the median pulse rate of patients with inactive UC and 5bpm greater than the median 
pulse rate of healthy volunteers. 
Fig 4.1 Baseline pulse rate (BPM) for healthy volunteers (HV) (n=32) and 
patients with inactive (n=35) and active UC (n=25). The median value is shown 
as the red bar. 
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4.4.1.2 Systolic BP (Figure 4.3 and Table 4.2) 
The systolic BP of the healthy volunteers was a median of 7mmHg lower than 
the patients with inactive UC and 10mmHg lower than patients with active UC. 
Fig 4.2 Baseline systolic BP (mmHg) for healthy volunteers (n=32) (HV) and 
patients with inactive (n=35) and active UC (n=25). Median value is shown as 
the red bar. 
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4.4.1.3 Diastolic BP (Figure 4.3 and Table 4.3) 
The diastolic BP of patients with active UC was a median of 8mmHg greater 
than that of healthy volunteers. 
Fig 4.3 Baseline diastolic BP (mmHg) for healthy volunteers (HV) (n=32) and 
patients with inactive (n=35) and active UC (n=25). Median value is shown as 
the red bar. 
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Table 4.2 Baseline pulse rate (bpm), systolic and diastolic blood pressure 
(mmHg) for healthy volunteers and patients with active and inactive UC. 
Median and IQR shown. *p<0.05 from healthy volunteer baseline. +p<0.05 from 
patients with inactive UC baseline. 
Healthy Patients with Patients with 
Volunteers inactive UC active UC 
Pulse Rate 68(60-76) 68(64-74) 73 (69-95) *'ý 
Systolic BP 116 (105-123) 123 (114-144)* 126 (119-136) 
Diastolic BP 70(62-76) 73(68-81) 78 (70-82)* 
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4.4.2 SYSTEMIC INFLAMMATORY VARIABLES 
4.4.2.1 Serum cytokine concentrations (Figure 4.4 and 4.5, and Table4.3) 
The median serum IL-6 concentration in patients with inactive UC was twice 
that of healthy volunteers. The median serum IL-6 concentration in patients with 
active UC was nearly four-fold greater than that of healthy volunteers and double that 
of patients with inactive UC. 
The median serum IL-13 concentration in patients with active UC was over 
five times that of healthy volunteers, and more than three time that ol'patients with 
inactive UC. 
Fig 4.4 Baseline serum IL-6 concentrations (pgIml) for healthy volunteers (HV) 
(n=32) and patients with inactive (n=35) and active UC (n=25). Median value is 
shown as the red bar. 
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Fig 4.5 Baseline Serum IL-13 concentrations (pg/ml) for healthy volunteers (HV) 
(n=32) and patients with inactive (n=35) and active UC (n=25). Median value is 
shown as the red bar. 
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4.4.4.2 LPS-stimulated cytokine production (Figure 4.6 and Table 4.3) 
The median LPS-stimulated TNF-a production was over five times greater 
than in healthy volunteers and fourfold greater than in patients with inactive UC. 
There was no difference in LPS-stimulated IL-6 production between the three groups. 
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Fig 4.6 Baseline LPS-stimulated TNF-a production (ng/ml) for healthy 
volunteers (HV) (n=32) and patients with inactive (n=35) and active UC (n=25). 
Median value is shown as the red bar. 
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Table 4.3 Serum IL-6 and IL-13 concentrations (pg/mI) and LPS-stimulated 
TNF-(x and IL-6 production (ng/ml) by whole blood in healthy volunteers and 
patients with inactive and active UC. *p<0.05 from baseline value for healthy 
volunteers. 
+p<0.05 from baseline for patients with inactive UC. 
Healthy Patients with Patients with 
Volunteers inactive UC active LJC 
Serum IL-6 1.0 (0.6-1.5) 2.0 (1.4-3.0)* 4.0 (1.9-11.5)* t 
Serum IL-13 1.5(0-4.3) 2.4 (1.1-3.4) 7.6 (2.5-15.2)* t 
ITS TNF-a 20(10-35) 25(15-57) 106 (68-189)*t 
ITS IL-6 208 (148-299) 233 (182-436) 262 (183-446) 
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4.4.2.3 Leukocyte count (Figure 4.7 and Table 4.4) 
Median leukocyte count was over a third greater in patients with active UC 
and over 20% greater in patients with inactive UC than in healthy volunteers. 
Fig 4.7 Baseline leukocyte count (cells x 104/nUU3) for healthy volunteers (HV) 
(n=32) and patients with inactive (n=35) and active UC (n=25). Median value 
shown as the red bar. 
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4.4.2.4 Natural Killer Cell count (Table 4.4) 
There was no difference in the baseline INK cell count between groups. L- 
4.4.2.5 Platelet activation (P-selectin expression) (Figure 4.8 and Table 4.4) 
Median platelet activation as measured by P-selectin expression was 40(/'(, 
greater in patients with active UC than patients with inactive UC. 
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Fig 4.8 Baseline platelet activation (P-selectin expression (%)) for healthy 
volunteers (HV) (n=32) and patients with inactive (n=35) and active UC (n=25). 
Median is shown as red bar. 
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4.4.2.6 Platelet- leukocyte aggregate formation (Table) 
There was no difference in platelet leukocyte aggregate fOrniation betwecn the 
three groups. 
Table 4.4 Leukocyte count (WBC)(cells x 10 4/MM3 ), natural killer cell count (%), 
platelet activation (p-selectin expression (%)) and platelet-leukocyte aggregrate 
(PLA) formation (%) in healthy volunteers and patients with active and inactive 
UC. *p<0.05 from baseline value for healthy volunteers. +p<0.05 from baseline 
value for patients with inactive UC. 
Healthy Patients with Patients with 
Volunteers inactive UC active UC 
WBC 5.5 (4.6-6.9) 6.7 (5.4- 8.1 )* 7.5 (6.7-9.8)* 
NK count 6.8 (5.3-9.3) 6.8 (4.4-9.7) 6.8 (4.8-9.1) 
P-selectin 3.1 (2.0-3.4) 2.6 (1.7-4.5) 3.6 (2.3 -5.4) 
PLA 2.7 (2.0-3.8) 2.4 (1.7-3.2) 2.9(2.2-3.5) 
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4.4.3 PSYCHOMETRIC QUESTIONNAIRES (Table 4.5) 
Hospital Anxiety and Depression Scale (HADS) 
Patients with active UC had higher scores on both the anxiety and depression 
scales than either patients with inactive UC (p=0.01, p=0.003 respectively) and 
healthy volunteers (p<0.0001, p<0.0001 respectively). Patients with inactive UC had 
a higher score on both the anxiety and depression scale than healthy volunteers 
(p=0.008, p=0.003 respectively). 
State Trait Anxiety Inventory (STAI) 
Patients with active UC had higher score on both the STAI-state scale and the 
STAI-trait. scale than patients with inactive UC (p=0.001, p=0.003 respectively) and 
healthy volunteers (p=0.0005, p=0.001 respectively). 
Perceived Stress Questionnaire (PSQ) 
Patients with active UC had higher score on the Perceived Stress 
Questionnaire than patients with inactive UC (p=0.02) and healthy volunteers 
(p<0.0001). Patients with inactive UC had a higher score on the Perceived Stress 
Questionnaire than healthy volunteers (p=0.01). 
Bradford Somatic Inventory (BSI) 
Patients with active UC had higher scores on the Bradford Somatic Inventory 
than patients with inactive UC (p=0.01) and healthy volunteers (p<0.0001). Patients 
with inactive UC had a higher score on the Bradford Somatic Inventory scale than 
healthy volunteers (p=0.001). 
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Table 4.5 Hospital Anxiety and Depression Scale-Anxiety (IIADS-A), Hospital 
Anxiety and Depression Scale-Depression (HADS-D), State Trait Anxiety 
Inventory-state (STAI-state), State Trait Anxiety Inventory-trait (STAI-trait), 
Perceived Stress Questionnaire (PSQ) and Bradford Somatic Inventory (BSI) 
scores for healthy volunteers (n=32) and patients with inactive (n=35) and active 
UC (n=25). *p<0.05 from baseline value for healthy volunteers. +p<0.05 from 
baseline value for patients with inactive UC. 
Healthy Patients with Patients with 
Volunteers inactive UC active UC 
N 32 35 25 
IIADS-A 4(3-7) 7 (5-10)* 11 (7.5-13)*-ý 
HADS-D 1(1-3) 3 (24)* 5.5 (4-8.5)*'ý 
STAI-state 31(26-36) 33(25-40) 43 (34-50)*-ý 
STAI-trait 24(28-44) 36(33-43) 46 (38-52)*-ý 
PSQ 52(47-62) 62 (53-70)* 68 (62-85)*'ý 
BSI 5(2-8.5) 9 (5-15)* 15 (11-19)*+ 
4.5 DISCUSSION 
In this chapter, we have compared the baseline values for the physiological 
and systemic inflammatory measures which were assessed as part of the experimental 
protocol (chapter 3) in the three subject groups. We found the majority of systemic 
inflammatory variables to be raised in patients with acute UC compared to patients 
with quiescent UC and healthy controls. Each will be discussed in turn. 
AUTONOMIC MEASURES 
Pulse rate was greater in patients with active UC than patients with inactive 
UC and healthy volunteers. This is not an unexpected finding as the presence of a 
tachycardia is well recognized as being a clinical marker of severely active UC. 
Systolic BP was greater in patients with active UC and inactive UC than HVs. 
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Diastolic BP was greater in patients with active UC than HVs. This is likely to be due 
to the differences in ages between the groups. The subjects with active and inactive 
UC were older than the HVs. Systolic and diastolic BP correlated with age in both 
patients with active (R=0.56, P=0.02 and R=0.58, P---0.02 respectively) and inactive 
UC (R=0.58, P=0.001 and R=0.41, P=0.03 respectively). The range of ages in the 
healthy volunteers was too narrow to allow assessment for a correlation in this group. 
The differences in pulse rate are unlikely to be explained by the differences in age as 
there was no correlation between age and pulse rate in any of the patient groups. 
SERUM CYTOKINES 
Serum IL-6 concentrations were greater in patients with active UC than 
patients with inactive and HVs. The serum IL-6 concentration was also greater in 
patients with inactive UC than HVs. IL-6 is a pleiotropic inflammatory cytokine with 
many inflammatory actions (see chapter 1). Its saliva and serum concentrations have 
previously been found to be raised both in CD and also in UC (170; 171; 416; 417); 
indeed an anti-IL6 antibody has also been shown to be of benefit in CD (177). The 
role of IL-6 in stimulating the hypothalamus to initiate the stress response also makes 
it a useful inflammatory measure in this study (168). 1 
Serum IL-13 concentrations were greater in patients with active UC than 
patients with inactive UC and HVs. There was no difference between the serum 
concentrations of IL, 13 in patients with inactive UC and HVs. 
Recent evidence suggests that IL-13 may be important in the pathophysiology 
of UC. Mucosal production of IL-13 is increased in oxazolone-induced colitis, a 
murine model of GI inflammation which closely resembles UC (418). In human 
studies, stimulated lamina propria mononuclear cells (LPMCs) from resected colonic 
specimens from patients with UC have been shown to produce more IL- 13 than 
LPMCs from colonic specimens from patients with CD or non-inflammatory controls 
(419). IL-13 has also been shown to impair the epithelial barrier function of colonic 
cells in vitro via increased apoptosis and expression of the pore-forming fightjunction 
protein claudin-2. (420) Although IL-13 production by LPMCs has been shown to be 
increased in active UC (421), as yet there appears to have been no data published 
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regarding the circulating levels of IL-13 in patients with UC. However, further work 
is needed to examine whether serum IL., 13 concentration might prove a useful marker 
of disease activity in UC. 
LPS-STIMULATED CYTOKINE PRODUCTION BY WHOLE BLOOD 
TNF-a production by whole blood was greater in patients with active UC than 
in patients with inactive UC and than in healthy volunteers. This is unlikely to be 
explained simply by the increased leukocyte count found in patients with active UC 
for two reasons. Firstly, there was no difference between the leukocyte counts in 
patients with active and inactive UC, and secondly TNF-a production by whole blood 
did not correlate with leukocyte count in any patient group. 
Ile finding that'INF-a production is raised in active UC supports the use of 
this variable as a measure of the systemic inflammatory response in this study. The 
production of inflammatory cytokines by macrophages in response to bacterial 
products such as LPS may well be an important process in the pathophysiology of 
IBD (51). Therefore changes in TNF-a production by LPS-stimulated blood in 
response to stress or hypnosis may be important in the explaining related changes in 
disease activity. 
LEUKOCYTE COUNT 
Total leukocyte, count was greater in patients with active and inactive UC than 
healthy volunteers. Leukocyte count is generally regarded as a poor marker of 
disease activity in UC compared to other laboratory measures such as CRP (422). 
This observation was not explained by the different ages of the three subject groups 
as age did not correlate with leukocyte count within any of these cohorts. None of the 
patients was taking, or had recently been on an oral corticosteroid, so steroid use can 
also not explain these findings. 
NK CELL COUNT 
Rises in NK cell count are consistently reported in response to acute 
experimental stress (137; 235; 236; 245). Its inclusion as a systemic inflammatory 
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measure in this study provided a means to assess whether the stress protocol was 
sufficiently stressful as to cause an inflammatory response. The recently recognized 
interactions between dendritic cells and NK cells also makes assessment of NK count 
pertinent to this study (see chapter 1) (423). However, our failure to find a difference 
between NK cell counts in the three patient groups would suggest that although a rise 
in NK cell count might act as an initiator for inflammation in IBD it is unlikely to 
have a longer term role. 
PLATELET ACTIVATION AND PLATELET-LEUKOCYTE AGGREGATE 
FORMATION 
Platelet activation and PLA fonnation have both been reported as being raised 
in patients with IBD (141; 143). However, in this study we did not find there to be a 
difference in either measure. between patients with UC and HVs. The cause for this 
discrepancy is not immediately apparent. The healthy volunteers were younger than 
the patients with UC. However, p-selectin expression and PLA formation are not 
recognised as being inversely associated with age (141; 143). Neither, in this study, 
did age correlate with p-selectin expression or PLA formation in healthy volunteers or 
patients with active or inactive UC. 
One possible explanation might be the use of concomitant drug therapy. Both 
clopidogrel and HMG-CoA reductase inhibitors have been shown to be associated 
with reduced p-selectin expression and PLA formation (424; 425). As these drugs are 
usually prescribed to reduce risks of cardiovascular events in a middle aged or elderly 
population, it is possible that more of the patients with UC than the healthy volunteers 
were taking them. However, unfortunately this data is not available. 
We did find platelet activation to be greater in patients with active than 
inactive UC. This was not found in previous studies performed in our unit but 
supports its use as a systemic inflammatory measure in this study. 
PSYCHOMETRIC QUESTIONNAIRES 
Patients with active UC had higher levels of short and long term stress, as 
assessed by psychometric questionnaires, than patients with inactive disease and 
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healthy volunteers. This is in keeping with the assumption that the presence of active 
disease is inherently stressful for patients. Similar results have been found by others 
(273; 274; 373). Patients with inactive UC scored higher than healthy volunteers on 
the majority of the psychometric questionnaires used to assess stress. This finding 
would suggest that the presence of inactive disease is also stressful. These 
observations are not explained by age differences between the HVs and patients with 
active and inactive disease as age did not correlate with the scores on any of the 
questionnaires. 
4.6 CONCLUSION 
Most of the inflammatory measures used to assess systemic inflammation 
were found to be raised in patients with active UC compared to patients with inactive 
UC and healthy volunteers. Of particular note serum IL-13 was greater in patients 
active UC than those with inactive disease and healthy volunteers, and greater in 
patients with inactive UC than healthy volunteers. Further work is needed to assess if 
serum IL-13 might be a useful measure of disease activity in UC. 
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CHAPTER5 
BASELINE VALUES FOR MUCOSAL MEASURES 
IN PATIENTS WITH ACTIVE AND INACTIVE 
ULCERATIVE COLITIS 
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5.1 SUMMARY 
Ainis: To compare the rectal mucosal measures of inflammation described in 
Chapter 3 and rectal mucosal blood flow in patients with inactive and active UC. 
Methods: As part of the stress and hypnotherapy protocols, several rectal mucosal 
inflammatory variables were assessed in patients with active and inactive disease. 
Results: The principal findings in this chapter are: 
1. Substance P (p=0.05), histamine (p=0.008), IL-13 (p=0.002) and TNF-a 
concentrations (p<0.0001) in rectal peri-mucosal fluid were higher in active than 
inactive UC. 
2. Reactive oxygen metabolite (ROM) production by mucosal biopsies (p--0.0002) 
was greater in patients with active than inactive UC. 
3. Rectal mucosal blood flow (RMBF) (p---0.009) was higher in patients with active 
disease. 
Conclusion: All the measures assessed were increased in active compared with 
inactive UC, suggesting that their levels reflect disease activity and supporting the 
view that they may be important in disease pathogenesis. 
5.2 INTRODUCTION 
In addition to the measurement of systemic inflammatory variables, as part of 
the experimental protocol several measures of mucosal inflammation were made 
before and after the stress, hypnotherapy and control sessions. In this chapter we will 
discuss the baseline pre-protocol levels of these measures in patients with active and 
inactive UC. Several of the inflammatory parameters assessed have not been 
analysed with these methods in acti. ve and inactive UC previously. As indicated in 
Chapter 3, we did not undertake sigmoidoscopy in healthy volunteers, so this group is 
not available for comparison. 
Although assessing the concentration of inflammatory mediators in rectal 
peri-mucosal fluid by the use of the filter paper technique is an established 
methodology (426), it has not been used previously to assess some of the mediators 
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described in this experimental protocol. Rectal fluid TNF-a concentrations have been 
shown to be raised in active UC with this technique (377), but SP, histamine and IL. - 
13 concentrations have not been previously assessed. ROM production by mucosal 
biopsies assessed using chemiluminescence has been shown previously to be greater 
in active UC than in quiescent disease (181). Rectal mucosal blood flow in UC has 
been assessed using laser Doppler flowmetry and was found to be increased in active 
disease, but the MOORIab equipment used in this protocol has not been used 
previously for this purpose (104). 
As before, demonstration that these measures are raised in active compared to 
inactive UC gives validity to their use as measures of inflammation; furthermore an 
appreciation of the magnitude of the differences between active and inactive disease 
is useful in assessing the responses to stress and hypnotherapy described in Chapters 
7 and 9. 
5.3 PATIENT DEMOGRAPHICS 
35 patients with inactive UC and 25 patients with active UC took part in the 
studies involving the stress, hypnotherapy and control protocols. Their demographics 
are described in Chapter 4 (Table 4.1) 
5.4 RESULTS 
Peri-mucosal fluid samples were available from 33 patients with inactive UC 
as in 2 patients with inactive UC the samples were defrosted by accident during 
storage and could not therefore be used. ROM production was assessed on 27 pairs 
of rectal mucosal biopsies from patients with inactive UC. Eight pairs of biopsies 
from patients with inactive UC were used for mast cell and mucosa-associated 
bacteria studies. ROM production and rectal mucosal blood flow were assessed in 23 
patients with active UC. In 2 patients with active UC these variables could not be 
assessed due to equipment failure. 
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5.4.1 CYTOKINE AND MEDIATOR CONCENTRATIONS IN RECTAL 
PERI-MUCOSAL FLUID (Figure 5.1,5.2,5.3 and 5.4 and Table 5.1) 
In rectal peri-mucosal fluid from patients with active UC, the median 
substance P concentration was over two and a half times greater, the median 
histamine concentration was over threefold greater, the median IL- 13 concentration 
over twofold greater and the median TNF-ot concentration over eight times greater 
than in peri-mucosal fluid from patients with inactive UC. 
Fig 5.1 Baseline substance P concentrations (pg/ml) in rectal peri-mucosal fluid 
for patients with inactive (n=33) and active UC (n=25). Median value shown as 
red bar. 
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Fig 5.2 Baseline histamine concentrations (pg/ml) in rectal peri-mucosal fluid for 
patients with inactive (n=33) and active UC (n=25). Median value shown as red 
bar. 
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Fig 5.3 Baseline 11,13 concentrations (pg/ml) in rectal peri-mucosal fluid for 
patients with inactive (n=33) and active UC (n=25). Median value shown as red 
bar. 
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Fig 5.4 Baseline TNF-a concentrations (pg/ml) in rectal peri-mucosal fluid for 
patients with inactive (n=33) and active UC (n=25). Median shown as red bar. 
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5.4.2 REACTIVE OXYGEN METABOLITE, PRODUCTION (Figure 5.5 and 
Table 5.1) 
ROM production by rectal mucosal biopsies from patients with active UC was 
over five times greater than by biopsies from patients with inactive UC. 
Fig 5.5 Baseline ROM production (photons/mcg/min) by rectal mucosal biopsies 
in patients with inactive (n=27) and active UC (n=23). Median value shown as 
red bar. 
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5.4.3 RECTAL MUCOSAL BLOOD FLOW (RMBF) (Figure 5.6 and, rable 5.1) 
Rectal mucosal blood flow in patients with active UC was a median of 75%, 
greater than in patients with inactive disease. 
Fig 5.6 Baseline RMBF (arbritary units) in patients with inactive (n=35) and 
active UC (n=23). Median value is shown as red bar. 
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'Fable 5.1 Substance P (pg/ml), histamine (pp/ml), 111,13 (pg/ml) and TN 1ý'-u 
(pg/ml) concentrations in peri-mucosal nuid, ROM production 
(photons/mcg/min) and RMBF (arbitrary units) in patients with inactive and 
active UC. 
Patients with 
inactive UC 
Patients with active 
U(I 
Perimucosal fluid cytokines 
Substance P 22(4-99) 57 (19-718)* 
Histamine 6.3 (0.7-14.4) 21.4 (9.4-33.3)* 
IL-1 3 6.7 (2.1-15.3) 18.7 (5.4-46.9)* 
TNF-ct 13.1 (8.6-22.2) 111.1 (43.1-241.3)* 
ROM Production 53(20-325) 275 (38-986)* 
Blood Flow 113 (88-152) 198 (133-241)* 
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5.5 DISCUSSION 
As with the comparison of systemic inflammatory measures, the rectal 
inflammatory measures assessed were found to be greater in patients with active LJC 
than inactive UC. Each will be discussed in turn. 
RECTAL PERI-MUCOSAL FLUID CYTOKINE LEVELS 
The filter paper technique has been used previously to assess the release of' 
various inflammatory cytokines in UC (377). TNF-a release has been shown 
previously by this method to be increased in active UC (377). and we have replicated 
this result in our study. The concentrations of substance P, histamine and IL, - 13 in 
peri-mucosal fluid have not been measured previously using this technique. 
Substance P is an inflammatory neurotransi-nittcr released principally by 
ncurones but also by macrophages, eosinophils, lymphocytes and dendritic cells 
(189). The maýjority of studies suggest that there is an increase in SP concentrations 
and SP-containing neurones in colonic tissue from patients with active IBI) ( 189), 
although there is not complete agreement. In this study we have shown for (lie I. irst 
time that there is increased mucosal release of'SP iii vivo in active UC. Tile pro- 
inflammatory effects of stress in animal models of colitis seem dependent oil the 
degranulation of mast cells (278; 314; 327). The stimulus for mast cell degranulat loll 
in response to stress is likely to involve the release of key neurotransmitters froln the 
ENS, and SP is a possible candidate. Indeed as already discussed, incubation with SP 
of colonic biopsies from patients with 1131) increases mast cell-mediated histamine 
release ( 190). 
As mast cell degranulation appears a key step in mediating stress-rclatcd 
changes in UC (278; 314; 327), the assessment of a mast cell mediator. histamine. is of' 
particular relevance to this study. Histamine release has been shown to be increased 
in active UC using the technique of rectal dialysis ( 123). In this study, we have found 
that rectal histamine release is increased as assessed by the filter paper technique also. 
A mucosal population of IL- 13-secreting NKT cells has recently been 
implicated in the pathogenesis of UC. LPMCs from patients with LIC have been 
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shown to produce more IL- 13 in response to stimulation in vitro than LPMCs trom 
healthy controls (427). In this study we have demonstrated that there is increased IL- 
13 release in vivo as assessed by the filter paper technique. There is no data on the 
role that IL- 13 release might play in the stress or relaxation-related changes in disease 
activity in UC (see Chapter 1). 
REACTIVE OXYGEN METABOLITE PRODUCTION BY REICTAL 
BIOPSIES 
Previous work has shown that ROM production by rectal inucosal biopsies is 
markedly increased inpatients with active colitis (181; 400). We have replicated this 
result in our own study. The increased ROM production is thought to derive largely 
from the presence of acute inflammatory neutrophils in the laniina propria ( 182). it 
must be noted, however, that there is large both inter and intra-individual varulhility 
with this technique (see Chapter 3). This might affect the sensitivity ofthis technique 
I'or detecting small changes in response to psychological stress and hYpnothempy. 
RECTAL MUCOSAL BLOOD FLOW 
As discussed in chapter 3, rectal mucosal blood I'low in thc licalthy m(fiVIdUal 
reflects the autonomic tone in the rectum at that time, it increases with increasing 
parasympathetic tone and decreases with increasing sympathetic tone (407). 
However, there is some evidence to suggest that rectal mucosal blood flow also 
increases in response to inflammation. In a study of the effects ofniucosal injcctlon 
of food antigens, RMBF was found to correlate with the development ol'sub-filucosal 
oedema and visible erythema (408). 
In UC there are mixed reports on the et'l'ccts ofan activc colitis on rcctal 
mucosal blood flow. Srivasta et al found RMBF to be increased in quiescent LJC 
compared to healthy controls ( 104). In contrast, Guslandi found rectal blood flow to 
be decreased in both active and inactive UC (409). In this study we have found rectal 
mucosal blood flow to be increased in active UC compared to inactive disease. We 
also found RMBF to be more variable in active colitis than inactive UC. There was a 
greater coefficient of variation between the four quadrantic regions in active UC than 
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in inactive UC (31 % vs 17%) and a greater IQR in active disease than inactive 
disease (133-241 vs 88-152 respectively). This increased variability may explain the 
discrepancies described between studies on the effects of active and inactive UC on 
rectal mucosal blood flow. The other factor which may be relevant is that different 
equipment was used to measure rectal mucosal blood flow in the various published 
studies. 
With regards to measuring RMBF in this study, the effects of each protocol 
may be complex and depend on two diffefing effects. If the stress protocol increases 
sympathetic innervation, as would be expected ( 137), then acting on autonomic 
function alone stress would be expected to decrease RMBF However, it' stress has a 
pro-inflammatory effect and, as this comparison suggests, RMBF is increased by 
active colitis, then RMBF should be increased. The opposite should apply to hypnosis 
which might be expected to increase rectal parasympathetic tone and have a possible 
anti- inflammatory effect. The results we obtained are described in Chapters 7 and 9. 
5.6 CONCLUSION 
The rectal mucosal release of'SP, histamine, IL- 13 and 'I'Nf--(x, as asscsscd by 
the filter paper method, were all more than doubled in patients with active UC 
compared to inactive disease. ROM was over five times greater in active IJC and 
RMBF more than 50% greater in active compared to inactive disease. 'rhese findings 
support the use of these variables as inflammatory measures in this study. 
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CHAPTER 6 
THE SYSTEMIC RESPONSE TO STRESS IN 
HEALTHY VOLUNTEERS AND PATIENTS Wl'FH 
INACTIVE ULCERATIVE COIXFIS 
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6.1 SUMMARY 
Aims: As per protocol (Chapter 3), to assess the effects of acute psychological stress 
at the systemic autonomic and inflammatory level. 
Methods: As described in Chapter 3, patients with inactive UC and healthy 
volunteers underwent the stress and control protocols. Autonomic and systemic 
inflammatory measures were assessed before and after each protocol in both groups. 
Results: The following results were found: 
1. Subjects found the stress protocol sulýjectively stressful, with an increase of 2.5 
units on the visual analogue scale (VAS) in patients with UC (p=0.003) and 2.5 units 
in healthy volunteers (HVs) (p=0.008). 
2. The stress test induced an autonomic response in both patients with LJC and HVs. 
In patients with UC, stress increased pulse rate by 7 bpm (p=O. (X)02), systolic BP by 
12mmHg (p<0.0001) and diastolic BP by 7mmHg (p<O. (X)OI). In HVss1rcss 
i ncreased pul se by II bpm (p=0.02) and systol ic BP by 9 nim Hg (1)=0.03). 
3. Stress increased LPS-stimulated TNF-(x and IL-6 production by 54, /(, (p=0.0()4) 
and II% (p=0.04) respectively in patients with UC, and TNF-(x production by 947c in 
HVs (p=0.03). 
4. Leukocyte count increased by 16%, in patients with UC (1)=0.01 ) and by 17(/c in 
HVs (p=0.04) in response to stress, 
5. NK cell count increased by 18% (p=0.008) in patients with LJC in response to 
stress. 
6. Stress increased platelet activation by 65%, in patients with UC (p<O. (X)O I) and by 
64% in HVs (p=0.001). PLA formation was increased by 251/c in patients with UC 
(p=0.004) and by 6% in HVs (p=0.03) in response to stress. 
7. There were no differences between the responses of the patients with UC and IM 
8. The control protocol did not change any ofthe variables measured in either the 
patients with UC or healthy volunteers. 
9. Chronic stress, as assessed by psychometric quest lonnai res, did not affect (lie 
autonomic or inflammatory response of patients with UC or HVs to the acute stress 
test. 
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Conclusion: It is possible that some of these systemic pro-inflammatory changes 
may contribute to the adverse effects of stress in UC. 
6.2 INTRODUCTION 
As described in Chapter 1, adverse life-events and chronic psychological 
stress have been found to be associated with an increased incidence of disease relapse 
in patients with quiescent UC (270; 273). Acute stress has been shown to contribute 
to the activation and reactivation of experimental colitis in animal modcls (299,3M). 
There have, however, been few studies which have examined the effects of stress on 
inflammation in patients with IBI) (279). The mechanisms by which stress might 
worsen UC remain unknown. 
In this chapter we will describe the systemic responses ol'both patients with 
quiescent UC and healthy volunteers to the stress protocol described in chapter 3. The 
hypothesis which underlies this work is that stress might lead to an increased rate of' 
relapse in UC via its pro-inflammatory effects on various systcniic inflammatory 
measures. 
The inflammatory response to stress was subsequently related to 
psychometric assessments of chronic perceived stress levels ofeach oftlic 
participants. 
For ease of reading the mucosal responses ofpatients with LJC to stress will he 
described separately in Chapter 7. 
179 
6.3 DEMOGRAPHICS OF PATIENTS AND HEALTHY 
VOLUNTEERS 
25 patients with inactive UC, as defined by a Baron's score of less than 2, and 
II healthy volunteers underwent the stress protocol. 10 patients with quiescent UC 
and II healthy volunteers underwent the control protocol. 
Table 6.1 Sex, age, disease extent, treatment, Baron's score and Simple Colitis 
Activity Index (SCCAI) for patients with inactive UC and healthy volunteers 
undergoing the stress and control protocols. 
Protocol 
Stress Control 
UC (n=25) UC (n= 10) 
Age 44(28-64) 52(23-65) 
Sex 13 Male 3 male 
Disease extent 48% total 30(X, total 
20% left-sided 30% left-sidcd 
32% distal 40('Ic, distal 
Treatment 76% on 5-ASA 90170 5-ASA 
12% thiopurines 10(/'(, thiopurmes 
4% methotrexate 0% corticosteroids 
0% corticosteroids 
Baron's score 0(0-1) 0(0-1) 
SSCAI 1 (0-2) 1 (0-2) 
HV (n=l 1) HV (n=1 1) 
Age 27(23-56) 36(27-57) 
Sex 4 male 6 malc 
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6.4 RESULTS 
6.4.1 SUBJECTIVE RESPONSE TO STRESS PROTOCOL (Figure 6.1 and 6.2) 
As assessed by visual analogue scale (VAS), patients with UC and healthy 
volunteers (HV) rated the stress protocol as stressful with a median increase of 2.5 
units in UC (3(1-5) vs. 5.5(4-8), p<0.0001) and 2.5 units in HV (2(2-3) vs. 4.5 (3.5- 
6.0), p=0.008). The one patient with UC and the two HV who scored the stress 
procedure non-stressful on VAS showed no autonomic response or inflammatory 
response in the majority of variables measured. These three subjects were included in 
the analysis ofchanges elicited in response to the stress protocol. 
Figure 6.1 Effects of stress protocol on visual analogue scale (VAS) stress score 
in patients with inactive UC (n=25). Median is shown in red. 
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p=0.003 
Figure 6.2 Effects of stress protocol on visual analogue score (VAS) stress score 
in healthy volunteers (n=1 1). Median is shown in red. 
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6.4.2 AUTONOMIC RESPONSE 
6.4.2.1 Pulse Rate (Figure 6.2 and 6.3 and Table 6.2) 
The mean of the three pulse rate readings measured during the stress protocol was 
increased compared to pre-test values by 7 bpm (median) in patients with quiescent 
UC and by II bpm in HV. Thirty minutes after the end of' the stress protocol, the 
mean pulse rate had returned to baseline in both groups. 
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p=0.008 
Figure 6.3 Effects of stress protocol on pulse rate (hpm) in patients with inactive 
UC (n=25). The points shown as "During" are the mean of the three readings 
taken during the stress test. Median is shown in red. 
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Figure 6.4 Effects of stress protocol on pulse rate (hpm) in healthy volunteers 
(n=I 1). The points shown as "During" is the mean ofthe three readings taken 
during the stress test. Median value is shown in red. 
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6.4.4.2 Systolic Blood Pressure (Figure 6.5 and 6.6 and Table 6.2) 
Mean systolic blood pressure increased during the stress protocol by a median 
of 12 mmHg in patients with UC and by 9 mmHg in HV. In patients with UC, the 
systolic BP fell, but remained elevated compared to pre-test levels, by median 
4mmHg when measured 30 minutes after the stress protocol. 
Figure 6.5 Effects of stress protocol on systolic BP (nimlig) in patients with 
inactive UC (n=25). The points shown as "During" is the mean ofthree readings 
taken during the stress test. Median value is shown in red. 
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Figure 6.6 Effects of stress protocol on systolic BP (numllg) in healthy volunteers 
(n=l 1). The points shown as "During" is the mean ofthe three reading laken 
during the stress test. Median value is shown in red. 
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6.4.2.3 Diastolic Blood Pressure (Figure 7.7 and 6.8 and Table 6.2) 
In patients with UC, mean diastolic BP increased by 7mmHg during stress 
(p<0.0001). As with systolic BP, in patients with UC the diastolic BP fell when 
measured 30 minutes later, but remained elevated by median 4mmHg compared to 
baseline (p=0.01). Diastolic BP was also elevated in HV 30 minutes after the stress 
protocol (p--0.006). 
Figure 6.7 Effects of stress protocol on diastolic BP (mmUlg) in patients with 
inactive UC (n=25). The points shown as "During" is the mean ofthe three 
readings taken during the stress test. Median value is shown in red. 
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Figure 6.8 Effects of stress protocol on diastolic BP (nintlig) in healthy 
volunteers (n=I 1). The points shown as "During" is the mean ofthe I hree 
readings taken during the stress test. Median value is shown in red. 
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Table 6.2 Pulse (bpm), systolic and diastolic BP (mmHg) in response to stress 
and control protocols in patients with UC and healthy volunteers (HV). * p<0.05 
from pre-procedure value. 
Protocol N 
Stress UC 25 
Before During/After 30 mins after 
HV 
Control uc 10 
HV 
Pulse 
Systolic BP 
Diastolic BP 
Pulse 
Systolic BP 
Diastolic BP 
Pulse 
Systolic BP 
Diastolic BP 
Pulse 
Systolic BP 
Diastolic BP 
70(65-74) 
118 (113-133) 
72(68-79) 
65(62-82) 
114 (109-122) 
74(66-83) 
67(55-82) 
139 (111-158) 
77(60-89) 
71 (56-74) 
114 (102-121) 
70(63-75) 
77 (70-85)* 
130 (119-148)* 
79 (75-99)* 
76 (74-82)* 
123 (112-134)* 
75(73-82) 
66(56-79) 
130 (109-150) 
75(61-88) 
66(61-74) 
110 (102-122) 
69(62-75) 
7()(66-76) 
122 (116-137)* 
76 (72-92)* 
69(64-81) 
122 (108-129) 
78 (73-84)* 
67(57-78) 
133 (113-150) 
76(60-87) 
69(60-73) 
112 (104-124) 
72(63-77) 
6.4.3 SYSTEMIC INFLAMMATORY RESPONSE 
6.4.3.1 Serum cytokine concentrations (Table 6.3) 
Serum IL-6 and It, 13 concentrations were unaffcctcd by stress In cither UC 
or in HV. 
6.4.3.2 ITS-stimulated cytokine production (Figure 6.9,6.10 and 6.11 and Table 
6.3) 
The production of TNF-(x by LPS-stimulated whole blood wits increased ill tile 
sample taken 30 minutes after stress by over 50%, in patients with LJC (1)=O. ()04) and 
nearly doubled in HVs (p=0.03). Median production ofIL-6 by LPS-stimulated 
whole blood rose in the sample taken 30 minutes after the stress protocol by I I(/(, in 
patients with UC (p=0.04). 
196 
Figure 6.9 The effects of stress on TNF-a LPS stimulated production by whole 
blood from patients with ulcerative colitis (n=25). Median value is shown in red. 
LL 
z 
p=0.004 
200- 
inn - ---------------------------- ----------- ---------- I-w 100 ------ 
50- 
0- 
Figure 6.10 The effects of stress on LPS stimulated TNF-(x production by blood 
from healthy volunteers (n=1 1). Median value is shown in red. 
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Figure 6.11 The effects of stress on IL-6 production by LPS-stimulated whole 
blood in patients with UC (n=25). Median value is shown in red. 
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Table 6.3 Serum IL-6 and IL-13 concentrations (pg/ml), and LPS'-stimulated IL- 
6 and TNF- production (ng/ml) by whole blood, in response to stress and control 
protocols in patients with UC and healthy volunteers (HV). * p<0.05 from pre- 
procedure value. 
Protocol N Before After 30 mins after 
Stress UC 25 Serum IL-6 1.3 (1.0-2.2) 1.4 (1.0-2.2) 1.5 (1.0-1.9) 
Serum IL- 13 1.9 (0.0-4.4) 1.7 (0.0-4.5) 1.7 (0.1-4.9) 
LPS TNF-a 28(17-57) 4307-69) 43 (20-62)* 
LPS IL-6 255 (204-387) 232 (179-306) 294 (214-411)* 
HV II Serum IL-6 1.1 (0.8-1.5) 0.84 (0.5-1.3) 1.2 (0.6-1.4) 
Serum IL- 13 0.2(0-2.3) 0.4(0-3.4) 0.8(0-2.5) 
LPS TNF- a 19(12-35) 27(19-60) 37 (14-60)* 
LPS IL-6 212 (156-293) 220 (187-305) 245 (211-392) 
Control UC 10 Serum IL-6 2.8 (2.4-4.4) 2.6 (2.4-3.4) 2.7 (2.1-3.7) 
Serum IL- 13 1.3 (0.8-2.2) 1.2 (0.9-2.3) 1.6 (0.9-2.1) 
LPS TNF- a 18(13-59) 19(12-60) 20(16-72) 
LPS IL-6 223 (169-537) 219 (143-427) 254 (173-527) 
HV II Serum IL-6 0.6 (0.5-0.9) 0.6 (0.4- 1.3) 0.7 (0.4-1.5) 
Serum IL- 13 0.8(0-2.1) 1.0(0-2.4) 0.7(0-1.8) 
LPS TNF- a 18(8-30) 1901-26) 2001-32) 
LPS IL-6 223 (164-302) 245 (203-345) 232 (195-315) 
6.4.3.3 Leukocyte Count (Figure 6.12 and 6.13 and Table 6.4) 
Total white cell count (WBC) increased compared to hasclinc in the sampic 
taken 30 minutes after stress by 16% (median) in patients with U(' (p=(). ()l ) and 1717c 
in HV (p=0.04). 
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Figure 6.12 The effects of stress on leukocyte count in patients with inactive UC 
(n=25). Median value shown in red. 
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Figure 6.13 The effects of stress on leukocyte count in healthy volunteers (n=1 1). 
Median value is shown in red. 
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6.4.3.4 Natural Killer (NK) cell numbers (Figure 6.14 and'Fable 6.4) 
In patients with quiescent UC, median NK cell numbers, expressed as a 
percentage of lymphocytes and monocytes, were increased by 18"/(, in the sample 
taken immediately after the stress protocol (p=0.008) but had returned to base line in 
the sample taken 30 minutes later. There was no change in NK cell count ]in HVs in 
response to stress. 
Figure 6.14 The effects of stress on NK cell count (% of lymphocytes and 
monocytes) in patients with inactive UC (n=25). Median value is shown in red. 
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6.4.3.5 Platelet Activation (Figure 6.15 and 6.16 and Table 6.4) 
The median percentage ot'platclets expressing p-selectin was increased by 
65"/(, in patients with UC (p<0.0001) and by 61 (7c in HV (p=0.04) in tile blood sample 
taken immediately after the stress protocol compared to tile pre-test sample. 'I'll''s 
percentage fell in the sample taken 30 minutes later but remained elevated compared 
to baseline (29% in patients with UC (p=0.001 ) and 22%, in [IV (p=(). ()oi )). 
191 
Figure 6.15 The effects of stress on platelet activation (p-selection expression (% 
of platelets positive for p-selectin)) in patients with inactive UC (n=25). Median 
value is shown in red. 
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Figure 6.16 The effects of stress on platelet activation (% of platelets positive for 
p-selectin expression) in healthy volunteers (n=1 1). Median value is shown in 
red. 
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6.4.3.6 Platelet-leukocyte aggregate (PLA) formation (Figure 6.17 and 6.18 and 
Table 6.4) 
The median percentage of leukocytes forming PLAs was increased by 251yc in 
patients with quiescent UC (p=0.004) and by 6% in HV (p=0.03) in the blood sample 
taken immediately after the stress protocol compared to base-line. In patients with 
quiescent UC, PLA formation remained elevated by 25% in the sample taken 30 
minutes later (p=0.00 I ). 
Figure 6.17 The effects of stress on PLA formation (% ofleukocYtes forming 
PI, As) in patients with inactive UC (n=25). Median value is shown in red. 
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Figure 6.18 The effects of stress on PLA formation (% of' leukocYtes forming 
PI, As) in healthy volunteers (n=l 1). Median value is shown in red. 
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Table 6.4 Total leukocyte count (WBQ (cells x 10%4/MM3), natural killer (NK) 
cell number (% of monocytes; and lymphocytes), platelet activation (% of 
platelets positive for p-selectin) and platelet-leukocyte aggregate (PLA) 
formation (% of leukocytes forming PLAs) in response to stress and control 
protocols in patients with UC and healthy volunteers (11V). * p<0.05 from pre- 
procedure value. 
Protocol N Before Immediately 30 mins after 
after 
Stress UC 25 WBC 6.3 (5.3-8.1) 7.0 (5.5-7.9) 7.3 (5.8-8.4)* 
NK count 6.4 (4.8-8.7) 7.6 (5.4-9.3)* 6.7 (4.0-8.8) 
P-selectin 2.2 (1.3-4.5) 3.5 (2.2-5.2)* 2.8 (2.1-4.6)* 
PLA 2.4 (1.7-3.3) 3.0 (2.4-3.9)* 3.0 (2.4-4.1) * 
HV 11 WBC 
NK count 
P-selectin 
PLA 
5.7 
6.2 
3.1 
3.4 
(5-7.5) 
(5.1-8.6) 
(2.4-3.7) 
(2.2-4.0) 
6.2 
7.4 
5.0 
3.6 
(5.6-8.7) 
(5.8-9.1) 
(2.5-6.3)* 
(2.7-4.8)* 
6.7 
5.8 
3.8 
4.1 
(5.8-8.3)* 
(5.1-7.0) 
(3.0-6.7)* 
(2.8-5.4) 
Control UC 10 WBC 7.4 (5.2-9.1) 7.7 (5.5-8.6) 7.8 (5.7-9.2) 
NK count 7.1 (3.2-9.4) 5.9 (3.7-9.0) 6.9 (4.0-8.0) 
P-selectin 3.1 (2.2-4.1) 3.5 (2.4-4.2) 3.0 (2.1-3.7) 
PLA 2.3 (1.7-3.2) 2.4 (1.8-3.3) 2.1 (1.8-2.9) 
HV 11 WBC 5.4 (4.6-8) 5(4.4-6.6) 4.9 (4.7-6.5) 
NK count 7.3 (6.1-10.1) 8.8 (6.0-10.6) 8.2 (5.6-9.9) 
P-selectin 3.1 (2.3-3.5) 2.9 (2.5-4.0) 3.2 (2.5-4.8) 
PLA 2.5 (2.2-3.8) 2.4 (2.0-3.4) 2.5 (2.0-4.2) 
Comparison of patients with quiescent UC and healthy volunteers 
There were no significant differences in the changes elicited by the stress 
protocol in any variables between patients with inactive UC and HV (Tables 6.2,6.3 
and 6.4). 
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Relationship between age and responses to stress protocol 
Although the patients with UC had a higher median age than the HV, age did 
not correlate with any of the changes seen in response to the stress protocol in either 
group. 
Effect of immunosuppressant medication on response to stress protocol 
Four of the patients with UC undergoing the stress protocol were taking either 
thiopurines or methotrexate. This is too small a number to allow comparison of the 
response to stress with that of patients who were not taking immunosuppressants. 
Furthermore removal of these four patients from the analysis did not significantly 
alter any of the results reported above. 
Psychometric questionnaires 
None of the measures of long term stress (STAI-T, HADS, PSQ or BSI) 
correlated with the changes in any of the variables measured in response to the stress 
protocol. However, scores on the STAI-S scale did correlate with changes in NK 
cells levels (R=+0.56, p=0.004) and PLA formation (R=+0.43, p=0.01). 7bere were 
no differences in scores of any of the psychometric questionnaires between patients 
with UC undergoing the stress protocol and patients with UC undergoing the control 
protocol. 
Effects of control protocol 
The control protocol caused no changes in any of the variables assessed in 
either patients with inactive UC or HV (Tables 6.2,6.3 and 6.4). 
6.5 DISCUSSION 
Stress was found to increase a range of systemic inflammatory variables each 
of which will be discussed in turn. 
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LPS-STIMULATED CYTOKINE PRODUCTION. 
The LPS-stimulated production of TNF-a and IL-6 by whole blood was 
increased in the samples taken after stress. This is unlikely to be explained simply by 
the stress-induced increase in leukocyte count as the percentage increases in TNF-a 
and IL-6 production by whole blood did not correlate with the percentage increases in 
leukocyte count in any patient group. 
Other studies have shown that stress alters cytokine production by whole 
blood in healthy volunteers. Blood taken from students before an exam produced 
more TNF-cE and IL, 6 when stimulated with LPS than blood taken after (228). 
Although the mechanism by which this occurs is unknown, adrenaline infusion has 
been shown to increase LPS-stimulated production of IL-8 and ]L- 10 by whole blood, 
and it is likely that sympathetic activation is important in mediating this effect 
(202; 203). TNF-a is a pivotal cytokine in the pathogenesis of IBD (428) and the 
therapeutic benefit of anti-TNF-a antibodies has been shown in both Crohn's disease 
(429) and UC (430). IL-6 is also a potentially important inflammatory cytokine in 
IBD (431) and is the stimulus for C-reactive protein production (432). It is at least 
conceivable that psychological stress could worsen UC by increasing the production 
of TNF-a and IL, 6 by leukocytes subsequently stimulated by exposure to bacterial 
products such as LPS. 
NK CELL NUMBERS. 
Increases in circulating NK cell number are consistently found in association 
with acute stress (219). Although traditionally considered a component of the innate 
immune system, more recently NK cells have also been shown to affect adaptive 
immunity via interactions with dendritic cells (433). NK cells can localise to areas of 
inflammation and interact with immature dendrific cells to stimulate their maturation 
and proliferation, which in turn influences their interactions with T-cells. flowcver, 
the increases in NK cell number in this study were short-lived, having resolved within 
30 minutes of the stress test. It therefore seems unlikely that changes in NK cell 
number play a major role in mediating stress-induced increases in IBD activity. 
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PLATELET ACTIVATION AND PLATELET-LEUKOCYTE AGGREGATE 
FORMATION. 
Platelet activation and PLA formation have been shown to be increased by 
experimental stress in healthy subjects (241; 242) We have found stress to have 
similar effects in quiescent UC. Beta-adrenergic stimulation may underlie this effect 
since exercise-induced platelet activation can be prevented by beta-blockers (241). 
Platelets circulate in a more activated state in patients with 1131) and platelet 
activation may contribute to pathogenesis through direct pro-inflammatory effects 
and by causing mucosal thrombosis and microinfarction as a result of microvascular 
ischaemia(141). PLA formation is also increased in 11313 and may facilitate 
extravasation of leukocytes to sites of mucosal inflammation(143). Increases in both 
platelet activation and PLA formation had not resolved in blood taken 30 minutes 
after stress and it is possible that increases in these variables could contribute to 
stress-induced increases in 1131) activity. 
COMPARISON OF PATIENTS WITH UC AND HEALTHY CONTROLS. 
Previous work has suggested that patients with IBD may have a relative 
imbalance of HPA axis and autonomic function, with autonomic hypereflexia, and 
that this may be important in driving mucosal inflammation. (168; 287) However, in 
our study there were no differences observed between patients with UC and healthy 
volunteers in both their autonomic and systemic inflammatory responses to the stress 
protocol. This would suggest that whilst stress may act as a trigger for exacerbations 
of UC, an exaggerated autonomic and inflammatory response to stress is not a 
primary aetiological factor in UC. 
PSYCHOMETRIC QUESTIONNAIRES. 
In animal studies, maternal deprivation in infancy, a model of chronic stress, 
rendered the adult rat more susceptible to the effects of acute restraint stress in 
augmenting dextran sulphate-induced colitis (297). Levenstein et al found high 
scores on the Perceived Stress Questionnaire to be predictive of relapse in patients 
with inactive UC (273). In our study, acute anxiety scores in patients with UC, as 
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measured by the STAI-S scale, directly correlated with stress-induced NK cell 
numbers and PLA formation. However, while patiýnts with inactive UC reported 
higher chronic stress levels (PSQ score), were more anxious (HADS-A), and 
somatised (BSI) more than healthy volunteers, scores in these indices did not 
correlate with the changes observed in any of the inflammatory, variables in response 
to the stress protocol. 
6.6 CONCLUSION 
The acute stress test stimulated an autonomic response in the majority of 
subjects with UC and HVs studied, and led to an increase in a range of inflammatory 
variables at the systemic level. Some of these changes may be important in mediating 
stress-related worsening of disease activity in UC. 
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CHAPTER 7 
THE MUCOSAL RESPONSE TO STRESS IN 
PATIENTS WITH INACTIVE ULCERATIVE 
COLITIS 
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7.1 SUMNURY 
Aim: To assess the effects of acute psychological stress on several inflammatory 
measures at the rectal mucosal level. 
Methods: Individuals with quiescent UC underwent the stress test or control 
procedure and the rectal mucosal release of inflammatory cytokines, mucosal blood 
flow, reaptive oxygen metabolite production and conventional histology were 
assessed before and after. 
Results: The following results were found: 
1. Stress more then doubled mucosal TNF-a release (p=0.03). 
2. Stress increased mucosal ROM production by over fivefold (p= 0.001). 
3. Rectal mucosal blood flow (RMBF) was reduced by 22% in response to stress 
(p=0.05). 
4. There was no overall change in histological score (n=17) but in all five cases 
where there was a degree of inflammation present in the pre-stress biopsy (assessed 
by Saverymuttu score), there was an increase in histological score in the post-stress 
sample. These five patients also demonstrated a greater percentage increase in rectal 
mucosal TNF-a release than did the other twelve (P=0.04). 
5. There was a trend towards increased mast cell degranulation detected by 
immunofluorescence (p=0.07) in the patients in whom this variable was assessed. 
6. There was a trend towards increased numbers of Ecoli present in the lamina 
propria as assessed by fluorescent-in-situ hybridisation in rectal biopsies taken after 
stress. 
7. Chronic stress, as assessed by psychometric questionnaires, did not affect the 
mucosal response to the acute stress test. 
8. The control protocol did not change any of the mucosal inflammatory measures 
assessed. 
Conlusion: Stress increased rectal mucosal release of TNF-a and reactive oxygen 
metabolite production by rectal mucosal biopsies. Conventional histological 
examination suggests that the effects of stress may be increased in individuals with a 
pre-existing mucosal of inflammation. 
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7.2 INTRODUCTION 
Acute physical stress has been shown to increase the release of mast cell 
mediators in the small bowel in healthy individuals (278). Repeated administration of 
a similar stress also caused increased mast cell degranulation at electron microscopy 
in mucosal biopsies in both healthy individuals and patients with IBD (279). Several 
of the stress-related pro-inflarnmatory changes seen in animal models of colitis also 
seem dependent on the degranulation of mast cells. The mechanism by which this 
might occur is unknown. 
In this chapter we will describe the mucosal. responses of patients with 
quiescent UC to the stress protocol described in chapter 3. The hypothesis underlying 
this work is that inflammatory changes occurring at the mucosal. level might 
contribute to the reported stress-related increase in disease activity in UC. The 
variables assessed include pro-inflammatory neurotransmitters which may be 
important in stimulating mast cell degranulation (substance P (190)), measures of 
mast cell degranulation (histamine (1ý3) and immunofluorescence), cytokines 
thought to be important in the pathogenesis of UC QL-13 (180), TNF-a (36)), 
inflammatory free radicals (reactive oxygen metabolite production (18 1)), mucosal- 
associated bacteria (434) and rectal autonomic measures (rectal mucosal blood 
flow(407)) and conventional histology (378). 
7.3 DEMOGRAPHICS OF PATIENTS AND HEALTHY 
VOLUNTEERS (Table 6.1) 
The demographics of the patients with quiescent UC and healthy volunteers 
undergoing the stress and control protocols has already been described in Chapter 6. 
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7.4 RESULTS 
Perimucosal fluid samples were available from 24 of 25 patients undergoing 
the stress protocol and 9 of 10 patients undergoing the control protocol. In these two 
patients the samples were accidentally defrosted and could therefore not be used. 
ROM and conventional histology could be performed on paired pre- and post-stress 
biopsies in 17 of the 25 patients undergoing the stress protocol. Biopsies from the 
other eight patients were used for studies of mast cell degranulation and mucosal 
associated bacteria. 
7.4.1 Cytokine and mediator concentrations in rectal peri-mucosal fluid (Figure 
7.1 and Table 7.1) 
In patients with UC, the median TNF-ot concentration in rectal pcri-niticosal 
fluid increased by over twofold after the stress protocol (p=0.03), the concentrations 
of IL- 13, histamine and substance P in the peri-mucosal fluld did not change. 
Figure 7.1 The effects of stress on TNF-ct concentration (pg/ml) in rectal peri- 
mucosal fluid in patients with inactive IJC (n=24). Median is shown in red. 
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7.4.2 Reactive oxygen metabolite production (Figure 7.2 and Table 7.1) 
The stress protocol increased median mucosal production of ROMs by over 
fivefold (p=0.001). 
Figure 7.2 The effects of stress on ROM production (photons/meg/min) by rectal 
mucosal biopsies from patients with inactive UC (n=17). Median value shown in 
red. 
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7.4.3 Rectal mucosal blood flow (Figure 7.3 and Table 7.1) 
Rectal mucosal blood flow, as assessed by laser Doppler flownictry, fell by 
22% (median) after stress (p=0.05). 
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Figure 7.3 Effects of stress on RMBF in patients with inactive UC (n=25). 
Median value shown in red. 
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7.4.4 Histological assessment (Figure 7.4 and 7.5 and Table 7.1) 
There was no overall change in inflammation, as assessed by Saverymut(LI 
score (379), in the seventeen pairs of biopsies available for assessment, with 12 pairs 
scoring zero both before and after the stress protocol. However, in all five patients 
where there was a degree of inflammation present in the pre-stress biopsy (scores I- 
6), there was an increase in histological score in the post-stress sample. 
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Figure 7.4 The effects of stress on histological score in mucosal biopsies in 
patients with inactive UC (n=17). Only rive lines are shown as in 12 samples the 
histological score was zero, as assessed by the Saverymuttu score (378), before 
and after the stress protocol and this is shown as one line. Median value is 
shown in red. 
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The five patients whose mucosa demonstrated an increase in histological score also 
showed a greater percentage increase in TNF-ct concentration in peri-mucosal fluid 
than the 12 cases where there was no change in histological score. 
Figure 7.5 Percentage increase in mucosal TNF-a production in patients with 
and without a change in histological score in response to stress. Median value is 
shown in red. 
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Table 7.1 Peri-mucosal fluid cytokine levels (pg/ml), reactive oxygen metabolite 
(ROM) production by mucosal biopsies (photons/meg/min), rectal blood flow 
(arbitrary units) and histological score in response to stress and control protocol 
in patients with quiescent UC. * P<0.05 from pre-procedure value. 
Protocol N Before After 
Stress 
Perimucosal fluid cytokines 
Substance P 24 21 (0-96) 15(0-24) 
Histamine 24 3.8 (0.7-14.5) 3.1 (1.4-21.9) 
IL-13 24 10.1 (4.5-16.8) 10 (4.3-28.5) 
TNF-ct 24 12.8 (8.6-20.2) 25.8 (12.7-41.5)* 
ROM production 17 64(24-833) 368 (123-1569)* 
Blood flow 25 122 (87-158) 95 (72-153)* 
Histological Score 17 0(0-0.5) 0(0-2) 
Control 
Perimucosal fluid cytokines 
Substance P 9 32(0-94) 0(0-5.2) 
Histamine 9 2.0 (0.1-12.2) 2.1 (0.6-14.7) 
IL-13 9 14.5 (8.5-20.1) 16.8 (9.2-25.2) 
TNF-ct 9 8.9 (0-15.5) 5.8 (0.6-12.2) 
ROM production 10 31 (5-56) 25(4-158) 
Blood flow 10 111 (106-141) 111 (71-142) 
Histological Score 10 () (()-I) () (()- I) 
7.4.5 Mast cell number and degranulation (Figure 7.6 and Table 7.2) 
Eight pairs of pre- and post- stress rectal biopsies froin patients with [V were 
available for immunofluorescence. There was a non-sig t , nificant trend owards an 
increase in the percentage of mast cells degranulating after stress (p=0.07). There 
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was no obvious trend towards a change in total mast cell number. There were no 
control biopsies available for comparison. 
Figure 7.6 The effects of stress on the percentage of mast cells degranulating in 
rectal biopsies from patients with inactive UC (n=8). Median value is shown in 
red. 
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'Fable 7.2 Mast cells numbers, as a percentage of total cells, and percentage of 
mast cells degranulating in pre and post stress biopsies in inactive UC (n=8). 
Pre-Stress Post-Stress 
Mast cell number 1.9 (1.3-2.3) 1.4 (1.0-1.9) 
(% total cells) 
Degranulating mast cells 7(5-28) 29(13-85) 
7.4.6 Mucosa-associated nora (Figure 7.7 and 'rable 7.3) 
Six pairs of pre- and post-stress biopsies were available for assessment of' 
mucosa-associated flora using FISH. The total number of'Lcoli, and Lcoli as a 
percentage of the total bacteria, were calculated for both bacterm adherent to thc 
surface of the mucosa and bacteria found in the lamina propria. Only sniall numbers 
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p=0.07 
of samples were available for analysis and none of the changes observed were 
statistically significant. However, there were non-significant trends to increased 
numbers of Ecoli in the lamina propria (p=O. 15). There were no control biopsies 
available for comparison. 
Fig 7.7 The effects of stress on number of Exo1i in the lamina propria in rectal 
biopsies in patients with inactive UC (n=6). Median value is shown in red. 
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Table 7.3 Number Exo1i and Exo1i as a percentage of total bacteria adherent to 
mucosal surface and in the lamina propria in pre and post stress biopsies in 
inactive UC (n=6). 
Pre-Stress Post-Stress 
Surface adherent Bacteria 
E. coli /mm epithelial surface 90(71-115) 112 (75-156) 
Total Bacteria /mm epithelial surface 554 (464-683) 534 (302-629) 
% E. coli 16(14-18) 24(14-61) 
Bacteria in lamina propria 
E. coli /mm 2 lamina propria 4(0-22) 17(5-42) 
Total Bacteria / MM2 lamina propria 8(2-24) 18(6-44) 
% E. coli 88(0-98) 94(41-98) 
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Before After 
Effect of inummosuppressant medication on response to stress protocol 
As with the systemic inflammatory reponse to stress, immunosuppressant 
therapy had no overt effect on the mucosal response to stress and the removal of the 
four patients taking thiopurines and methotrexate from the analysis did not 
significantly alter any of the results reported above. 
Psychometric questionnaires 
As with the systemic response to stress, none of the measures of long term 
stress (STAI-T, HADS, PSQ or BSI) correlated with the changes in the variables 
observed at the mucosal level in response to the stress protocol. The STAI-S, a 
measure of stress at that moment, also did not correlate with any of the changes 
observed in response to stress. 
Effects of control protocol 
The control protocol caused no changes at the mucosal level in any of the 
variables assessed (Tables 7.1). However as stated above, there were no control 
biopsies available for comparison with the effects of stress on mast cell numbers or 
mucosa-associated bacteria. 
7.5 DISCUSSION 
Experimental stress caused increases in several rectal mucosal inflammatory 
variables, which could theoretically contribute to stress-induced relapses in UC. 
RECTAL PERI-MUCOSAL CYTOKINE AND MEDIATOR RELEASE. 
It has been proposed that stress-induced increases in inflammation are 
mediated through increases in intestinal permeability, allowing exposure of the 
mucosal immune system to bacterial flora. 
Restraint stress in rodents increased epithelial permeability to inert marker 
molecules such as EDTA and to antigenic proteins such as horseradish peroxidase 
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(305) and increased the phagocytic uptake of E. coli into follicular-associated 
epithelium (313). 
The effects of restraint stress in these experiments did not occur in mast cell- 
depleted animals and it is likely that mucosar mast cell degranulation is an important 
step in mediating the pro-inflammatory effects of stress on the GI tract (311; 314). 
Physical stress, caused by immersion of the hand in iced water, has been shown to 
increase'the proportion of activated and degranulating mast cells seen on electron 
microscopy in healthy controls and even more so in patients with 1131) (279). Mast 
cell granules contain a range of inflammatory cytokines, including histamine and 
TNF-a (435). In vitro studies have shown that increases in ileal permeability are 
dependent on the production and release of TNF-a (436). In this study, we have 
shown an increase in the concentration of TNF-a, but not of histamine, in rectal peri- 
mucosal fluid after stress and this could conceivably lead to an increase in mucosal 
permeability and consequently inflammation. 
The stimulus for mast cell degranulation after stress is likely to involve the 
release of specific neuropeptides from the enteric and autonomic nervous systems. 
One candidate neuropeptide, substance P (SP), has been shown to increase the release 
of mast cell mediators from colonic biopsies in patients with UC (190). SP also has 
direct pro-inflammatory effects, stimulating IL-8 secretion from epithelial cells (189). 
In our study stress did not increase the concentration of SP in rectal peri-mucosal 
fluid. This result may partly reflect the sensitivity of our method for assessing SP 
release, since in many samples the SP concentrations were below the limit of 
detection. I 
HISTOLOGICAL ASSESSMENT. 
In most patients (12/17), there was no active histological inflammation on the 
Saverymuttu score (378) in the pre-stress biopsy: this could be either because the 
patients were in complete histological remission or because the Saverymuttu score is 
insufficiently sensitive to detect minor degrees of inflammation. 
The failure to find an overall increase in inflammation in pre and post-stress 
rectal biopsies may be partly due to the short time course of the protocol and the 
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relatively mild nature of the stressor. However, we did observe an increase in 
histological score in all five pairs of biopsies in patients in whom there was a degree 
of inflammation (24) already present prior to the protocol. This observation might 
suggest that in individuals who are "primed", with a degree of inflammation already 
present, acute stress is able to able to worsen microscopic inflammation. Furthermore 
the patients who showed an increase in histological score also showed a greater 
percentage increase in rectal mucosal TNF-a release compared to those whose 
histological score remained unchanged. Given the importance of TNF-a as a key 
cytokine in the pathogenesis of IBD (36), this observation also supports the theory 
that patients who already have a mild degree of colonic inflammation present are 
more vulnerable to the pro-inflammatory effects of stress. 
DEGRANULATING MAST CELLS 
As described above, mast cell degranulation is likely to be an important step 
in mediating the pro-inflammatory effects of stress on the GI tract. Enhanced mast 
cell activation (122) and rectal mucosal histamine release (123) have reported 
previously in active UC. Furthermore, an inhibitor of the mast cell mediator, tryptase 
(129), and the mast cell stabiliser, ketotifen (130), have been shown to be of 
therapeutic benefit in small open-labelled trials in UC. 
Although we did not find an increase in the mucosal release of histamine (see 
above) there was a non-significant trend to an increased percentage of activated mast 
cells as assessed by immunofluoresence in the post-stress biopsies of the patients 
studied. This is in keeping with the results of a previous study in which an increase in 
activated mast cells, as assessed by electron microscopy, occurred after rcpeated 
sessions of a physical stressor. (279) However, it must be stressed that in our work 
the number of samples available for analysis was small and there is no control data. 
MUCOSA-ASSOCIATED BACTERIAL FLORA 
The aetiology of IBD is thought to involve an abnormal immune responsc to 
luminal. bacteria (107). Alteration in bacterial-mucosal interactions in response to 
stress could contribute to stress-related increases in intestinal inflammation in 1131). 
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Increased adherence of pathogenic bacteria to colonic mucosa has been shown 
to occur in response to long term stress in animal models (437). The stress hormone 
noradrenaline increases the adherence of E. coli 0157 to murine caecal mucosa (317). 
As well as adherence, stress has been shown to increase uptake of bacteria into the 
gut mucosa in animal models. Chronic stress in n-dce increases the phagocytic uptake 
of killed Ecoli into the follicle-associated epithelium which overlies Peyer's patches 
(313), and leads to increased numbers of animals with detectable levels of bacteria in 
their inguinal and mesenteric lymph nodes (316). 
In this study we have observed a non-significant trend to increased numbers of 
Ecoli found in the lamina propria in rectal biopsies taken after the stress protocol 
(p=O. 15). However, the number of paired biopsies available for analysis was low and 
there were no control biopsies available for comparison. Previous work has shown 
the number of Ecoli adherent to the rectal mucosa and the number of Ecoli found in 
the lamina propria to be increased in patients with active UC compared to inactive 
UC and healthy controls (64). 
RECTAL MUCOSAL REACTIVE OXYGEN METABOLITE (ROM) 
PRODUCTION. 
Mucosal ROM production is increased in active compared with inactive UC 
(181) and may playa pathogenic role in 1131). Short-term mental stress has been 
shown to increase the oxidative activity of neutrophils in peripheral blood from 
healthy volunteers (438). In this study we have shown that psychological stress 
substantially increases rectal mucosal ROM production, an effect which could 
contribute to mucosal damage. 
RECTAL MUCOSAL BLOOD FLOW. 
Psychological stress reduced RMBF in patients with quiescent UC as it does 
in patients with irritable bowel syndrome and in healthy volunteers. (439) This is 
thought to be due to alterations in autonomic tone, with stress increasing sympathetic 
and reducing parasympathetic activation. Any cytokine induced increases in RMBF 
as a result of the pro-inflammatory effects of stress appear to be outweighed by its 
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autonomic effects. Indeed, it is conceivable that stress-induced reductions in RMBF 
could trigger relapse by causing mucosal ischaernia. 
7.6 CONCLUSION 
Stress appears able to increase a range of inflammatory variables at the 
mucosal level, an effect which is increased in individuals with pre-existing 
inflammation. Preliminary data suggests that stress may also increase mast cell 
degranulation and lead to an increased number of Ecoli in the lamina propria. 
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CHAPTER 8 
THE EFFECTS OF HYPNOTHERAPY ON 
SYTEMIC MEASURES IN PATIENTS WITH 
ACTIVE ULCERATIVE COLITIS AND HEALTHY 
VOLUNTEERS 
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8.1 SUMMARY 
Aims: As per protocol (chapter 3), to assess the effects of one 50 minute session of 
gut-formalised hypnotherapy at the systemic autonomic and inflammatory levels. 
Methods: As described in chapter 3, patients with active UC and healthy volunteers 
underwent the hypnotherapy and control protocols. Autonomic and systemic 
inflammatory measures were assessed before and after in both groups as described in 
Chapter 3. 
Results: The principal findings described in this chapter are: 
1. Trance was successfully induced in 16 of 17 (94%) of patients with active UC and 
9 of 10 healthy volunteers (90%). There was no difference in hypnotisability score 
(383) or depth perception between patients with UC and healthy volunteers. 
2. At the autonomic level, hypnotherapy reduced the pulse rate by 7 bpm in patients 
with UC (p=0.0009) and I lbpm in HVs (p=0.004). Systolic BP was reduced by 
2mmHg in patients with UC (p=0.04) and 3mmHg in IlVs (p=0.02). 
3. Hypnotherapy reduced serum IL-6 concentration by 53% in patients with UC 
(p=0.001) and 23% in HVs (p=0.02). There was a transient fall in NK cells in 
response to hypnosis by 18% in patients with UC (p=0.01) and by 34% in IlVs 
(p=0.04). 
4. There was no difference between the responses of patients with UC and IlVs to 
hypnosis. 
5. Chronic stress, as assessed by psychometric questionnaires, hypnotisability, as 
assessed by Spiegel's score (383), and depth perception had no effect on the 
autonon-dc or inflammatory response to hypnosis. 
5. The control protocol had no effect on any of the variables assessed. 
Conclusion: Hypnotherapy altered autonomic balance temporarily in patients with 
active UC and HVs, with an increased para-sympathetic and reduced sympathetic 
tone. Hypnotherapy also reduced serum IL, 6 levels, a cytokine which may be 
important in the pathogenesis of 1131). 
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8.2 INTRODUCTION 
As previously described, hypnotherapy has been shown to be of therapeutic 
benefit in a range of inflammatory diseases which have a psychosomatic component. 
It is not known whether hypnotherapy works in these circumstances via a direct effect 
on the immune system or by altering symptom interpretation at a cognitive level. 
Few studies have examined the direct effects of hypnotherapy on the immune system. 
In one study hypnosis led to a brief reduction in NK-cell activity and lymphocyte 
proliferative responses to mitogens (351). In a second study, the proportion of T-cells 
expressing IFN-y and IL-2 was reduced in blood samples taken from seven highly 
hypnotizable healthy volunteers immediately after hypnosis (352). 
In this chapter we will describe the systemic responses of patients -with 
active 
UC and healthy volunteers to the hypnotherapy protocol. The hypothesis underlying 
this work is that relaxation achieved through hypnosis is capable of reducing 
inflammation at the systemic level. The effects of hypnosis on the systemic 
inflammatory measures assessed in this protocol have not been previously examined. 
There is also limited data available on the effects of hypnotherapy in patients with UC 
(365). 
The response to hypnotherapy was subsequently related to scores of 
hypnotisability (383) and to psychometric assessments of chronic perceived stress 
levels.. 
For ease of reading the mucosal responses of patients with UC to stress will be 
described separately in Chapter 9. 
8.3 DEMOGRAPHICS OF PATIENTS AND HEALTHY 
VOLUNTEERS 
17 patients with active UC, as defined by a Baron's sigmoidoscopic score of 
>1, and 10 healthy volunteers (HV) underwent the hypnotherapy protocol. 8 patients 
with active UC and II healthy volunteers underwent the control protocol. 
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Table 8.1 Sex, age, disease extent, treatment, Baron's score and Simple Colitis 
Activity Index for patients with active UC and healthy volunteers undergoing 
the hypnotherapy and control protocols. 
Protocol 
Hypnosis 
UC (n=17) 
Age 
Sex 
40(23-63) 
II male 
Disease extent 65% total 
11 % left-sided 
24 % distal. 
Treatment 94% on 5-ASA 
24% thiopurines 
7% oral ciclosporin 
0% corticosteroids 
18% topical therapy 
Control 
UC (n=8) 
43(25-60) 
4 male 
50% total 
12% left-sided 
38% distal 
100% on 5-ASA 
38% thiopurines 
0% corticosteroids 
25% topical therapy 
Baron's score 2(2-3) 2.5(2-3) 
SSCAI 6(5-7.5) 6.5(6-9) 
HV (n= 10) IIV (n=l 1) 
Age 29(23-42) 36(27-57) 
Sex 5 male 6 male 
8.4 RESULTS 
8.4.1 INDUCTION OF TRANCE 
As assessed by subjective depth perception and the experience of time 
distortion, trance was successfully induced in 16 of 17 patients and 9 of 10 healthy 
volunteers. In the one patient with UC and one healthy volunteer where trance could 
not be induced, the subjects reported this to be due to an inability to relax sufficiently 
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to allow trance to occur. The median score of Spiegel's test of hypnotisability was 5 
(lQR 4-6.5) for patients with active UC and 4.5 (IQR 3-6) for healthy volunteers 
(p=0.33). The median of the three self-rated scores of depth perception was 6 (IQR 3- 
7) for patients with active UC and 5 (IQR 4-7) for healthy volunteers (p=O. 19) 
8.4.2 AUTONOMIC RESPONSE TO HYPNOTHERAPY 
8.4.2.1 Pulse rate (Figure 8.1 and 8.2 and Table 8.2) 
The mean of the three pulse rate readings measured during hypnosis was lower than 
pre-test values by 7 bpm (median) in patients with active UC (p=O. O(X)9) and by 
II bprn in HV (p=0.004). Thirty minutes after the end ofthe hypnosis protocol, pulse 
rate had returned to baseline in both groups. 
Figure 8.1 The effects of hypnotherapy on pulse rate (bpm) in patients with 
active UC (n=17). The points shown as "During" are the mean of the three 
readings taken during the stress test. Median is shown in red. 
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Figure 8.2 The effects of hypnotherapy on pulse rate (bpm) in healthy volunteers 
(n=10). The points shown as "During" are the mean of the three readings taken 
during the stress test. Median is shown in red. 
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8.4.2.2 Systolic blood pressure (Figure 8.3 and 8.4 and Table 8.2) 
Mean systolic blood pressure decreased during hypnosis by 2 111111119 in patients with 
UC (p=0.04) and 3 mmHg in HV (p=0.004). In HV, when measured 30 111inUteS after 
the hypnotherapy protocol, the systolic BP remained lower than prc-tcst levels by 
4mmHg (p=0.02). 
Figure 8.3 The effects of hypuotherapy on systolic BP (mmllg) in patients with 
active UC (n=17). The points shown as "During" are the mean ofthe three 
readings taken during the stress test. Median is shown in red. 
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Figure 8.4 The effects of hypnotherapy on systolic BP (mmHg) in healthy 
volunteers (n=10). The points shown as "During" are the mean of the three 
readings taken during the stress test. Median is shown in red. 
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8.4.2.3 Diastolic blood pressure (Table 8.2) 
Hypnosis had no effect on diastolic blood pressure in either grOL11) OfSUh. jCCIS. 
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Table 8.2 Pulse (bpm), systolic and diastolic BP (mmHg) in response to hypnosis 
and control protocols in patients with UC and healthy volunteers (HV). Results 
are shown as median (IQR). * p<0.05 from pre-procedure value (paired data). 
Protocol N Before During/After 30 mins after 
Hypnosis UC 17 Pulse 76(70-86) 69 (03-83)* 76(72-86) 
Systolic BP 125 (116-132) 123 (112-137)* 122 (114-139) 
Diastolic BP 79(70-82) 69(75-90) 70(75-81) 
HV 10 Pulse 68(60-81) 57 (63-74)* 65(61-81) 
Systolic BP 119010-135) 116(()5-132)* 1 15 (98-129)* 
Diastolic BP 68(61-74) 68(56-73) 69(60-76) 
Control UC 8 Pulse 69(67-76) 72(64-75) 70(67-74) 
Systolic BP 130 (122-153) 131 (117-148) 
Diastolic BP 75(70-80) 75(70-84) 
HV II Pulse 71 (56-74) 66(61-74) 
Systolic BP 114 (102-121) 110 (102-122) 
Diastolic BP 70(63-75) 69(62-75) 
8.4.3 SYSTEMIC INFLAMMATORY RESPONSE 
8.4.3.1 Serum cytokine concentrations (Figure 8.5 and 8.6 and Table 8.3) 
134 (116-147) 
75(71-79) 
69(60-73) 
112 (104-124) 
72(63-77) 
In patients with active UC, median serum IL-6 concentrafion in the hlood 
sample taken immediately after hypnosis was decreased by over hall'coniparcd to the 
pre-procedural value (p=0.0009) and had fallen slightly further in the sample taken 
thirty minutes later (p=0.01). In healthy volunteers, there was a more than 2017c 
reduction in the median serum IL-6 concentration immediately after hypnosis 
(p=0.02) but none thirty minutes later. Serum IL- 13 concentrations were unalterccl 
after hypnotherapy in either UC or in HV. 
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Figure 8.5 The effects of hypnotherapy on serum IL-6 concentrations (pglml) in 
patients with active UC (n=17). Median is shown in red. 
2 
(0 r- 3-m- 
- 0.1 
Before Immediately 30 mins 
after after 
Figure 8.6 The effects of hypnotherapy on serum IL-6 concentrations (pg/ml) ill 
healthy volunteers (n=10). Median is shown in red. 
p=0.02 
101 
---- ------------------------- --------------------- 
5 
w r- 
Before Immediately 30 mins 
af ter af ter 
222 
----------------------------------- 
P=0.01 
8.4.3.2 LPS-stimulated cytokine production (Table 8.3) 
The production of TNF-(x and IL-6 by LPS-stimulated whole blood was 
unchanged by hypnosis in patients with active UC or in healthy volunteers. 
Table 8.3 Serum IL-6 and IL-13 concentrations (pg/ml), and LPS-stimulated IL- 
6 and TNF-a production (nWml) by whole blood, in response to hypnosis and 
control protocols in patients with UC and healthy volunteers (FIV). Results are 
shown as median (IQR). * p<0.05 from pre-procedure value (paired data). 
Protocol N Before Immediately 30 mins after 
after 
Hypnosis UC 17 Serum IL-6 6.9 (1.7-12.3) 3.2 (1.5-8.7)* 2.8 (1.6-7.2)* 
Serum IL- 13 5.0 (2.4 -16) 5.5 (2.5-14.1) 4.8 (2.7-14.7) 
LPS TNF-a 99(59-243) 152 (32-436) 138 (26-459) 
LPS IL-6 285 (159-578) 254 (175-449) 262 (154-487) 
HV 10 Serum IL-6 1.3 (0.8-2.3) 1.0 (0.5-1.5)* 1.6 (1.2-2.8) 
Serum IL- 13 1.0(0-5.2) 0.5(0-3.6) 0.4(0-3.9) 
LPS TNF- a 29(18-52) 35(30-93) 40(15-56) 
LPS IL-6 189 (134-276) 211 (168-304) 176 (135-266) 
Control UC 8 Serum IL-6 2.7 (2.1-6.0) 2.8 (1.9-4.7) 3.2 (2.3-4.9) 
Serum IL- 13 6.4 (2.5-11.2) 3.1 (7.0-12.3) 5.2 (2.1-13.7) 
LPS TNF- a 121 (70-154) 107 (63-247) 148 (75-255) 
LPS IL-6 237 (134-461) 255 (161-342) 264 (182-430) 
HV 11 Serum IL-6 0.6 (0.5-0.9) 0.6 (0.4-1.3) 0.7 (0.4-1.5) 
Serum IL- 13 0.8(0-2.1) 1.0(0-2.4) 0.7(0-1.9) 
LPS TNF- a 18(8-30) 1901-26) 2001-32) 
LPS IL-6 223 (164-302) 245 (203-345) 232 0 95-315) 
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8.4.3.3 Leukocyte count (Table 8.4) 
Total white cell count (WBC) was unaffected by hypnotherapy in either 
group. 
8.4.3.4 Natural Killer (NK) cell numbers (Figure 8.7 and 8.8 and Table 8.4) 
In patients with active UC, median INK cell numbers, expressed as a 
percentage of lymphocytes and monocytes, were decreased by 1817c in the sample 
taken immediately after the hypnotherapy protocol (p=0.01 ) but had returned to base 
line taken 30 minutes later. Similarly, in healthy volunteers NK cell nurnbers were 
decreased by 34% immediately after hypnosis (p=0.04) but had returned to baseline 
taken 30 minutes later. 
Figure 8.7 The effects of hypnotherapy on NK cell count (%) in patients with 
active UC (n=17). Median value is shown in red. 
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Figure 8.8 The effects of hypnotherapy on NK cell count (%) in healthy 
volunteers (n=10). Median value is shown in red. 
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8.4.3.5 Platelet activation and platelet-leukocyte aggregate (PLA) formation 
(Table 8.4) 
Neither platelet activation (p-selectin expression), nor the percentage of' 
platelets fonning PLAs, changed after hypnotherapy in either group. 
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Table 8.4 Total leukocyte count (WBQ (cells x 10 A /Mm 3 ), natural killer (NK) 
cell number (%), platelet activation (p-selectin expression (%)) and platelet- 
leukocyte aggregate (PLA) formation (%) in response to hypnosis and control 
protocols in patients with UC and healthy volunteers (HV). Results are shown 
as median (IQR). * p<0.05 from pre-procedure value. 
Protocol Before Immediately 30 mins after 
after 
Hypnosis UC 17 WBC 7.5 (6.9-9.8) 7.5 (6.8-10.1) 7.9 (6.9-10.1) 
NK count 6.8 (5.2-9.3) 5.6 (4.6-8.8)* 6.5 (4.8-8.4) 
P-selectin 3.8 (2.2-6.8) 4.7 (1.9-7.0) 5.7 (3.9-6.8) 
PLA 3.0 (2.3-4.4) 3.0 (2.5-4.2) 3.4 (2.5-4.0) 
HV 10 WBC 
NK count 
P-selectin 
PLA 
5.2 
7.0 
2.6 
2.6 
(4.3-7.0) 
(4.6-12.7) 
(1.9-3.9) 
(1.6-3.5) 
5.4 
4.6 
2.8 
2.3 
(4.6-6.9) 
(3.6-5.6)* 
(2.0-6.2) 
(1.5-3.4) 
5.3 
6.2 
5.0 
3.6 
(4.7-7.3) 
(5.0-6.7) 
(2.0-7.3) 
(2.9-5.5) 
Control UC 8 WBC 7.2 (6.3-10.0) 7.8 (6.1-9.8) 8.0 (6.2-10.2) 
NK count 6.9 (3.8-8.1) 4.8 (3.4-7.6) 5.3 (3.9-7.9) 
P-selectin 2.0 (1.7-2.3) 2.1 (1.3-3.0) 2.0 (1.7-3.1) 
PLA 2.9 (2.0-3.3) 2.7 (2.6-2.8) 2.6 (2.1-3.0) 
HV 11 WBC 5.4 (4.6-8) 5(4.4-6.6) 4.9 (4.7-6.5) 
NK count 7.3 (6.1-10.1) 8.8 (6.0-10.6) 8.2 (5.6-9.9) 
P-selectin 3.1 (2.3-3.5) 2.9 (2.5-4.0) 3.2 (2.5-4.8) 
PLA 2.5 (2.2-3.8) 2.4 (2.0-3.4) 2.5 (2.0-4.2) 
Comparison of responses to hypnosis in patients with active UC and healthy 
volunteers 
The absolute reductions in serum 11,6 concentrations in response to hypnosis 
were greater in patients with active UC than in HV (p=0.03, Table 8.3). However, as 
the baseline value was higher in the patients with UC, the percentage change in serum 
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IL-6 was similar in both groups. There were no other differences in the magnitude of 
the changes elicited by the hypnotherapy protocol in any of the autonomic or 
inflammatory variables assessed between patients with UC and HV (Tables 8.2,8.3 
and 8.4). 
Hypnotisability, depth perception and response to hypnosis 
There were no differences in Spiegel's score of hypnotisability or the mean of 
the three self-rated depth scores between patients with active UC and healthy 
volunteers. Neither did either of these measures correlate with the changes observed 
in any of the autonomic or inflammatory variables in response to hypnosis. 
Psychometric questionnaires 
None of the measures of long term stress (STAI-T, HADS, PSQ or BST) 
correlated with the changes in any of the variables occurring in response to the 
hypnotherapy protocol. However, scores on the STAI-S scale did correlate directly 
with the reductions in pulse rate produced by hypnosis (R=+0.54, p=0.03). 
Relationships of age to response to hypnotherapy protocol 
The median age (40yrs) of the patients with UC was not quite significantly 
higher than that of the HV (23yrs, p=0.07) (Table 8.1). Age did not correlate with any 
of the changes seen in response to hypnosis in either group. 
Effects of control protocol 
The control protocol caused no changes in any of the variables assessed in 
either patients with active UC or HV (Tables 8.2,8.3 and 8.4). 
8.5 DISCUSSION 
We have assessed the effects of hypnotherapy given to patients with active 
UC on a range of systemic inflammatory variables, the majority of which we have 
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described as being raised in active compared to inactive disease (Chapter 4). 
Hypnotherapy reduced some, but not all, of these variables, at the systemic level 
towards the values found in quiescent UC. 
AUTONOMIC RESPONSE. 
During hypnosis there was a reduction in pulse rate and systolic blood 
prýssure. Although the changes were small, they are opposite to those observed in 
response to acute stress (Chapter 5), and indicate a change in the autonomic balance, 
with a decrease in sympathetic, and an increase in parasympathetic tone. Acute 
stimulation of the sympathetic nervous system, with the release of adrenaline and 
noradrenaline, has been shown to have mainly pro-inflammatory effects (201; 204). 
Parasympathetic stimulation of the vagus nerve with release of acetylcholine reduces 
the production of certain inflammatory cytokines including TNF-a and has been 
shown recently to be a key regulator in several animal models of inflammatory 
disease (440). The changes in autonomic tone induced by hypnotherapy could thus be 
a mechanism by which the observed reductions in some of the inflammatory variables 
assessed occurred. 
SERUM CYTOKINES 
Perhaps the most important finding in this chapter was that hypnotherapy 
reduced serum concentrations of IL, 6 by a median of 53% in patients with active UC 
and by 23% in healthy volunteers. The base-line median serum IL-6 concentration 
was over three times that previously found in patients with quiescent disease (Chapter 
4). However, IL'6 concentrations after hypnosis did not significantly differ from 
those found in inactive UC. IL-6 is a major inflammatory cytokine and the principal 
stimulus for C-reactive protein production by the liver. It is involved in many disease 
processes and may be important in the pathogenesis of 1131) (441). A fall in serum 
IL-6 could therefore contribute to the reported benerits of hypnotherapy in 1131) and 
other inflammatory diseases. In healthy individuals, IL-6 stimulates a stress-response 
in the hypothalamus, culminating in the release of glucorticoids, which have mainly 
anti-inflammatory. actions, from the adrenal cortex. This creates an anti-inflammatory 
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feedback loop serving to reduce peripheral inflammation (442). However, in 
individuals with chronic inflammatory conditions, such as IBD, the hypothalamic 
response to IL-6 is blunted: the associated loss of the anti-inflammatory feedback 
loop may predispose to stress-induced worsening of inflammation (443). A 
hypnotherapy-induced reduction in serum ILA concentration could thus prevent 
stress-induced worsening of 1131). 
NATURAL KILLER CELLS 
As reported previously, hypnotherapy transiently decreased NK cell numbers, 
a change opposite to that we observed in response to acute stress. While it is 
conceivable that brief decreases in NK cell number could down-regulate mucosal 
inflammation via the interactions between NK and dendritic: cells (444), the short 
lived nature of the changes observed make them unlikely to explain any possible 
long-term therapeutic effects of hypnosis in 11313. 
8.6 CONCLUSIONS 
Hypnosis reduced serum IL-6 concentration and led to a transient fall in NK 
cell count. These changes may be mediated by the change in autonomic balance 
observed in response to hypnosis and may be relevant to any therapeutic effects of 
hypnotherapy in UC. 
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CHAPTER 9 
THE EFFECTS OF HYPNOTHERAPY ON 
MUCOSAL MEASURES IN PATIENTS WITH 
ACTIVE ULCERATIVE COLITIS 
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9.1 SUMMARY 
Aim: To assess the effects of hypnotherapy on several inflammatory measures at the 
mucosal level. 
Methods: 25 individuals with active UC underwent a session of hypnotherapy or the 
control protocol and the rectal release of inflammatory cytokines, rectal mucosal 
blood flow and reactive oxygen metabolite production were assessed before and afier 
the procedures. 
Results: The principal findings were: 
1. Hypnotherapy reduced rectal peri-mucosal fluid concentrations of Substance P 
(SP) by 81% (p=0.001), histamine by 35% (p=0.002) and IL-13 by 53% (p=0.003). 
2. Rectal mucosal blood flow was reduced by 18% (p=0.0004) in response to 
hypnosis. 
3. Chronic stress, as assessed by psychometric questionnaires, hypnotisability, as 
assessed by Spiegel's score (383), and depth perception had no effect on the 
autonomic or inflammatory response to hypnosis. 
4. The control protocol had no effect on any of the variables assessed. 
Conclusions: Hypnosis reduced the rectal mucosal release of several potentially 
pathogenic inflammatory mediators. 
9.2 INTRODUCTION 
Hypnotherapy is of proven to be of benefit in functional GI disorders such as 
IBS and dyspepsia (359; 363; 445)., However, the mechanisms by which it leads to 
therapeutic benefit in these conditions are unknown. Hypnotherapy has been shown 
to have various effects on GI physiology. It reduces orocaecal transit time and 
decreases colonic motility (361). Hypnotherapy also reduces sensitivity to rectal 
distension in patients with IBS, and this may be of relevance to the reduced 
symptoms described by some patients with UC in response to hypnosis (362). There 
have, however, been no studies of the effects of hypnotherapy on mucosal 
inflammatory measures in patients with UC. 
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In this chapter we will describe the effects of one session of hypnosis on the 
mucosal measures described in the experimental protocol. The hypothesis underlying 
this work is that relaxation achieved through hypnosis is capable of reducing 
inflammation at the mucosal level. 
9.3 PATIENT DEMOGRAPHICS (Table 8.1) 
17 patients with active UC, as defined by a Baron's sigmoidoscopic score of 
>1 underwent the hypnotherapy protocol and 8 patients with active UC underwent the 
control protocol. Their demographics are described in chapter 8. 
9.4 REA SULTS 
The data for ROM production and rectal mucosal blood flow was available in 
only fifteen of the seventeen patients who underwent hypnotherapy. In the other two 
patients the data could not be obtained due to technical problems with the equipment. 
9.4.1 Cytokine and mediator concentration in rectal peri-mucosal fluid (Figure 
9.1,9.2 and 9.3 and Table 9.1) 
In patients with active UC, the median concentrations of SP, histamine and 
IL- 13 in rectal peri-mucosal fluid were decreased by 81 % (p=0.00 1), 35% (p=0.002) 
and 53% (p=0.003) respectively after hypnotherapy. Mucosal release of TNF-a did 
notchange. 
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Figure 9.1 The effects of hypnotherapy on substance P concentration (pg/ml) in 
rectal peri-mucosal fluid in patients with active UC (n=17). Median shown in 
red 
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Figure 9.2 The effects of hypnotherapy on histamine concentration (pg/ml) in 
rectal peri-mucosal fluid in patients with active UC (n= 17). Median shown in 
red. 
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Figure 9.3 The effects of hypnotherapy on 11,13 concentration (pglml) in rectal 
peri-mucosal nuid in patients with active UC (n=17). Median shown in red. 
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9.4.2 Reactive oxYgen metabolite (ROM) production (Table 9.1) 
The hypnotherapy protocol did not alter the rectal IIILICOSý11 p1-0dUCtIOII 01' 
ROMs in the patients with UC. 
9.4.3 Rectal mucosal blood flow (Figure 9.4 and Table 9.1) 
Rectal mucosal blood flow fell by 1817r, (median) after hypnotherapy 
(p=0.0004). 
Figure 9.4 The effects of hypnotherapy on rectal mucosal blmd flow (arbitrary 
units) in patients with active UC (n=17). Median shown in red. 
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Table 9.1 Rectal peri-mucosal fluid cytokine concentrations (pgIml), reactive 
oxygen metabolite (ROM) production by rectal mucosal biopsies 
(photons/mcgImin), rectal blood flow (arbitrary units) in response to hypnosis 
and control protocol in patients with active UC. Results are shown as median 
(IQR). * P<0.05 from pre-procedure value (paired data). 
Protocol N Before After 
Hypnosis 
Perimucosal fluid cytokines 
Substance P 17 55(18-610) 10 (5-129)* 
Histamine 17 26(15-34) 17 (6-25)* 
IL, 13 17 19(5-99) 9 (5-27)* 
TNF-a 17 111 (42-251) 140 (62-253) 
ROM production 15 275 (38-1175) 463 (175-666) 
Blood flow 15 205 (139-245) 169 (115-198)* 
Control 
Peri-mucosal fluid cytokines 
Substance P 8 57(38-451) 99(24-363) 
Histamine 8 21(9-31) 19(5-32) 
IL, 13 8 17(11-21) 20(13-23) 
TNF-a 8 99(65-224) 135 (54-319) 
ROM production 8 199 (31-502) 293 (65-600) 
Blood flow 8 152 (133-223) 183 (145-232) 
Hypnotisability, depth perception and response to hypnosis 
As with the systemic response to hypnotherapy, hypnotisability and depth 
perception did not correlate with the changes observed in the rectum in response to 
hypnosis. 
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Psychometric questionnaires 
None of the measures of long term stress (STAI-T, HADS, PSQ or BSI) 
correlated with the changes observed at the mucosal level in response to the 
hypnotherapy protocol. Neither did scores on the STAI-S, a measure of aniiety at 
that time, correlate with the changes observed. 
Relationships of age to response to hypnotherapy protocol 
Age did not correlate with any of the rectal changes occurring in response to 
the hypnosis. 
Effects of control protocol 
The control protocol caused no changes in any of the rectal mucosal variables 
assessed. 
9.5 DISCUSSION 
Hypnotherapy reduced the levels of several of the rectal mucosal 
inflammatory measures assessed. Each of the measures found to be affected will be 
discussed in turn. 
MUCOSAL SUBSTANCE P AND HISTAMINE RELEASE. 
Baseline concentrations of SP and histamine in peri-mucosal fluid in patients 
with active UC were more than twice those found in quiescent UC (see Chapter 5). 
Hypnosis reduced the peri-mucosal concentrations of both, in the case of SP to values 
similar to those found in inactive disease. 
SP is found in neurones throughout the enteric nervous system, many of 
which are found in close association with mast cells (189). As described previously, 
SP has a range of inflammatory actions (see Chapter 1), some of which may 
contribute to the aetiology of IBD. Increases in numbers of neurones containing SP 
have been reported in the colon of patients with 1131) (189). The possibility of SP 
acting as a stimulus for mucosal mast cell degranulation is supported by the 
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observation that incubation with SP of colonic biopsies from patients with IBD 
increases mast cell-mediated histamine release (190). This may contribute to the 
increased activation of mast cells (122) and enhanced rectal mucosal release of 
histamine observed in active UC (123). Acute physical stress stimulates mast cell 
degranulation in patients with IBD (279), while, in animal models, the presence of 
mast cells is required to mediate the increases in intestinal permeability and mucosal 
bacterial uptake caused by stress (311; 3 14). 
Our results suggest that hypnotherapy, by reducing neuronal. release of SP, 
decreases release of histamine, and by implication possibly that of other pathogenic 
mast cell mediators such as tryptase. However, although it is also released by mast 
cells, we did not find that a single session of hypnosis alters the mucosal release of 
TNF-ct (12 1). 
MUCOSAL IL-13 RELEASE. 
Recent work has suggested that a mucosal population of IL-13-secreting NKT 
cells may be important in the aetiology of UC (446). These NKT cells are cytotoxic 
to colonic epithelial cells in vitro whilst (447), also in vitro, IL-13 has been shown to 
impair colonic epithelial barrier function (180). Using the filter paper method, we 
have found baseline mucosal production of IL- 13 in active UC to be nearly three 
times that foqnd in inactive disease. After hypnosis the median peri-mucosal IL, 13 
concentration was less than twice that found in inactive UC. If IL-13 is important in 
the pathogenesis of IBD, then the reductions we observed in the mucosal release of 
IL-13 in response to hypnosis could contribute to any therapeutic effect. 
RECTAL MUCOSAL BLOOD FLOW 
RMBF was reduced by hypnotherapy. In the normal rectum, RMBF reflects 
autonomic tone, being decreased by higher sympathetic and recuced parasympathetic 
tone (407). While in the normal rectum, therefore, hypnosis might be predicted to 
increase RMBF, mucosal. blood flow in active UC is likely to reflect not only 
autonomic tone but also vasodilation caused by local production of inflammatory 
mediators (448). Baseline RMBF was 75% higher in patients with active UC 
237 
compared with inactive disease, but only 50% greater after hypnosis. This may 
reflect reduced mucosal production of inflammatory mediators as a result of hypnosis. 
9.6 CONCLUSION 
Hypnosis markedly reduced the rectal mucosal release of SP and to a lesser 
extent histamine. If SP does act as a stimulus for mast cell degranulation, and the 
latter is important in the aetiology. of UC, then these changes may be important in 
mediating hypnotherapy-induced reductions in mucosal inflammation. Hypnosis also 
reduced IL-13 release, an inflammatory cytokine of possible importance in the 
aetiology of UC, and RMBF. 
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CHAPTER10 
SUMMARY AND CONCLUSIONS 
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10.1 INTRODUCTION 
The rationale for studying the effects of acute experimental stress in UC was 
based on the observation that for many years by patients with UC have identified 
psychological stress as being an important factor in provoking relapse of their disease 
(449). Studies assessing the effects of adverse life events on disease activity in UC 
have produced con 
, 
flicting results (270; 450), although studies assessing the effects of 
chronic perceived stress seem more conclusive (273). There is strong evidence from 
animal models of colitis to suggest that stress can act as a contributing factor to 
relapses of mucosal inflammation (299; 300). 
The aim of this work was therefore to study the effects of psychological stress 
and relaxation achieved though hypnosis, on a range of inflammatory variables in 
UC. The hypotheses were that stress might increase and that hypnosis might reduce 
these measures. We also tested whether patients with UC had a different response to 
stress at the systemic level compared to healthy volunteers, and whether chronic 
stress affected the response to acute stress. 
10.2 SUMMARY OF MAIN FINDINGS 
COMPARISON OF BASELINE VALUES IN PATIENTS WITH QUIESCENT 
AND ACTIVE UC 
Several of the inflammatory measures assessed in this study have not been 
measured previously in patients with active and inactive UC. The concentration of 
SP and IL-13 in rectal peri-mucosal fluid was found to be greater in active than 
inactive UC. 
Substance P is a neurotransmitter which has several pro-inflammatory actions 
(189). SP containing neurones have been reported as being increased in UC, although 
studies are conflicting (see Chapter 1) (189). This is the first time that the in vivo 
rectal release of SP has been measured and found to be increased in active UC 
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compared to that in inactive disease. Our results are compatible with the proposal 
that SP may play a role in the pathogenesis of UC. 
Recent evidence suggests that an IL, 13 producing population of NKT cells 
maybe important in the pathophysiology of UC (180; 451). LPMCs from patients 
with UC produce more IL-13 in vitro in response to stimulation with antibodies to 
CD2 and CD28 than LPMCs from individuals with Crohn's disease (452). As with 
SP, this is the first occasion that the in vivo rectal release of IL- 13 has been measured 
and shown to be increased in active UC compared to inactive disease. 
In addition to the rectal release of IL-13, we also found serum levels of IL-13 
to be increased in active UC compared to inactive disease. To the best of our 
knowledge this has not been reported previously. 
THE EFFECTS OF STRESS 
In this study, psychological stress was found to increase a range of 
inflammatory variables at both the systemic and mucosal levels. It is possible that 
increases in some of these variables may be involved in the stress-related relapses in 
colonic inflammation reported by both patients with UC and seen in animal models of 
colitis. Of particular note, this is the first occasion that acute stress has been shown to 
increase rectal mucosal release of TNF-a and reactive oxygen metabolite production 
by mucosal biopsies. 
Stress increased a range of inflammatory variables systemically. It is possible 
that some of the increases are relevant to other inflammatory conditions where stress 
is thought to play a role. For example stress-related increases in platelet activation 
and PLA formation may be important in myocardial infarction. 
We did not find that participants with high chronic stress, as assessed by 
psychometric questionnaires, showed a greater autonomic and inflammatory response 
to acute stress. This is in contradiction to other reported studies involving both 
humans and animals (137; 223; 231; 297; 309; 453). This may in part be due to the 
relatively low levels of chronic stress present in the individuals in our study. Most of 
the reported data from human studies showing an increased response to acute stress in 
the presence of chronic stress has focused on individuals in chronically highly 
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stressful situations. For instance, chronic caregivers showed a greater autonomic 
response to acute stress than healthy volunteers (137). In animal studies, the model 
used to simulate chronic stress is usually maternal separation which seems to induce 
prolonged depression and augements the pro-inflammatory effects of acute stress. In 
both cases it is likely that the level of chronic stress affecting the response to acute 
stress is greater than that present in the patients in our study. 
We did not find that patients with UC had more abnormal autonomic or 
inflammatory responses to acute stress than healthy volunteers. As stated in chapter 
6, it is likely that whilst stress may contribute to exacerbations in UC, an abnormal 
stress response is not a necessary aetiological factor. 
One weakness of this study is that it is difficult to know if the stress induced 
by this protocol and the magnitude of the immune response are physiologically 
relevant. However stress did relevant 
THE EFFECTS OF HYPNOTHERAPY 
The effects of hypnotherapy were not as wide ranging as those seen in 
association with stress (see below). Hypnotherapy reduced some, but not all of the 
inflammatory measures assessed in this protocol. Of particular note, hypnotherapy 
reduced the rectal mucosal release of SP, histamine and IL- 13. 
Hypnotherapy has been shown to be beneficial in IBS although the 
mechanism by which this occurs is unknown (360). Hypnosis has also been shown 
previously to affect GI physiology with reduced colonic transit and rectal sensitivity 
(454). This is the first occasion that hypnosis has been shown to reduce inflammatory 
variables in UC. It is possible that some of the effects described in this present study 
are relevant to the anecdotally reported beneficial effects of hypnotherapy by patients 
with UC. The fall in serum IL-6 in response to hypnosis may also be relevant to the 
reported beneficial effects of hypnotherapy in other inflammatory diseases (355; 357). 
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RELATIONSHIP BETWEEN THE EFFECTS OF HYPNOTHERAPY AND 
OF STRESS. 
Although we have found that hypnotherapy reduced several of the 
inflammatory measures assessed in patients with active UC, we did not find that it 
reduced most of the measures that were increased by experimental stress in inactive 
disease. In some instances, this may reflect the different suitability of the assays used 
for assessing inflammation in patients with active and inactive UC. In particular, our 
failure to find a reduction in ROM production in response to hypnosis may reflect the 
wide variation in ROM production by biopsies from patients with active UC, and 
could represent a type 11 statistical error. Although chemiluminescence is very 
sensitive for detecting increases from baseline of ROM production in inactive UC, it 
is less sensitive for detecting reductions in ROM release in active disease. 
There is also no a priori reason why the effects on the systemic and mucosal 
inflammatory responses of hypnosis in active UC and of acute stress in quiescent 
disease should be mirror images of each other. Hypnotherapy may act through 
different pathways from those involved in the pathophysiology of stress. 
Furthermore, systemic and mucosal inflammatory responses in quiescent UC are 
likely to be different from those in established active disease. 
10.3 LIMITATTIONS OF THE STUDY 
HETEROGENICITY OF PATIENTS 
In order to include sufficient patients in both the stress and hypnosis sections 
of this study, patients were not differentiated on the basis of disease characteristics or 
medical treatment. Clearly patients with UC represent a heterogeneous group 
depending on disease distribution and duration. It is quite possible that these 
differences may have affected the response to stress or hypnosis. Similalry it must be 
acknowledged that drugs such as immunosuppressants (thiopurines and methotrexatc) 
and to a lesser extent 5-ASA may have also affected the immune responses to either 
stress or hypnosis. 
243 
HETEROGENICITY OF RESPONSE TO HYPNOSIS 
The ability of an individual to be hypnotised is known to vary depending on 
the individual and the hypnotic technique used. We assessed hypnotisability using 
Spielberger's score but did not find it to relate to the physiological or immune 
responses observed in response to hypnosis. It could be suggested that only 
individuals with high hypnotisabilty scores should have been included in the study. 
This may have increased the likelihood of detecting an immune response to hypnosis. 
However, this would have limited the number of patients eligible for the study and in 
fact the vast majority of patients were hypnotisable to some degree. Furthermore it 
could also be argued that by limiting the study in this way it would reduce the 
applicability of the findings to the general population with ulcerative colitis. 
The technique used to induce trance in this study relied on visualisation. 
Whilst Spielberger's score assesses suggestibility it does not directly assess 
, visualistion. 
The effects of hypnosis in this study may therefore have been limited in 
patients who are unable to visualise. This may have added further heterogenicity to 
the patient group 
PHYSIOLOGICAL RELEVANCE OF THE CHANGES OBSERVED IN 
RESPONSE* TO STRESS AND HYPNOSIS 
Since the inflammatory variables assessed in this study were measured only 
up to 30 minutes after stress and hypnosis, we do not know if these changes are 
sustained over a longer period. This may limit the physiological relevance of our 
findings. Further studies of different design would be needed to explore the long- 
term anti-inflammatory effects of a single (or serial) sessions of hypnosis. 
It is difficult to know if the magnitude of the changes observed in response 
to stress and hypnosis have physiological relevance. However ROM production by 
mucosal biopsies from patients with inactive disease after the stress protocol was 
similar in magnitude to the baseline ROM production by mucosal biopsies from 
patients with inactive disease undergoing hypnosis. Similarly serum IL-6 
concentration and peri-mucosal fluid levels of Substance P and IL-13 were similar 
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after hypnosis in patients with active UC to the baseline values observed in patients 
with inactive disease. 
10.4 POSSIBILITIES FOR FURTHER STUDY 
STUDIES RELATING TO THE EFFECTS OF STRESS 
We did not find that our model of stress increased the mucosal release of 
histamine. This is in contrast to the majority of studies in humans and animals, where 
stress has been found to lead to mast cell degranulation (278; 279; 311; 314). Indeed, 
mast cell de granulation is thought to be a key step in mediating the effects of stress on 
the GI tract. In our pilot studies using immunofluorescnce we did find a trend to an 
increased percentage of degranulating mast cells in biopsies taken after stress 
compared to those taken before (see Chapter 7). Further samples and a control group 
are required to confirm this finding. 
Stress has been shown to increase GI bacterial adherence and internalisation 
in animal models (316; 318). In this study we have presented limited data which hints 
this may also be the case in patients with UC (see chapter 7). However, currently the 
number of patients studied is too few to make definite conclusions and there is no 
control group with which to compare. 
The changes observed in response to stress and hypnosis occurred over the 
relatively short time span of approximately 90 minutes. Further studies should be 
undertaken to establish whether these changes continue to be present over longer time 
periods. Ibis would clearly add weight to the theory that the alterations we observed 
are important in mediating the effects of stress or hypnosis in UC. 
The stress protocol used was effective in inducing stress subjectively and 
provoking a cardiovascular and immune response in the majority of patients studied. 
It would therefore seem sensible to continue using this model for future studies. 
However, the studies could also be repeated using the different models of stress 
described in Chapter 3. immersion of the hand in iced water has the advantage of 
being a technique which is easy to administer and less subject to psychological 
overlay by the subject and could therefore be very reliable and useful in future 
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studies. However, as described previously it is strictly a physical stress and not 
sustainable for fifty minutes as was required for this protocol. Various emotions can , 
be induced during hypnosis and this technique has been used to study the effects of 
various emotions, including anger and happiness on the GI tract (455). It might 
therefore be possible to induce stress via hypnosis and use this technique in future 
studies. However there is no data relating to the immune effects of stress induced via 
hypnosis and clearly the technique depends on a patient being hypnotisable. For these 
reasons this technique was not used for this protocol. 
STUDIES RELATING TO THE EFFECTS OF HYPNOTHERAPY IN UC 
The data presented in this study suggests that hypnotherapy can reduce certain 
inflammatory variables in UC. As already discussed, only a single session of 
hypnosis was given. In trials of hypnosis in IBS, the maximum benefits of 
hypnotherapy occur after several sessions and this may also be the case in IBD 
(360; 456; 457). It might have been more effective to study the effects of several 
sessions of hypnosis on the immune response in patients with IBD. This may not 
have required multiple sessions of hypnosis with the hypnotherapist as hypnosis and 
self-hypnosis can be practiced with the aid of recorded script. However as hypnosis 
was given to patients with active disease, to avoid the effects of confounding 
medication changes, patients with active UC would have had to remain untreated for 
several weeks whilst hypnosis was performed. Alternatively a group of patients with 
chronic refractory active UC would have had to be identified for whom medication 
changes were unnecessary. 
As yet the only reports of the benefits of hypnotherapy in UC are anecdotal 
accounts and one published abstract which showed a trend to clinical improvement 
(365). It would now seem appropriate to undertake a formalised trial of the 
therapeutic benefit of hypnotherapy in UC. 
The identification of the correct group of patients for this study will be 
essential. A course of hypnotherapy requires several weeks which may make its use 
in patients with active UC unethical when compared to the response to steroids which 
often requires only a few days. Hypnotherapy could be given to patients with 
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chronic active disease in whom other treatments for acute UC have failed. However, 
given. that these patients are already refractory to most conventional medical 
-. treatments, 
in cluding immunomodulators and immunosuppressives, the likelihood of 
detecting a therapeutic effect for hypnotherapy is low. Alternatively one could study 
hypnosis as a treatment to prevent relapse in patients with quiescent disease. 
However, the low relapse rate observed in most patients with quiescent UC may lead 
to the number of patients required to power a study of the benefits of hypnotherapy in 
quiescent UC being prohibitively large. An alternative design might to identify a 
group of patients with quiescent disease, but in whom the predicted relapse rate is 
higher, for example patients stopping thiopurine treatment (458). 
We are in fact now undertaking a trial of hypnotherapy to prevent relapse in 
patients who are stopping therapy with azathioprine or 6-mercaptopurine (6-MP). 
Patients who have been stable on azathioprine/6-MP and who now wish to stop are 
randomised to either the hypnotherapy or control arm (simple discussion regarding 
their condition). Patients are then followed for six months and the occurrence of 
relapse recorded. They are allowed to continue with their other medications. The 
principal investigator is blinded to which therapy the patients have received. As the 
number of patients who fulfil these criteria is small, patients have not been excluded 
on the basis of their disease characteristics or hypnotisability. 
If hypnosis does in fact transpire to have therapeutic benefit in UC it is 
tempting to speculate how it might be administered and where it might fit in the UC 
treatment algorithm. In the first instance hypnosis is labour intensive and time 
consuming. Although a relatively simple technique its administration requires 
practice and experience. It is therefore unlikely to be administered by 
gastroenterologists but rather by trained hypnotherapists. The best model might in 
fact be a trained hypnotherapist operating within specialist gastroenterology unit and 
under the supervision of a gastroenterologist. Alternatively it is possible that a 
gastroenterology nurse specialist could be trained in hypnotherapy and provide this 
service within a gastroenterology department. After the initial period, self hypnosis 
can be practiced at home and improvement in patients with IBS with this technique 
have been demonstrated up to five years (360). 
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One of the key factors in the success of hypnosis is the willingness of the 
individual to participate in the technique. I suspect this will be the key factor in 
determining to whom it is applicable. It may also be especially useful for individuals 
who find psychological stress an important factor in their disease. For these reasons I 
think it is unlikely to have a specific place in any treatment algorithm but rather could 
serve as an adjunctive treatment at any point for individuals who find it helpful. 
Clearly it has advantages over pharmacotherapy of having few or no side-effects. 
STUDIES RELATING TO SERUM IL-13 CONCENTRATION 
Assessment of disease activity in inflammatory bowel disease (1131)) is 
important in selecting and monitoring the effects of medical therapy.. However, 
objective measurement of disease activity in both Crohn's and UC remains 
problematic. Self-reported symptoms are often unreliable and can be confounded by 
co-existent conditions such as irritable bowel syndrome (IBS). Clinical indices, 
combining both objective and subjective measurements, are useful in assessing 
clinical response in therapeutic trials, but are usually too cumbersome for day-to-day 
use (262). Endoscopic assessment is invasive, unpleasant for the patient, and may be 
unsafe in active disease (376). 
A variety of laboratory measures including C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), platelet count, haemoglobin, haematocrit and 
albumin have been used to assess disease activity in IBD, but none is sufficiently 
sensitive or specific (459; 460). Faecal calprotectin shows promise as a marker of 
disease activity but requires stool collection and is not, as yet, widely available (461). 
As yet there appears to have been no data published regarding the systemic 
levels of IL-13 in patients with UC. In this study we found serum IL-13 
concentrations to be raised in active disease. Serum IL-13 concentration might prove 
to'be a useful marker of disease activity in UC. In order to answer this question, 
serum IL-13 concentrations would need to measured in more patients with UC and 
should be compared with other commonly used laboratory markers to find the best 
discriminator of disease activity. The concentration of serum IL-13 should also be 
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measured in patients with Crohn's, and other inflammatory conditions, such as 
infective diarrhoea, to act as control groups. 
10.5 CONCLUSIONS 
Ulcerative colitis and Crohn's disease were initially considered examples of 
psychosomatic diseases in which psychological factors played a major role. 
However, as knowledge of the genetic, environmental and molecular pathogenesis of 
1131) increased, the possible contribution to its aetiology of psychological stress was 
progressively neglected. Indeed, stress was often dismissed as a vague subjective 
concept, a view which some of the early and methodologically flawed studies of 
stress in relation to 1131) did nothing to diminish. 
In recent years, however, considerable evidence has accumulated that 
psychological stress does indeed contribute to the', risk of relapse in IBD. 
Furthermore, laboratory research has indicated a variety of mechanisms by which 
stress can affect both the systemic and gastro-intestinal immune and inflammatory 
responses. In this study we have to some degree linked these separate, lines of 
enquiry by showing that acute experimental stress can increase a range of 
inflammatory variables in patients with UC. 
Translating these findings into therapeutic interventions based, on stress 
reduction has proved a challenge. 'Ibis is in part due to the wide range of stress- 
reducing psychotherapeutic interventions available. In this study, we have shown that 
hypnotherapy can reduce a range of both systemic and mucosal inflammatory 
measures in patients with active UC. We believe that this datajustifies a clinical trial 
to assess whether hypnotherapy has clinical benefit in UC. The solution to this 
question may not only benefit patients, but also shed further light on the pathogenesis 
of IBD. " 
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PSYCHOMETRIC QUESTIONNAIRES AND HYPNOTISABILITY TESTS 
Below are reproductions of the Perceived Stress Questionnaire (PSQ) (373) 
and the Bradford Somatic Inventory (BSI) (374). The State Trait Anxiety Inventory 
(STAI) (462) and Hospital Anxiety Depression Scale (HADS) (387) could not be 
reproduced as they are under copyright. Similarly Spiegel's test of hypnotisability 
could not be reproduced (383). 
Perceived Stress Questionnaire (373) 
Instructions 
For each sentence circle the number that describes how often it applies to you 
in general during the last year or two. Work quickly without bothering to check your 
answers and be careful to describe your life in the long run. 
1. You feel rested 
Almost never Sometimes Often Usually 
1234 
2. You feel that too many demands 
Almost never Sometimes 
12 
3. You are irritable or grouchy 
Almost never Sometimes 
12 
are being made on you 
Often Usually 
34 
Often Usually 
34 
4. You have too many things to do 
Almost never Sometimes Often Usually 
1234 
5. You feel lonely or isolated 
Almost never Sometimes Often Usually 
1234 
6. You find yourself in situations of conflict 
Almost never Sometimes Often Usually 
12,34 
7. You feel you are doing things you really like 
Almost never Sometimes Often Usually 
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1234 
8. You feel tired 
Almost never Sometimes Often Usually 
1234 
9. You fear that you may not manage to attain your goals 
Almost never Sometimes Often Usually 
1234 
10. You feel calm 
Almost never Sometimes Often Usually 
1234 
11. You have too many decisions to make 
Almost never Sometimes Often Usually 
1 2 3 4 
12. You feel frustrated 
Almost never Sometimes Often Usually 
1 2 3 4 
13. You are full of energy 
Almost never Sometimes Often Usually 
1 2 3 4 
14. You feel tense 
Almost never Sometimes Often Usually 
1 2 3 4 
15. Your problems seem to be piling up 
Almost never Sometimes Often Usually 
1 2 3 4 
16. You feel you are in a hurry 
Almost never Sometimes Often Usually 
12 3 4 
17. You feel safe and protected 
Almost never Sometimes Often Usually 
12 3 4 
18. You have too many worries 
Almost never Sometimes Often Usually 
12 3 4 
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19. You are under pressure from other people 
Almost never Sometimes Often Usually 
112 3 4 
20. You feel discouraged 
Almost never Sometimes Often Usually 
12 3 4 
21. You enjoy yourself 
Almost never Sometimes Often Usually 
12 3 4 
22. You are afraid for the future 
Almost never Sometimes Often Usually 
12 3 4 
23. You feel that you are doing things because you have to and not because you 
want to 
Almost never Sometimes Often Usually 
12 3 4 
24. You feel criticised. orjudged 
Almost never Sometimes Often Usually 
12 3 4 
25. You are light hearted 
Almost never Sometimes Often Usually 
12 3 4 
26. You feel mentally exhausted 
Almost never Sometimes Often Usually 
12 3 4 
27. You have trouble relaxing 
Almost never Sometimes Often Usually 
12 3 4 
28. You feel loaded down with responsi bility 
Almost never Sometimes Often Usually 
12 3 4 
29. You have enough time for yourself 
Almost never Sometimes Often Usually 
I-234 
30. You feel under pressure from deadlines 
253 
Almost never Sometimes Often Usually 
1234 
Scoring the questionnaire 
Score 5-circled number for items 1,7,10,13,17,21,25,29. Score number circles 
for all other items. 
Bradford Somatic Inventory (374) 
During the past one month 
1. Have you had severe headaches ? YES/NO 
2. Have you had fluttering or a feeling of something YES/NO 
moving in your stomach? 
3. Have you had a pain or tension in your neck and YES/NO 
shoulders? 
4. Has your skin been burning or itching all over? YES/NO 
5. Have you had a feeling of constriction in your head YESNO 
as if being gripped from outside? 
6. Have you felt pain in the chest or heart? YES/NO 
7. Has your mouth or throat felt dry? YES/NO 
8. Has there been darkness or mist in front of your eyes? YES/NO 
9. Have you felt a burning sensation in your stomach? YES/NO 
10. Have you felt a lack of energy much of the time? YES/NO 
11. Has your head felt hot or burning? YES/NO 
12. Have you been sweating a lot? , YES/NO 
13. Have you felt as if there were a pressure or tightness YES/NO 
on your chest or heart? 
14. Have you been suffering from a discomfort in the YES/NO 
abdomen? 
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15. Has there been a choking sensation in your throat? YES/NO 
16. Have your hands or feet had pins or needles or YES/NO 
17., Have you felt aches or pains all over the body? YES/NO 
18. Have you had a feeling of heat inside your body? YES/NO 
19. Have you been aware of palpitations (heart thumping) ? YES/NO 
20. Have you felt pain or burning in your eyes? YES/NO 
21. Have you suffered from indigestion? YES/NO 
22. Have you been trembling or shaking? YES/NO 
23. Have you been passing urine more frequently? YES/NO 
24. Have you been having lower back trouble? YES/NO 
25. Has your stomach felt swollen or bloated? YES/NO 
26. Has your head felt heavy? YES/NO 
27. Have you been feeling fired even when you are YES/NO 
not working? 
28. Have you been getting pain in your legs? YES/NO 
29. Have you had difficulty in breathing'even when YES/NO 
resting? 
30. Have you had a feeling of pressure inside your head? YES/NO 
31. Have you had difficulty in breathing even when YES/NO 
resting? 
32. Have you felt pins and needles all over your body? YES/NO 
33. Have you been troubled by constipation? YES/NO 
34. Have you wanted to open your bowels YES/NO 
( go to the toilet) more often than usual? 
35. Have your palms been sweating a lot? YES/NO 
255 
36. Have you had difficulty in swallowing as if there 
were a lump in your throat? 
37. Have you been feeling dizzy or giddy? 
38. Have you had a bitter taste in your mouth? 
39. Has your whole body felt heavy? 
40. Have you had a burning sensation when passing 
urine? 
41. Have you been hearing a buzzing noise in your ears 
or head? 
42. Has your heart felt weak or sinking? 
43. Have you suffered from excess wind or belching? 
44. Have your hands or feet felt cold? 
Scoring the questionnaire 
Total the number of questions answered yes 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YES/NO 
YESNO 
YES/NO 
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HYPNOTHERAPY SESSIONS 
Below is given a brief overview of each hypnotherapy session 
Pre-Hypnotherapy Session Discussion 
Each patient was interviewed for 10-15 minutes prior to the hypnotherapy 
session. Firstly, an explanation of the nature of hypnosis was given incorporating the 
ideas of suggestion and trance. The subject was told that hypnosis required 
compliance but that they could not be made to do things against their will, as their 
unconscious mind would only accept suggestions congruent with their belief system. 
The therapist also gave a brief explanation of the role that stress and 
psychological factors might play in the aetiology of UC. Particular attention was 
paid to explaining how common stress is and that even a person who considers 
themself not particularly stressed often experiences considerable worry and anxiety in 
day to day life. The subject was asked to identify the things they found stressful. 
Depth Perception and Hypnotisability 
Before commencing the hypnotherapy session, the subject was told that they 
would be assessed whilst in the process of hypnosis. The subject was infonned that 
they would be requested to give a score between one and ten at three time points 
during the session to signify how deep they felt themselves to be in the process. A 
score of ten indicated that they were deeply into hypnosis and a score of one only 
slightly. They were then tested for hypnotisability by the Spiegel score (383). 
Induction (347), 
A relaxation induction procedure was used, based on the personal experience 
of the individual. A relaxing situation was identified, for instance a recent enjoyable 
holiday or hobby. The person was instructed to imagine themselves in that situation: 
great care was taken to identifying the sights, sounds, smells, noises and sensory 
feelings of the surroundings. 71bey were encouraged to imagine themselves relaxing 
and instructions for progressive muscular relaxation were given, using words such as 
these: 
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"The muscles of your ankles will become limp and slack and they will be relaxed. 
Then the muscles of your calves will go limp and slack, a pleasant feeling is 
spreading up your body as the muscles of your calves relax. " 
As, each muscle group was mentioned, the idea of relaxation was encouraged 
until it was suggested that the whole body was sinking into the couch. During the 
process particular attention was paid to relaxing the muscles of the face. 
"All the worry wrinkles and care creases are disappearing as the muscles of your face 
and scalp relax". 
Following this the patient was told that they were feeling "Cool, calm and 
comfortable. Secure and serene". This phrase was repeated several times. 
On average this initial stage of relaxation lasted 15 minutes. Before moving 
on to the next segment, the patient was told to prepare for their pulse and blood 
pressure to be measured. They were also asked to make their first estimation of depth 
of trance. 
Further relaxation and stress reduction techniques 
First an acknowledgement was made of the patents willingness to participate 
in hypnotherapy. It was, 
-suggested 
that their UC would benefit from their decision to 
participate in the study. 
A further relaxation technique was then employed using a breathing exercise. 
Subjects were instructed to take three deep breaths and were told that with each 
exhalation a phrase would be given to help them relax further. With the first 
exhalation the phrase "Exit toil and trouble" was given. 
With the second breath the phrase "Exit pain and problems" was stated and 
with the third, the phrase "Exit today's dross". 
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The subject was then asked to take a further three deep breaths and on this 
occasion, a phrase given with inhalation to increase relaxation. With the first breath 
the statement "Fresh oxygen and energy" was made. The subject was asked to 
imagine the oxygen reaching all the cells in their body, bringing new energy and 
taking away all the toxins. With the second inspiration, the phrase "renewed, 
refreshed restored" was used and with the third the, phrase ý'Strength for the problems 
of today". 
For each individual, specific relevant stressful situations were identified and 
described. However, the therapist suggested and re-enforced repeatedly that, rather 
than feeling stressed, as was the usual in these situations, the subject would continue 
to feel relaxed as they did now. It was suggested that each patient would no longer 
find these situations stressful in the future. Subjects were asked to imagine 
themselves feeling relaxed in these previously stressful situations. It was suggested 
that the feeling of deep relaxation that they were currently experiencing, would be 
carried forward into their lives once the hypnosis session was over. 
This second session took approximately another fifteen minutes at the end of 
which time a second pulse and blood pressure reading was taken and a second self- 
assessment of depth. 
Disease specific therapy 
Several techniques of visualisation were used which were disease-focussed. 
The first technique involved the subject imagining the lining of their bowel to be a 
bright red colour in accordance with the associated inflammation. It was suggested 
that the subject could then imagine this redness slowly turning to orange. An image 
an orange with its associated smell and texture was used to reinforce this colour. The 
patient was asked to confirm that they had changed the red to orange by nodding their 
head. Thereafter, a further shift in colour was made to yellow and an association to 
an image of a field of corn. Finally the yellow colour was then changed to a cream. 
The suggestion was then made that this cream was the colour of the normal un- 
inflamed mucosa of the gut. It was suggested that with the same technique the subject 
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could imagine the lining of the gut changing from an inflamed red to a non-nal cream 
colour. 
The second technique involved imaging the gut as a canal or river. The patient 
was invited to imagine a canal where the water was flowing in a stately, steady and 
controlled fashion; the banks of the canal were smooth and solid and there was no 
erosion of the banks. The patient was invited to imagine taking a boat from the bank 
and setting out on the canal. Attention was paid to the calmness and steadiness of the 
water. The idea of a lock was introduced, the process of controlled passage through 
the lock described in great detail. The idea was then introduced of the gut being a 
canal and that all of these beneficial characteristics might apply. For example, the 
motion of the gut contents would be stately and smooth with no turbulence. It was 
also suggested that the process of evacuation might be similar to that of negotiating 
the lock with the process being calm and under the patient's control. 
In a third technique, patients were asked to place a hand on their abdomen. 
They were asked to imagine a feeling of warmth emanating from their hand and 
radiating throughout their abdomen. Associated with this feeling of warmth would be 
a process of healing throughout the gut. 
It was also suggested to the patient that science does not, as yet, fully 
understand either the process of hypnotherapy or the aetiology of UC. It was 
suggested that hypnotherapY may work via currently unknown mechanisms to 
improve disease activity in UC. A brief description of the complexity of the brain 
and its links to inflammatory processes was given. It was hoped that this would 
improve patients' confidence in the value of hypnotherapy as a therapeutic technique 
for UC. 
Ego-Strengthening (347) 
Prior to emergence, a brief period of time was given to ego-strengthening. 
Individuals were reminded of their past achievements and the characteristics they had 
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shown which had enabled their success. It was suggested that these same character 
traits would enable them to cope with their UC successfully in the future. 
Prior to emergence a third pulse and blood pressure reading was taken and a 
final self-assessment of depth. 
Emerging Technique 
Before emergence, patients were asked to imagine themselves in their place of 
comfort once more. They were then woken by counting from 1 to 5 and being told 
that by the count of 5 they would be wide awake feeling refreshed and ready for the 
day ahead. 
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PUBLICATIONS RESULTING FROM THIS THESIS 
Articles 
Mawdsley JED, Macey MG, Feakins RM, Langmead L, Rampton DS. The effect of 
acute psychological stress on systemic and rectal mucosal measures of inflammation 
in UC. Gastroenterology 2006; 131(2): 410-419 
Mawdsley JED, Rampton DS. Psychological stress in IBD; new insights into 
pathogenic mechanisms and therapeutic implications. Gut. 2005; 54(10): 1481-91. 
Mawdsley JED, Rampton DS. The role of psychological stress in inflammatory 
bowel disease. Neuroirnmunomod. 2007. In Press 
Mawdsley JED, Jenkins DG, Macey MG, Langmead L, Rampton DS. The effect of 
hypnotherapy on systemic and rectal mucosal measures of inflammation in UC. Am J 
Gastro 2007. Submitted. 
Book Chapters 
Mawdsley JED, Rampton DS. Psychological stress in IBD; Something to worry 
about? P Irving, D. Rampton &F Shanahan, eds. Clinical Dilemmas in IDD. 
Blackwell Scientific Publishing 2006: 129-132 
PRESENTATIONS AT INTERNATIONAL MEETINGS 
Oral presentations 
Mawdsley JED, Rampton DS. The effects of acute and chronic stress on syternic and 
mucosal measures of inflammation in ulcerative colitis. 1131) Symposia at American 
Psychosomatic Society Meeting 2007. Psychsomatic Medicine 2007; 69 (1); All. 
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Mawdsley JED, Rampton DS. 'Acute psychological stress increases rectal mucosal 
and LPS-stimulated whole blood release of TNF-a in patients with inactive UC. IBD 
free paper session at BSG. Gut 2006; 55 (Suppl 11): A14 
Mawdsley JED, Jenkins DG, Macey MG, Rampton DS. Natural Killer cells are 
increased by psychological stress and decreased by hypnotherapy in ulcerative colitis. 
1131) plenary session at BSG. Gut 2005; 54 (SuppI 11): A23 
Poster Presentations, 
Mawdsley JED, Jenkins DG, Rampton DS. Hypnotherapy decreases rectal mucosal 
release of substance P, Histamine and IL-13 in patients with active UC. BSG and 
DDW 2006. Gastroenterology 2006; 130 (SuppI 11); A146 and Gut 2006; 55 (SuppI 
II): A75 
Mawdsley JED, Rampton DS. Acute psychological stress increases rectal mucosal 
and LPS-stimulated whole blood release of TNF-a in patients with inactive UC. 
DDW 2006. Gastroenterology 2006; 130 (Suppl 11); A146 
Mawdsley JED, Rampton DS. Acute psychological stress increases reactive oxygen 
metabolite production by rectal biopsies in patients with inactive ulcerative colitis. 
UEGW 2005. Gut 2005; 54 (Suppl VII); A223 
Mawdsley JED, Jenkins DG, Rampton DS. Acute psychological stress increases IL-6 
production by lipopolysaccharide stimulated blood whilst hypnotherapy decreases 
serum IL-6 levels in patients with ulcerative colitis. UEOW 2005. Gut 2005; 54 
(Suppl VII); A223 
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Mawdsley JED, Rampton DS. Serum IL-13 concentrations are raised in active 
ulcerative colitis and correlate with disease activity and mucosal inflammation. 
UEGW 2005. Gut 2005; 54 (Suppl VII); A224 
Mawdsley JED, Macey MG, Rampton DS. Acute psychological stress increases 
platelet activation and platelet-leukocyte aggregate formation in patients with inactive 
ulcerative colitis. BSG meeting Gut 2005; 54 (SuppI II): A91 
Mawdsley JED, Jenkins DG, Rampton DS. Rectal Blood flow is increased in active 
ulcerative colitis and decreased by hypnotherapy Poster at UEGW. Gut 2004; 53 
(Suppl Vl): A224 
Mawdsley JED, Jenkins DG, Macey MG, Rampton DS. Natural Killer cells are 
increased by psychological stress and decreased by hypnotherapy in ulcerative colitis. 
AGA-BSG meeting on immunology of IBD Oxford Sept 2004 
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